|
MASH | Abstract Library |
|
|
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13. | A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease |
|
Hepatol Int. 2024 Jun 15. doi: 10.1007/s12072-024-10702-5. Online ahead of print.
Huai Zhang 1, Giovanni Targher 2, Christopher D Byrne 3, Seung Up Kim 4, Vincent Wai-Sun Wong 5, Luca Valenti 6 7, Myer Glickman 8, Jaime Ponce 9, Christos S Mantzoros 10, Javier Crespo 11, Henning Gronbaek 12, Wah Yang 13, Mohammed Eslam 14, Robert J Wong 15, Mariana Verdelho Machado 16, Ming-Lung Yu 17 18, Omar M Ghanem 19, Takeshi Okanoue 20, Jun-Feng Liu 21, Yong-Ho Lee 22, Xiao-Yuan Xu 23, Qiuwei Pan 24, Meili Sui 25, Amedeo Lonardo 26, Yusuf Yilmaz 27, Li-Yong Zhu 28, Christophe Moreno 29, Luca Miele 30, Monica Lupsor-Platon 31, Lei Zhao 32, Teresa LeAnn LaMasters 33, Robert G Gish 34, Huijie Zhang 35, Marius Nedelcu 36, Wah Kheong Chan 37, Ming-Feng Xia 38, Fernando Bril 39, Jun-Ping Shi 40, Christian Datz 41, Stefano Romeo 42 43 44, Jian Sun 45, Dan Liu 46, Silvia Sookoian 47 48 49, Yi-Min Mao 50, Nahum Méndez-Sánchez 51, Xiao-Yan Wang 52, Nikolaos T Pyrsopoulos 53, Jian-Gao Fan 54, Yasser Fouad 55, Dan-Qin Sun 56 57, Cosimo Giannini 58, Jin Chai 59, Ze-Feng Xia 60, Dae Won Jun 61, Guo-Jing Li 62, Sombat Treeprasertsuk 63, Ying-Xu Li |
|
|
|
|
|
|
16. | Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis |
|
Hepatology. 2024 Jul 1;80(1):173-185. doi: 10.1097/HEP.0000000000000723.Epub 2023 Dec 19.
Vlad Ratziu 1, Sven Francque 2 3 4, Cynthia A Behling 5, Vanja Cejvanovic 6, Helena Cortez-Pinto 7, Janani S Iyer 8, Niels Krarup 6, Quang Le 8, Anne-Sophie Sejling 6, Dina Tiniakos 9 10, Stephen A Harrison 11
|
|
|
|
|
|
|
19. | The cost implications of Wilson disease among hospitalized patients: analysis of USA hospitals |
|
Eur JGastroenterolHepatol. 2024Jul1;36(7):929940. doi:10.1097/MEG.0000000000002777.Epub 2024 Apr 23.
David Uihwan Lee 1, Ashton Harmacinski 1, Aneesh Bahadur 2, Ki Jung Lee 2, Hannah Chou 2, Mohammed Rifat Shaik 1, Harrison Chou 2, Gregory Hongyuan Fan 2, Jean Kwon 2, Reid Ponder 2, Kevin Chang 2, KeeSeok Lee 2, Zurabi Lominadze 1
|
|
|
|
|
|
|
|
|
|
|
24. | A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease |
|
Hepatol Int. 2024 Jun 15. doi: 10.1007/s12072-024-10702-5. Online ahead of print.
Huai Zhang 1, Giovanni Targher 2, Christopher D Byrne 3, Seung Up Kim 4, Vincent Wai-Sun Wong 5, Luca Valenti 6 7, Myer Glickman 8, Jaime Ponce 9, Christos S Mantzoros 10, Javier Crespo 11, Henning Gronbaek 12, Wah Yang 13, Mohammed Eslam 14, Robert J Wong 15, Mariana Verdelho Machado 16, Ming-Lung Yu 17 18, Omar M Ghanem 19, Takeshi Okanoue 20, Jun-Feng Liu 21, Yong-Ho Lee 22, Xiao-Yuan Xu 23, Qiuwei Pan 24, Meili Sui 25, Amedeo Lonardo 26, Yusuf Yilmaz 27, Li-Yong Zhu 28, Christophe Moreno 29, Luca Miele 30, Monica Lupsor-Platon 31, Lei Zhao 32, Teresa LeAnn LaMasters 33, Robert G Gish 34, Huijie Zhang 35, Marius Nedelcu 36, Wah Kheong Chan 37, Ming-Feng Xia 38, Fernando Bril 39, Jun-Ping Shi 40, Christian Datz 41, Stefano Romeo 42 43 44, Jian Sun 45, Dan Liu 46, Silvia Sookoian 47 48 49, Yi-Min Mao 50, Nahum Méndez-Sánchez 51, Xiao-Yan Wang 52, Nikolaos T Pyrsopoulos 53, Jian-Gao Fan 54, Yasser Fouad 55, Dan-Qin Sun 56 57, Cosimo Giannini 58, Jin Chai 59, Ze-Feng Xia 60, Dae Won Jun 61, Guo-Jing Li 62, Sombat Treeprasertsuk 63, Ying-Xu Li |
|
|
|
|
|
|
|
|
|
|
|
|
30. | Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study |
|
BMC Med. 2024 Jun 3;22(1):221. doi: 10.1186/s12916-024-03366-3.
Ana-Lucia Mayén 1, Mirna Sabra 1, Elom K Aglago 2, Gabriel Perlemuter 3 4 5, Cosmin Voican 3 4 5, Ines Ramos 1, Charlotte Debras 1, Jessica Blanco 1, Vivian Viallon 1, Pietro Ferrari 1, Anja Olsen 6 7, Anne Tjønneland 6 7, Fie Langmann 7, Christina C Dahm 7, Joseph Rothwell 8, Nasser Laouali 8, Chloé Marques 8, Matthias B Schulze 9, Verena Katzke 10, Rudolf Kaaks 10, Domenico Palli 11, Alessandra Macciotta 12, Salvatore Panico 13, Rosario Tumino 14, Claudia Agnoli 15, Marta Farràs 16, Esther Molina-Montes 17 18 19 20, Pilar Amiano 18 21 22, María-Dolores Chirlaque 18 23, Jesús Castilla 18 24, Mårten Werner 25, Stina Bodén 26, Alicia K Heath 2, Kostas Tsilidis 2, Dagfinn Aune 2 27 28, Elisabete Weiderpass 29, Heinz Freisling 1, Marc J Gunter 2, Mazda Jenab 30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40. | Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD |
|
Clin Gastroenterol Hepatol. 2024 May;22(5):1024-1036.e2. doi:10.1016/j.cgh.2023.12.009.Epub 2023 Dec 23.
Chaowapong Jarasvaraparn 1, Eduardo Vilar-Gomez 2, Katherine P Yates 3, Laura A Wilson 3, Brent Neuschwander-Tetri 4, Rohit Loomba 5, Oscar Cummings 6, Miriam Vos 7, Stavra Xanthakos 8, Jeffrey Schwimmer 9, Jean P Molleston 1, Arun Sanyal 10, James Tonascia 11, Naga Chalasani 12
|
|
|
|
|
|
|
43. | Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study |
|
Hepatology. 2024 Jun 1;79(6):1401-1411. doi: 10.1097/HEP.0000000000000712.Epub 2023 Dec 12.
Arvid Engström 1, Viktor Wintzell 1, Mads Melbye 2 3 4 5, Henrik Svanström 1 6, Björn Eliasson 7, Soffia Gudbjörnsdottir 7 8, Kristian Hveem 4 9, Christian Jonasson 4 9, Anders Hviid 6 10, Peter Ueda 1, Björn Pasternak 1 6
|
|
|
|
|
|
|
46. | Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population |
|
Aliment Pharmacol Ther. 2024 Jun;59(11):1402-1412. doi: 10.1111/apt.17953. Epub 2024 Mar 18.
Antonio De Vincentis 1, Federica Tavaglione 2 3, Shinichi Namba 4, Masahiro Kanai 4 5 6, Yukinori Okada 4 7 8 9 10 11, Yoichiro Kamatani 12, Samantha Maurotti 13, Claudio Pedone 14, Raffaele Antonelli Incalzi 1, Luca Valenti 15 16, Stefano Romeo 3 13 17, Umberto Vespasiani-Gentilucci 2
|
|
|
47. | Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice |
|
Lancet Gastroenterol Hepatol. 2024 Jun;9(6):577-582.doi: 10.1016/S2468-1253(23)00453-3. Epub 2024 Feb 28.
Paul N Brennan 1, Oliver D Tavabie 2, Wenhao Li 3, Thomas Marjot 4, Lynsey Corless 5, Jonathan A Fallowfield 6, Helen Jarvis 7, Dina Mansour 8, Stuart McPherson 9, William Rosenberg 10, Karen Rockell 11, Jeremy Tomlinson 4, Andrew Yeoman 12, Emmanuel A Tsochatzis 10, John F Dillon 1, William Alazawi 3, Kushala W M Abeysekera 13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56. | Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt |
|
J Viral Hepat. 2024 Apr 15. doi: 10.1111/jvh.13935. Online ahead of print.
Saleh A Alqahtani 1 2 3, Yusuf Yilmaz 1 4, Mohamed El-Kassas 1 5, Khalid Alswat 1 6, Faisal Sanai 7, May AlZahrani 8, Faisal Abaalkhail 9 10, Manal AlShaikh 8, Waleed K Al-Hamoudi 2 6, Fatema Nader 1 11 12, Maria Stepanova 1 11 12, Zobair M Younossi 1 11 12; Global NASH Council
|
|
|
|
|
|
|
59. | Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease |
|
JAMA. 2024 Mar 21. doi: 10.1001/jama.2024.1447. Online ahead of print.
Huapeng Lin 1 2, Hye Won Lee 3, Terry Cheuk-Fung Yip 1 2, Emmanuel Tsochatzis 4, Salvatore Petta 5, Elisabetta Bugianesi 6, Masato Yoneda 7, Ming-Hua Zheng 8, Hannes Hagström 9 10, Jérôme Boursier 11 12, José Luis Calleja 13, George Boon-Bee Goh 14, Wah-Kheong Chan 15, Rocio Gallego-Durán 16, Arun J Sanyal 17, Victor de Lédinghen 18, Philip N Newsome 19, Jian-Gao Fan 20, Laurent Castéra 21, Michelle Lai 22, Stephen A Harrison 23 24, Céline Fournier-Poizat 25, Grace Lai-Hung Wong 1 2, Grazia Pennisi 5, Angelo Armandi 6, Atsushi Nakajima 7, Wen-Yue Liu 26, Ying Shang 9, Marc de Saint-Loup 11, Elba Llop 13, Kevin Kim-Jun Teh 14, Carmen Lara-Romero 16, Amon Asgharpour 17, Sara Mahgoub 19, Mandy Sau-Wai Chan 25, Clemence M Canivet 11 12, Manuel Romero-Gomez 16, Seung Up Kim 3, Vincent Wai-Sun Wong 1 2; VCTE-Prognosis Study Group
|
|
|
|
|
61. | Impact of age on NIS2+â„¢ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH |
|
JHEP Rep. 2024 Jan 19;6(4):101011. doi: 10.1016/j.jhepr.2024.101011. eCollection 2024 Apr.
Quentin M Anstee 1 2, Jeremy Magnanensi 3, Yacine Hajji 3, Alexandra Caron 3, Zouher Majd 3, Christian Rosenquist 3, Dean W Hum 3, Bart Staels 4, Margery A Connelly 5, Rohit Loomba 6, Stephen A Harrison 7 8, Vlad Ratziu 9, Arun J Sanyal 10
|
|
|
62. | Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial |
|
JAMA. 2024 Mar 19;331(11):920-929. doi: 10.1001/jama.2024.1215.
Tracey G Simon 1 2 3, Robert M Wilechansky 1 2 4, Stefania Stoyanova 4, Alessandra Grossman 4, Laura E Dichtel 2 5, Georg M Lauer 2 4, Karen K Miller 2 5, Yujin Hoshida 6, Kathleen E Corey 1 2 4, Rohit Loomba 7, Raymond T Chung 1 2 4, Andrew T Chan 1 2 4
|
|
|
|
|
64. | Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study |
|
ClinGastroenterolHepatol. 2024Mar4:S15423565(24)00226X.doi:10.1016/j.cgh.2024.02.022. Online ahead of print.
Stephen A Harrison 1, Juan P Frias 2, K Jean Lucas 3, Gary Reiss 4, Guy Neff 5, Sureka Bollepalli 6, Yan Su 7, Doreen Chan 8, Erik J Tillman 8, Ali Moulton 8, Brittany de Temple 8, Arian Zari 8, Reshma Shringarpure 9, Timothy Rolph 8, Andrew Cheng 8, Kitty Yale 8
|
|
|
|
|
|
|
67. | Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease |
|
J Pharmacol Exp Ther. 2024 Feb 26:JPET-AR-2023001900. doi:10.1124/jpet.123.001900.Online ahead of print.
David Hollenback 1, Eva Hambruch 2, Gero Fink 2, Manfred Birkel 2, Andreas Schulz 2, Martin Hornberger 2, Kathy Liu 3, Kelly MacLennan Staiger 4, Helen Desiree Krol 2, Ulrich Deuschle 2, Christoph Steeneck 2, Olaf Kinzel 2, John T Liles 3, Grant Budas 3, William J Watkins 3, Claus Kremoser 5
|
|
|
|
|
|
|
70. | Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis |
|
Clin Mol Hepatol. 2024 Apr 16. doi: 10.3350/cmh.2024.0109. Online ahead of print.
Harry Crane 1, Guy D Eslick 2, Cameron Gofton 1 3, Anjiya Shaikh 4, George Cholankeril 5, Mark Cheah 6, Jian-Hong Zhong 7, Gianluca Svegliati-Baroni 8, Alessandro Vitale 9, Beom Kyung Kim 10, Sang Hoon Ahn 10, Mi Na Kim 10, Simone Strasser 11, Jacob George 1
|
|
|
|
|
|
|
73. | The effects of food insecurity on hepatic steatosis and fibrosis in people with HIV |
|
ClinGastroenterolHepatol. 2024Apr5:S15423565(24)002994.doi:10.1016/j.cgh.2024.03.017. Online ahead of print.
Ani Kardashian 1, Audrey Lloyd 2, Eduardo Vilar-Gomez 3, Susanna Naggie 4, Mark S Sulkowski 5, Tinsay Woreta 5, Jordan E Lake 6, Holly Crandall 3, Rohit Loomba 7, Laura A Wilson 8, Richard K Sterling 9, Sonya Heath 10, Samer Gawrieh 11, Naga P Chalasani 11, Jennifer C Price 12; HIV NASH Clinical Research Network
|
|
|
|
|
75. | Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors |
|
Dig Liver Dis. 2024 Apr;56(4):551-558. doi: 10.1016/j.dld.2023.09.023. Epub 2023 Oct 14.
Rosa Lombardi 1, Alessandro Mantovani 2, Annalisa Cespiati 3, Paolo Francione 4, Gabriele Maffi 3, Elena Del Zanna 3, Claudio Maffeis 5, Antonio Colecchia 6, Nicola Passigato 7, Alberto Ferrarese 7, Caterina Daniela Cusumanu 7, Rosanna Villani 8, Emanuela Orsi 9, Valeria Grancini 9, Lorena Airaghi 10, Daniela Bignamini 10, Gaetano Serviddio 8, Giovanni Targher 11, Paola Dongiovanni 10, Silvia Fargion 12, Anna Ludovica Fracanzani 3
|
|
|
76. | Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature |
|
J Pediatr Gastroenterol Nutr. 2024 Mar 26. doi: 10.1002/jpn3.12156. Online ahead of print.
European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN); Pietro Vajro; European Association for the Study of the Liver (EASL); North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN); Latin-American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (LASPGHAN); Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN); Pan Arab Society for Pediatric Gastroenterology and Nutrition (PASPGHAN); Commonwealth Association of Paediatric Gastroenterology & Nutrition (CAPGAN); Federation of International Societies of Pediatric Hepatology, Gastroenterology and Nutrition (FISPGHAN)
Collaborators
Ulrich Baumann, Bart G P Koot, Emer Fitzpatrick, Jake Mann, Pietro Vajro, Aleksander Krag, Debbie Shawcross, Sven Francque, Tobias Böttler, Benjamin D Gold, Jenifer R Lightdale, Marialena Mouzaki, Norberto Rodriguez-Baez, Rohit Kohli, Vicky L Ng, Daniel D'Agostino, Gilda Porta, José Spolidoro, Miguel Klünder-Klünder, Rodrigo Vázquez-Frias, Anupam Sibal, Jae Sung Ko, Kyung Mo Kim, Suporn Treepongkaruna, Yen-Hsuan Ni, Mohamed El-Guindi, Neelam Mohan, Elvira Verduci, Iqbal Memon, Mahmoud Bozo, Marcela Godoy, Marina Orsi, Marion Aw, Robert Bandsma, Samar Ibrahim, Stavra Xanthakos, Suporn Treepongkaruna, Tania Mitsinikos
|
|
|
|
|
78. | Accuracy, Reliability, and Comprehensibility of ChatGPT-Generated Medical Responses for Patients With Nonalcoholic Fatty Liver Disease |
|
Clin Gastroenterol Hepatol. 2024 Apr;22(4):886-889.e5. doi: 10.1016/j.cgh.2023.08.033.Epub 2023 Sep 15.
Nicola Pugliese 1, Vincent Wai-Sun Wong 2, Jörn M Schattenberg 3, Manuel Romero-Gomez 4, Giada Sebastiani 5; NAFLD Expert Chatbot Working Group; Alessio Aghemo 14
Collaborators
NAFLD Expert Chatbot Working Group:
Laurent Castera 6, Cesare Hassan 7, Pinelopi Manousou 8, Luca Miele 9, Raquel Peck 10, Salvatore Petta 11, Luca Valenti 12, Zobair M Younossi 13
|
|
|
|
|
80. | No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC |
|
Liver Int. 2024 Apr;44(4):931-943. doi: 10.1111/liv.15833. Epub 2024 Jan 30.
Francisca-Dora Copil 1, Claudia Campani 2, Marie Lequoy 3, Philippe Sultanik 1, Lorraine Blaise 4, Mathilde Wagner 5, Nathalie Ganne-Carrié 2 4, Violaine Ozenne 3, Dominique Thabut 1 6, Jean-Charles Nault 2 4, Vlad Ratziu 1 6, Manon Allaire 1 2 7
|
|
|
|
|
82. | Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together |
|
Int J Mol Sci. 2024 Mar 14;25(6):3278. doi: 10.3390/ijms25063278.
Rossella Maresca 1, Irene Mignini 1, Simone Varca 1, Valentin Calvez 1, Fabrizio Termite 1, Giorgio Esposto 1, Lucrezia Laterza 1, Franco Scaldaferri 1, Maria Elena Ainora 1, Antonio Gasbarrini 1, Maria Assunta Zocco 1
|
|
|
|
|
84. | Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease |
|
JAMA. 2024 Mar 21. doi: 10.1001/jama.2024.1447. Online ahead of print.
Huapeng Lin 1 2, Hye Won Lee 3, Terry Cheuk-Fung Yip 1 2, Emmanuel Tsochatzis 4, Salvatore Petta 5, Elisabetta Bugianesi 6, Masato Yoneda 7, Ming-Hua Zheng 8, Hannes Hagström 9 10, Jérôme Boursier 11 12, José Luis Calleja 13, George Boon-Bee Goh 14, Wah-Kheong Chan 15, Rocio Gallego-Durán 16, Arun J Sanyal 17, Victor de Lédinghen 18, Philip N Newsome 19, Jian-Gao Fan 20, Laurent Castéra 21, Michelle Lai 22, Stephen A Harrison 23 24, Céline Fournier-Poizat 25, Grace Lai-Hung Wong 1 2, Grazia Pennisi 5, Angelo Armandi 6, Atsushi Nakajima 7, Wen-Yue Liu 26, Ying Shang 9, Marc de Saint-Loup 11, Elba Llop 13, Kevin Kim-Jun Teh 14, Carmen Lara-Romero 16, Amon Asgharpour 17, Sara Mahgoub 19, Mandy Sau-Wai Chan 25, Clemence M Canivet 11 12, Manuel Romero-Gomez 16, Seung Up Kim 3, Vincent Wai-Sun Wong 1 2; VCTE-Prognosis Study Group
|
|
|
|
|
86. | Impact of age on NIS2+â„¢ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH |
|
JHEP Rep. 2024 Jan 19;6(4):101011. doi: 10.1016/j.jhepr.2024.101011. eCollection 2024 Apr.
Quentin M Anstee 1 2, Jeremy Magnanensi 3, Yacine Hajji 3, Alexandra Caron 3, Zouher Majd 3, Christian Rosenquist 3, Dean W Hum 3, Bart Staels 4, Margery A Connelly 5, Rohit Loomba 6, Stephen A Harrison 7 8, Vlad Ratziu 9, Arun J Sanyal 10
|
|
|
87. | Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial |
|
JAMA. 2024 Mar 19;331(11):920-929. doi: 10.1001/jama.2024.1215.
Tracey G Simon 1 2 3, Robert M Wilechansky 1 2 4, Stefania Stoyanova 4, Alessandra Grossman 4, Laura E Dichtel 2 5, Georg M Lauer 2 4, Karen K Miller 2 5, Yujin Hoshida 6, Kathleen E Corey 1 2 4, Rohit Loomba 7, Raymond T Chung 1 2 4, Andrew T Chan 1 2 4
|
|
|
|
|
|
|
|
|
91. | Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease |
|
J Pharmacol Exp Ther. 2024 Feb 26:JPET-AR-2023001900. doi:10.1124/jpet.123.001900.Online ahead of print.
David Hollenback 1, Eva Hambruch 2, Gero Fink 2, Manfred Birkel 2, Andreas Schulz 2, Martin Hornberger 2, Kathy Liu 3, Kelly MacLennan Staiger 4, Helen Desiree Krol 2, Ulrich Deuschle 2, Christoph Steeneck 2, Olaf Kinzel 2, John T Liles 3, Grant Budas 3, William J Watkins 3, Claus Kremoser 5
|
|
|
92. | Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study |
|
ClinGastroenterolHepatol. 2024Mar4:S15423565(24)00226X.doi:10.1016/j.cgh.2024.02.022. Online ahead of print.
Stephen A Harrison 1, Juan P Frias 2, K Jean Lucas 3, Gary Reiss 4, Guy Neff 5, Sureka Bollepalli 6, Yan Su 7, Doreen Chan 8, Erik J Tillman 8, Ali Moulton 8, Brittany de Temple 8, Arian Zari 8, Reshma Shringarpure 9, Timothy Rolph 8, Andrew Cheng 8, Kitty Yale 8
|
|
|
93. | MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH |
|
Gut. 2024 Feb 28:gutjnl-2023-331401. doi: 10.1136/gutjnl-2023-331401. Online ahead of print.
Rohit Loomba 1 2, Maral Amangurbanova 3, Ricki Bettencourt 3, Egbert Madamba 3, Harris Siddiqi 3, Lisa Richards 3, Cynthia Behling 4, Claude B Sirlin 5, Mildred D Gottwald 6, Shibao Feng 6, Maya Margalit 7, Daniel Q Huang 1 8 9
|
|
|
|
|
|
|
|
|
|
|
98. | Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information |
|
PLoS One. 2024 Feb 29;19(2):e0299487. doi: 10.1371/journal.pone.0299487. eCollection 2024.
Matthew McTeer 1, Douglas Applegate 2, Peter Mesenbrink 3, Vlad Ratziu 4, Jörn M Schattenberg 5, Elisabetta Bugianesi 6, Andreas Geier 7, Manuel Romero Gomez 8, Jean-Francois Dufour 9, Mattias Ekstedt 10, Sven Francque 11, Hannele Yki-Jarvinen 12, Michael Allison 13, Luca Valenti 14, Luca Miele 15, Michael Pavlides 16, Jeremy Cobbold 16, Georgios Papatheodoridis 17, Adriaan G Holleboom 18, Dina Tiniakos 17 19, Clifford Brass 2, Quentin M Anstee 19 20, Paolo Missier 1; LITMUS Consortium investigators
|
|
|
|
|
|
|
101. | Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease |
|
J Hepatol. 2024 Mar;80(3):419-430. doi: 10.1016/j.jhep.2023.11.004. Epub 2023 Nov 18.
Zobair M Younossi 1, Saleh A Alqahtani 2, Khalid Alswat 3, Yusuf Yilmaz 4, Caglayan Keklikkiran 4, Jesús Funuyet-Salas 5, Manuel Romero-Gómez 6, Jian-Gao Fan 7, Ming-Hua Zheng 8, Mohamed El-Kassas 9, Laurent Castera 10, Chun-Jen Liu 11, Vincent Wai-Sun Wong 12, Shira Zelber-Sagi 13, Alina M Allen 14, Brian Lam 15, Sombat Treeprasertsuk 16, Saeed Hameed 17, Hirokazu Takahashi 18, Takumi Kawaguchi 19, Jörn M Schattenberg 20, Ajay Duseja 21, Phil N Newsome 22, Sven Francque 23, C Wendy Spearman 24, Marlen I Castellanos Fernández 25, Patrizia Burra 26, Stuart K Roberts 27, Wah-Kheong Chan 28, Marco Arrese 29, Marcelo Silva 30, Mary Rinella 31, Ashwani K Singal 32, Stuart Gordon 33, Michael Fuchs 34, Naim Alkhouri 35, Kenneth Cusi 36, Rohit Loomba 37, Jane Ranagan 38, Wayne Eskridge 39, Achim Kautz 40, Janus P Ong 41, Marcelo Kugelmas 42, Yuichiro Eguchi 43, Moises Diago 44, Ming-Lung Yu 45, Lynn Gerber 15, Lisa Fornaresio 46, Fatema Nader 47, Linda Henry 48, Andrei Racila 49, Pegah Golabi 50, Maria Stepanova 48, Patrizia Carrieri 51, Jeffrey V Lazarus 52; Global NASH Council
|
|
|
102. | Links between gut microbiome, metabolome, clinical variables and non-alcoholic fatty liver disease severity in bariatric patients |
|
Liver Int. 2024 Feb 14. doi: 10.1111/liv.15864. Online ahead of print.
Katherine J P Schwenger 1, Divya Sharma 1 2, Yasaman Ghorbani 1 3, Wei Xu 2 4, Wendy Lou 4, Elena M Comelli 5, Sandra E Fischer 1 6, Timothy D Jackson 7 8, Allan Okrainec 7 8, Johane P Allard 1 5 9
|
|
|
|
|
|
|
105. | A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis |
|
Hepatology. 2024 Mar 1;79(3):674-689. doi: 10.1097/HEP.0000000000000607.Epub 2023 Sep 21.
Mary E Rinella 1, Hsiao D Lieu 2, Kris V Kowdley 3 4, Zachary D Goodman 5, Naim Alkhouri 6, Eric Lawitz 7, Vlad Ratziu 8, Manal F Abdelmalek 9, Vincent Wai-Sun Wong 10, Ziad H Younes 11, Aasim M Sheikh 12, Donald Brannan 13, Bradley Freilich 14, Fernando Membreno 15, Marie Sinclair 16, Liza Melchor-Khan 2, Arun J Sanyal 17, Lei Ling 2, Stephen A Harrison 18 19
|
|
|
|
|
|
|
|
|
109. | Myeloid cell MHC I expression drives CD8+ T cell activation in nonalcoholic steatohepatitis |
|
Front Immunol. 2024 Jan 11:14:1302006. doi: 10.3389/fimmu.2023.1302006. eCollection 2023
Victoria R Adams 1, Leonard B Collins 2, Taufika Islam Williams 2 3, Jennifer Holmes 4, Paul Hess 4, Hannah M Atkins 5 6, Grace Scheidemantle 1, Xiaojing Liu 1, Mareca Lodge 1, Aaron J Johnson 7, Arion Kennedy 1
|
|
|
110. | Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living with HIV and Steatotic Liver Disease |
|
Am J Gastroenterol. 2024 Feb 5. doi: 10.14309/ajg.0000000000002700. Online ahead of print.
Richard K Sterling 1, Eduardo Vilar-Gomez 2, Laura A Wilson ScM 3, Rohit Loomba 4, Samer Gawrieh 2, Jennifer Price 5, Susanna Naggie 6, Jordan E Lake 7, Sonya Heath 8, James Tonascia 3, Mark Sulkowski 3, Naga Chalasani 2; HIV-NASH CRN
|
|
|
111. | A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis |
|
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
Stephen A Harrison 1, Pierre Bedossa 1, Cynthia D Guy 1, Jörn M Schattenberg 1, Rohit Loomba 1, Rebecca Taub 1, Dominic Labriola 1, Sam E Moussa 1, Guy W Neff 1, Mary E Rinella 1, Quentin M Anstee 1, Manal F Abdelmalek 1, Zobair Younossi 1, Seth J Baum 1, Sven Francque 1, Michael R Charlton 1, Philip N Newsome 1, Nicolas Lanthier 1, Ingolf Schiefke 1, Alessandra Mangia 1, Juan M Pericàs 1, Rashmee Patil 1, Arun J Sanyal 1, Mazen Noureddin 1, Meena B Bansal 1, Naim Alkhouri 1, Laurent Castera 1, Madhavi Rudraraju 1, Vlad Ratziu 1; MAESTRO-NASH Investigators
Collaborators
MAESTRO-NASH Investigators:
John Bate, Mark Danta, Lay Gan, Jacob George, Mohammad Haque, Alexander Hodge, Nicholas Kontorinis, Christopher Leung, Stuart Roberts, Richard Skoien, Siddharth Sood, Simone Strasser, Martin Weltman, Stephanie Hametner-Schreil, Harald Hofer, Bertram Hölzl, Bernhard Ludvik, Andreas Maieron, Markus Peck-Radosavljevic, Michael Trauner, Jochen Decaestecker, Sven Francque, Anja Geerts, Sebastien Kindt, Wim Laleman, Nicolas Lanthier, Luc Lasser, Christophe Moreno, Geert Robaeys, Christophe Van Steenkiste, Harpreet Bajaj, Meredith Borman, Natasha Chandok, Magdy El Khashab, Hughie Fraser, Hin Ko, Aldo Montano-Loza, Keyur Patel, Marco Puglia, Eric Yoshida, Armando Abergel, Edouard Bardou-Jacquet, Jerome Boursier, Jean-Pierre Bronowicki, Christophe Bureau, Laurent Castera, Vincent Di Martino, François Habersetzer, Dominique Larrey, Véronique Loustaud Ratti, Isabelle Mabile-Archambeaud, Philippe Mathurin, Marianne Maynard-Muet, Eric Nguyen-Khac, Stanislas Pol, Dominique Roulot, Lawrence Serfaty, Albert Tran, Anne Varaut, Keikawus Arastéh, Katrin Arelin, Susanne Beckebaum, Christel Contzen, Münevver Demir, Yvonne Doer?el, Andreas Geier, Patrick Ingiliz, Frank Lammert, Maria Lehretz, Ingolf Schiefke, Natalia Schüte, Stefan Zeuzem, Tivadar Banyai, Miklós Lesch, Mihaly Makara, József Nemes, Tamás Nyéky, Márta Varga, István Zsolt Várkonyi, Ziv Ben-Ari, Marius Braun, Adi Francis, Helena Katchman, Yoav Lurie, Assy Nimer, Rifaat Safadi, Ella Veitsman, David Yardeni, Eli Zuckerman, Mario Angelico, Maria Del Ben, Stefano Fagiuoli,
|
|
|
112. | The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement |
|
Hepatol Commun. 2024 Feb 3;8(2):e0386. doi: 10.1097/HC9.0000000000000386.eCollection 2024 Feb 1.
Hannes Hagström 1 2, Leon A Adams 3, Alina M Allen 4, Christopher D Byrne 5 6, Yoosoo Chang 7, Ajay Duseja 8, Henning Grønbæk 9, Mona H Ismail 10 11, Peter Jepsen 9, Fasiha Kanwal 12, Jennifer Kramer 12, Rohit Loomba 13, Henry E Mark 14, Philip N Newsome 15 16, Mary E Rinella 17, Ian A Rowe 18, Seungho Ryu 7 19, Arun Sanyal 20, Jörn M Schattenberg 21, Marina Serper 22, Nick Sheron 23, Tracey G Simon 24 25, C Wendy Spearman 26, Elliot B Tapper 27, Marcela Villota-Rivas 28, Sarah H Wild 29, Vincent Wai-Sun Wong 30, Yusuf Yilmaz 31, Shira Zelber-Sagi 32 33, Fredrik Åberg 34 35, Jeffrey V Lazarus 28 36 37
|
|
|
113. | Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH |
|
Liver Int. 2024 Jan 31. doi: 10.1111/liv.15816. Online ahead of print.
Naim Alkhouri 1 2, Carl LaCerte 3, Jeffrey Edwards 3, Fred Poordad 1, Eric Lawitz 1, Lois Lee 3, Sharon Karan 3, Sangeeta Sawhney 4, Mary Erickson 3, Leigh MacConell 3, Luna Zaru 3, Jianfen Chen 3, Jason Campagna 3
|
|
|
|
|
|
|
116. | Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD |
|
Metabolism. 2024 Feb:151:155759. doi: 10.1016/j.metabol.2023.155759. Epub 2023 Dec 13.
Josh Bilson 1, Carolina J Oquendo 2, James Read 3, Eleonora Scorletti 4, Paul R Afolabi 1, Jenny Lord 2, Laure B Bindels 5, Giovanni Targher 6, Sumeet Mahajan 3, Diana Baralle 2, Philip C Calder 7, Christopher D Byrne 8, Jaswinder K Sethi 9
|
|
|
|
|
|
|
|
|
120. | Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States |
|
Aliment Pharmacol Ther. 2023 Dec 29. doi: 10.1111/apt.17849. Online ahead of print.
Samer Gawrieh 1, Eduardo Vilar-Gomez 1, Tinsay A Woreta 2, Jordan E Lake 3, Laura A Wilson 4, Jennifer C Price 5, Susanna Naggie 6, Richard K Sterling 7, Sonya Heath 8, Kathleen E Corey 9, Edward R Cachay 10, Veeral Ajmera 11, James Tonascia 4, Mark S Sulkowski 12, Naga Chalasani 1, Rohit Loomba 11 13
|
|
|
|
|
122. | Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage |
|
Liver Int. 2024 Jan;44(1):39-51. doi: 10.1111/liv.15725. Epub 2023 Sep 12.
Daniel Clayton-Chubb 1 2 3, William W Kemp 1 2, Ammar Majeed 1 2, John S Lubel 1 2 4, Robyn L Woods 5, Cammie Tran 5, Joanne Ryan 5, Alexander Hodge 3 6 7, Hans G Schneider 5 8, John J McNeil 5, Stuart K Roberts 1 2
|
|
|
123. | Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum |
|
Aliment Pharmacol Ther. 2024 Jan;59(2):201-216. doi: 10.1111/apt.17762. Epub 2023 Oct 25.
Melissa Palmer 1, David E Kleiner 2, Zachary Goodman 3, Elizabeth Brunt 4, Mark I Avigan 5, Arie Regev 6, Paul H Hayashi 7, James H Lewis 8, Ruby Mehta 9, Stephen A Harrison 10, Massimo Siciliano 11, Charles A McWherter 12, Raj Vuppalanchi 13, Cynthia Behling 14, Veronica Miller 15, Naga Chalasani 16, Arun J Sanyal 17 18
|
|
|
|
|
|
|
126. | A global action agenda for turning the tide on fatty liver disease |
|
Hepatology. 2024 Feb 1;79(2):502-523. doi: 10.1097/HEP.0000000000000545.Epub 2023 Aug 4.
Jeffrey V Lazarus 1 2 3, Henry E Mark 4 5, Alina M Allen 6, Juan Pablo Arab 7 8 9, Patrizia Carrieri 10, Mazen Noureddin 11, William Alazawi 12, Naim Alkhouri 13, Saleh A Alqahtani 14, Quentin M Anstee 15, Marco Arrese 9, Ramon Bataller 16, Thomas Berg 17, Paul N Brennan 18, Patrizia Burra 19, Graciela E Castro-Narro 20 21 22, Helena Cortez-Pinto 23, Kenneth Cusi 24, Nikos Dedes 25, Ajay Duseja 26, Sven M Francque 27 28, Amalia Gastaldelli 29, Hannes Hagström 30, Terry T K Huang 3 31, Dana Ivancovsky Wajcman 1, Achim Kautz 32, Christopher J Kopka 33, Aleksander Krag 34, Philip N Newsome 35, Mary E Rinella 36, Diana Romero 37, Shiv Kumar Sarin 38, Marcelo Silva 39, C Wendy Spearman 40, Norah A Terrault 41, Emmanuel A Tsochatzis 42, Luca Valenti 43 44, Marcela Villota-Rivas 1, Shira Zelber-Sagi 45 46, Jörn M Schattenberg 47, Vincent Wai-Sun Wong 48, Zobair M Younossi 49; on behalf of the Healthy Livers, Healthy Lives Collaborators
|
|
|
|
|
|
|
|
|
|
|
131. | Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum |
|
Aliment Pharmacol Ther. 2024 Jan;59(2):201-216. doi: 10.1111/apt.17762. Epub 2023 Oct 25.
Melissa Palmer 1, David E Kleiner 2, Zachary Goodman 3, Elizabeth Brunt 4, Mark I Avigan 5, Arie Regev 6, Paul H Hayashi 7, James H Lewis 8, Ruby Mehta 9, Stephen A Harrison 10, Massimo Siciliano 11, Charles A McWherter 12, Raj Vuppalanchi 13, Cynthia Behling 14, Veronica Miller 15, Naga Chalasani 16, Arun J Sanyal 17 18
|
|
|
132. | Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States |
|
Aliment Pharmacol Ther. 2023 Dec 29. doi: 10.1111/apt.17849. Online ahead of print.
Samer Gawrieh 1, Eduardo Vilar-Gomez 1, Tinsay A Woreta 2, Jordan E Lake 3, Laura A Wilson 4, Jennifer C Price 5, Susanna Naggie 6, Richard K Sterling 7, Sonya Heath 8, Kathleen E Corey 9, Edward R Cachay 10, Veeral Ajmera 11, James Tonascia 4, Mark S Sulkowski 12, Naga Chalasani 1, Rohit Loomba 11 13
|
|
|
|
|
134. | Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality |
|
Aliment Pharmacol Ther. 2024 Jan;59(1):80-88. doi: 10.1111/apt.17783.Epub 2023 Nov 15
Sung Won Lee 1 2, Daniel Q Huang 1 3, Ricki Bettencourt 1, Veeral Ajmera 1 4, Monica Tincopa 1 4, Nabil Noureddin 1 4, Maral Amangurbanova 1, Harris Siddiqi 1, Egbert Madamba 1, Abdul M Majzoub 5, Tarek Nayfeh 5, Nobuharu Tamaki 6, Namiki Izumi 6, Atsushi Nakajima 7, Masato Yoneda 7, Ramzan Idilman 8, Mesut Gumussoy 8, Digdem Kuru Oz 9, Ayse Erden 9, Rohit Loomba 1 4
|
|
|
135. | Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage |
|
Liver Int. 2024 Jan;44(1):39-51. doi: 10.1111/liv.15725. Epub 2023 Sep 12.
Daniel Clayton-Chubb 1 2 3, William W Kemp 1 2, Ammar Majeed 1 2, John S Lubel 1 2 4, Robyn L Woods 5, Cammie Tran 5, Joanne Ryan 5, Alexander Hodge 3 6 7, Hans G Schneider 5 8, John J McNeil 5, Stuart K Roberts 1 2
|
|
|
|
|
137. | Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study |
|
BMJ Open. 2024 Jan 18;14(1):e074918. doi: 10.1136/bmjopen-2023-074918.
Hamish Miller 1 2, David Harman 3, Guruprasad Padur Aithal 4, Pinelopi Manousou 5, Jeremy F Cobbold 6 7, Richard Parker 8, David Sheridan 9, Philip N Newsome 10, Fredrik Karpe 1, Matthew Neville 1, Wiebke Arlt 11 12, Alice J Sitch 10 13, Marta Korbonits 14, Michael Biehl 15 16, William Alazawi 2, Jeremy W Tomlinson 17
|
|
|
|
|
|
|
|
|
141. | Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study |
|
Clin Gastroenterol Hepatol. 2024 Jan;22(1):102-112.e9.doi: 10.1016/j.cgh.2023.04.011. Epub 2023 Apr 23.
Rohit Loomba 1, Arun J Sanyal 2, Atsushi Nakajima 3, Brent A Neuschwander-Tetri 4, Zachary D Goodman 5, Stephen A Harrison 6, Eric J Lawitz 7, Nadege Gunn 8, Kento Imajo 3, Natarajan Ravendhran 9, Takemi Akahane 10, Bradly Boone 11, Masayuki Yamaguchi 11, Arkendu Chatterjee 11, Giridhar S Tirucherai 11, Diane E Shevell 11, Shuyan Du 11, Edgar D Charles 12, Manal F Abdelmalek 13
|
|
|
|
|
143. | Low Health Literacy, Lack of Knowledge, and Self-Control Hinder Healthy Lifestyles in Diverse Patients with Steatotic Liver Disease |
|
Dig Dis Sci. 2023 Dec 19. doi: 10.1007/s10620-023-08212-9. Online ahead of print.
Gloria Figueroa 1 2, Stephanie Castañeda 1 2, Hayley McLean 1 2, Jasmine Dukandar 1, Shanique Wilson 3, Paul Martin 1, Sara M St George 2 4, Luis Araya-Acero 1, Patricia D Jones 5 6
|
|
|
144. | Nonalcoholic fatty liver disease, liver fibrosis, and structural brain imaging: The Cross-Cohort Collaboration |
|
Eur J Neurol. 2024 Jan;31(1):e16048. doi: 10.1111/ene.16048.Epub 2023 Aug 28
Galit Weinstein 1, Adrienne O'Donnell 2 3, Stefan Frenzel 4, Tian Xiao 5, Amber Yaqub 5, Pinar Yilmaz 6, Robert J de Knegt 7, Gladys E Maestre 8 9, Debora Melo van Lent 3 10 11, Michelle Long 12, Monica Gireud-Goss 10, Till Ittermann 13, Fabian Frost 14, Robin Bülow 15, Ramachandran S Vasan 3 16 17, Hans J Grabe 4 18, M Arfan Ikram 5 6, Alexa S Beiser 2 3 17, Sudha Seshadri 3 10 11
|
|
|
145. | Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study |
|
Clin Gastroenterol Hepatol. 2024 Jan;22(1):81-90.e4.doi: 10.1016/j.cgh.2023.06.020. Epub 2023 Jul 3.
Daniel Q Huang 1, Noora Ahlholm 2, Panu K Luukkonen 2, Kimmo Porthan 2, Maral Amangurbanova 3, Egbert Madamba 3, Richele Bettencourt 3, Harris Siddiqi 3, Vanessa Cervantes 3, Christie Hernandez 3, Scarlett J Lopez 3, Lisa Richards 3, Katriina Nemes 4, Helena Isoniemi 5, Hannele Yki-Järvinen 2, Rohit Loomba 6
|
|
|
|
|
147. | An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations |
|
Hepatology. 2023 Dec 1;78(6):1843-1857. doi: 10.1097/HEP.0000000000000474.Epub 2023 May 25.
Rotonya M Carr 1, Yun Li 2, Lillian Chau 3, Elliot S Friedman 3, Jung-Jin Lee 4, Luciano Adorini 5, Mary Erickson 5, Luna Zaru 5, Reshma Shringarpure 5, Leigh MacConell 5, Kyle Bittinger 3 4, Hongzhe Li 2, Gary D Wu 3
|
|
|
148. | Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study |
|
Hepatol Commun. 2023 Dec 22;8(1):e0325.doi: 10.1097/HC9.0000000000000325. eCollection 2024 Jan 1.
Arun J Sanyal 1, Rohit Loomba 2, Quentin M Anstee 3, Vlad Ratziu 4, Kris V Kowdley 5, Mary E Rinella 6, Stephen A Harrison 7, Murray B Resnick 8, Thomas Capozza 9, Sangeeta Sawhney 9, Nirav Shelat 9, Zobair M Younossi 10
|
|
|
149. | Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort |
|
Clin Gastroenterol Hepatol. 2023Oct;21(11):28892900.e10. doi:10.1016/j.cgh.2023.02.024.Epub 2023 Mar 5.
Arun J Sanyal 1, Breda Munoz 2, Kenneth Cusi 3, A Sidney Barritt 4th 4, Mark Muthiah 5, Andrea R Mospan 2, K Rajender Reddy 6, Roberto Firpi-Morell 7, Paul J Thuluvath 8, Kalyan Ram Bhamidimarri 9, Michael W Fried 2; TARGET-NASH Investigators
|
|
|
|
|
|
|
152. | A multisociety Delphi consensus statement on new fatty liver disease nomenclature |
|
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520.Epub 2023 Jun 24.
Mary E Rinella 1, Jeffrey V Lazarus 2 3, Vlad Ratziu 4, Sven M Francque 5 6, Arun J Sanyal 7, Fasiha Kanwal 8 9, Diana Romero 2, Manal F Abdelmalek 10, Quentin M Anstee 11 12, Juan Pablo Arab 13 14 15, Marco Arrese 15 16, Ramon Bataller 17, Ulrich Beuers 18, Jerome Boursier 19, Elisabetta Bugianesi 20, Christopher D Byrne 21 22, Graciela E Castro Narro 16 23 24, Abhijit Chowdhury 25 26, Helena Cortez-Pinto 27, Donna R Cryer 28, Kenneth Cusi 29, Mohamed El-Kassas 30, Samuel Klein 31, Wayne Eskridge 32, Jiangao Fan 33, Samer Gawrieh 34, Cynthia D Guy 35, Stephen A Harrison 36, Seung Up Kim 37, Bart G Koot 38, Marko Korenjak 39, Kris V Kowdley 40, Florence Lacaille 41, Rohit Loomba 42, Robert Mitchell-Thain 43, Timothy R Morgan 44 45, Elisabeth E Powell 46 47 48, Michael Roden 49 50 51, Manuel Romero-Gómez 52, Marcelo Silva 53, Shivaram Prasad Singh 54, Silvia C Sookoian 15 55 56, C Wendy Spearman 57, Dina Tiniakos 11 58, Luca Valenti 59 60, Miriam B Vos 61, Vincent Wai-Sun Wong 62, Stavra Xanthakos 63, Yusuf Yilmaz 64, Zobair Younossi 65 66 67, Ansley Hobbs 2, Marcela Villota-Rivas 68, Philip N Newsome 69 70; NAFLD Nomenclature consensus group
|
|
|
|
|
154. | Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality |
|
Aliment Pharmacol Ther. 2024 Jan;59(1):80-88. doi: 10.1111/apt.17783.Epub 2023 Nov 15.
Sung Won Lee 1 2, Daniel Q Huang 1 3, Ricki Bettencourt 1, Veeral Ajmera 1 4, Monica Tincopa 1 4, Nabil Noureddin 1 4, Maral Amangurbanova 1, Harris Siddiqi 1, Egbert Madamba 1, Abdul M Majzoub 5, Tarek Nayfeh 5, Nobuharu Tamaki 6, Namiki Izumi 6, Atsushi Nakajima 7, Masato Yoneda 7, Ramzan Idilman 8, Mesut Gumussoy 8, Digdem Kuru Oz 9, Ayse Erden 9, Rohit Loomba 1 4
|
|
|
|
|
|
|
|
|
|
|
|
|
160. | Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort |
|
Clin Gastroenterol Hepatol. 2023Oct;21(11):28892900.e10. doi:10.1016/j.cgh.2023.02.024.Epub 2023 Mar 5.
Arun J Sanyal 1, Breda Munoz 2, Kenneth Cusi 3, A Sidney Barritt 4th 4, Mark Muthiah 5, Andrea R Mospan 2, K Rajender Reddy 6, Roberto Firpi-Morell 7, Paul J Thuluvath 8, Kalyan Ram Bhamidimarri 9, Michael W Fried 2; TARGET-NASH Investigators
|
|
|
|
|
162. | Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis |
|
Aliment Pharmacol Ther. 2024 Jan;59(1):51-63.doi: 10.1111/apt.17734. Epub 2023 Oct 2.
Stephen A Harrison 1 2, Vlad Ratziu 3, Quentin M Anstee 4, Mazen Noureddin 5, Arun J Sanyal 6, Jörn M Schattenberg 7, Pierre Bedossa 8, Mustafa R Bashir 9, David Schneider 10, Rebecca Taub 10, Meena Bansal 11, Kris V Kowdley 12, Zobair M Younossi 13, Rohit Loomba 14
|
|
|
163. | Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH |
|
Hepatology. 2023 Oct 1;78(4):1200-1208.doi: 10.1097/HEP.0000000000000417. Epub 2023 May 1.
Jiahui Li 1, Xin Lu 1 2, Zheng Zhu 1, Kyle J Kalutkiewicz 1, Taofic Mounajjed 3, Terry M Therneau 4, Sudhakar K Venkatesh 1, Yi Sui 1, Kevin J Glaser 1, Safa Hoodeshenas 1, Armando Manduca 1, Vijay H Shah 5, Richard L Ehman 1, Alina M Allen 5, Meng Yin 1
|
|
|
|
|
165. | Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium |
|
Radiology. 2023 Oct;309(1):e231092. doi: 10.1148/radiol.231092.
Kathryn J Fowler # 1, Sudhakar K Venkatesh # 1, Nancy Obuchowski 1, Michael S Middleton 1, Jun Chen 1, Kay Pepin 1, Jessica Magnuson 1, Kathy J Brown 1, Danielle Batakis 1, Walter C Henderson 1, Sudha S Shankar 1, Tania N Kamphaus 1, Alex Pasek 1, Roberto A Calle 1, Arun J Sanyal 1, Rohit Loomba 1, Richard Ehman 1, Anthony E Samir 1, Claude B Sirlin # 1, Sarah P Sherlock # 1
|
|
|
166. | Comparison of Radiologists and Deep Learning for US Grading of Hepatic Steatosis |
|
Radiology. 2023 Oct;309(1):e230659. doi: 10.1148/radiol.230659.
Pedro Vianna 1, Sara-Ivana Calce 1, Pamela Boustros 1, Cassandra Larocque-Rigney 1, Laurent Patry-Beaudoin 1, Yi Hui Luo 1, Emre Aslan 1, John Marinos 1, Talal M Alamri 1, Kim-Nhien Vu 1, Jessica Murphy-Lavallée 1, Jean-Sébastien Billiard 1, Emmanuel Montagnon 1, Hongliang Li 1, Samuel Kadoury 1, Bich N Nguyen 1, Shanel Gauthier 1, Benjamin Therien 1, Irina Rish 1, Eugene Belilovsky 1, Guy Wolf 1, Michaël Chassé 1, Guy Cloutier 1, An Tang 1
|
|
|
|
|
|
|
169. | Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study |
|
Metabolism. 2023 Nov:148:155694.doi: 10.1016/j.metabol.2023.155694. Epub 2023 Sep 25.
Laura Valenzuela-Vallejo 1, Pavlina Chrysafi 1, Matina Kouvari 1, Valentina Guatibonza-Garcia 1, Sophia C Mylonakis 1, Angeliki Katsarou 1, Ornella Verrastro 2, Georgios Markakis 3, Mohammed Eslam 4, Georgios Papatheodoridis 3, Geltrude Mingrone 2, Jacob George 5, Christos S Mantzoros 6
|
|
|
170. | Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis |
|
Aliment Pharmacol Ther. 2023 Nov;58(10):1005-1015. doi: 10.1111/apt.17709. Epub 2023 Sep 18.
Naim Alkhouri 1, Donald Lazas 2, Rohit Loomba 3, Juan P Frias 4, Shibao Feng 5, Leo Tseng 5, Kemal Balic 5, Germaine D Agollah 5, Tinna Kwan 5, Janani S Iyer 6, Linda Morrow 7, Hank Mansbach 5, Maya Margalit 8, Stephen A Harrison 9 10
|
|
|
|
|
172. | The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis |
|
Aliment Pharmacol Ther. 2023 Nov;58(10):1062-1074. doi: 10.1111/apt.17714. Epub 2023 Sep 11.
Pojsakorn Danpanichkul 1, Cheng Han Ng 2, Mark D Muthiah 2 3, Kwanjit Duangsonk 4, Jie Ning Yong 2, Darren Jun Hao Tan 2, Wen Hui Lim 2, Zhen Yu Wong 5, Nicholas Syn 2, Tsubasa Tsusumi 6, Hirokazu Takahashi 7, Mohammad Shadab Siddiqui 8, Vincent Wai-Sun Wong 9 10, Christos S Mantzoros 11 12, Daniel Q Huang 2 3, Mazen Noureddin 13, Rohit Loomba 14 15, Arun J Sanyal 8, Karn Wijarnpreecha 16 17
|
|
|
173. | Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV |
|
AIDS. 2023 Nov 15;37(14):2149-2159.doi: 10.1097/QAD.0000000000003671. Epub 2023 Jul 27.
Jordan E Lake 1, Jana Taron 2 3, Heather J Ribaudo 4, Jorge Leon-Cruz 4, Netanya S Utay 5, Shobha Swaminathan 6, Kathleen V Fitch 7, Emma M Kileel 7, Kayla Paradis 3, Evelynne S Fulda 7, Ken S Ho 8, Anne F Luetkemeyer 9, Carrie D Johnston 10, Markella V Zanni 7, Pamela S Douglas 11, Steven K Grinspoon 7, Michael T Lu 3, Carl J Fichtenbaum 12; REPRIEVE Trial Investigators
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
181. | Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants |
|
BMC Med. 2023 Apr 3;21(1):123. doi: 10.1186/s12916-023-02793-y.
Fanny Petermann-Rocha 1 2, Michael D Wirth 3 4, Jirapitcha Boonpor 1 5, Solange Parra-Soto 1 6, Ziyi Zhou 7, John C Mathers 8, Katherine Livingstone 9, Ewan Forrest 10, Jill P Pell 7, Frederick K Ho 7, James R Hébert 4, Carlos Celis-Morales 11 12
|
|
|
|
|
|
|
184. | Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria |
|
Dig Dis Sci. 2023 Mar;68(3):1016-1025. doi: 10.1007/s10620-022-07579-5. Epub 2022 Jun 7.
Anshuman Elhence 1, Abhinav Anand 1, Sagnik Biswas 1, Manas Vaishnav 1, Rajni Yadav 2, Prasenjit Das 2, Rajesh Panwar 3, Sandeep Agarwal 4, Shivanand Gamanagatti 5, Ramesh Kumar 6, Shalimar 7
|
|
|
185. | Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial |
|
Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1080-1093.doi: 10.1016/S2468-1253(23)00272-8. Epub 2023 Oct 3.
Stephen A Harrison 1, Juan P Frias 2, Guy Neff 3, Gary A Abrams 4, K Jean Lucas 5, William Sanchez 6, Sudhanshu Gogia 7, Muhammed Y Sheikh 8, Cynthia Behling 9, Pierre Bedossa 10, Lan Shao 11, Doreen Chan 12, Erica Fong 12, Brittany de Temple 12, Reshma Shringarpure 13, Erik J Tillman 12, Timothy Rolph 12, Andrew Cheng 12, Kitty Yale 12; HARMONY Study Group
|
|
|
|
|
187. | The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories |
|
Hepatology. 2023 Sep 1;78(3):911-928. doi: 10.1097/HEP.0000000000000361.Epub 2023 Apr 18.
Jeffrey V Lazarus 1 2 3 4, Hannah Han 5, Henry E Mark 2, Saleh A Alqahtani 6, Jörn M Schattenberg 7, Joan B Soriano 8 9, Trenton M White 1, Shira Zelber-Sagi 10 11, M Ashworth Dirac 5 12; GBD Fatty Liver Disease Sustainable Development Goal Collaborators
Collaborators
- GBD Fatty Liver Disease Sustainable Development Goal Collaborators:
Amirali Aali, Mohsen Abbasi-Kangevari, Eman Abu-Gharbieh, Osama Abu-Shawer, Manik Aggarwal, Bright Opoku Ahinkorah, Aqeel Ahmad, Ali Ahmadi, Fares Alahdab, Motasem Alkhayyat, Sami Almustanyir, Hubert Amu, Amir Anoushiravani, Tahira Ashraf, Bantalem Tilaye Tilaye Atinafu, Sina Azadnajafabad, Nayereh Baghcheghi, Sara Bagherieh, Mainak Bardhan, Diana Fernanda Bejarano Ramirez, Akshaya Srikanth Bhagavathula, Neeraj Bhala, Ajay Nagesh Bhat, Mariah Malak Bilalaga, Antonio Biondi, Saeid Bitaraf, Srinivasa Rao Bolla, Antoine Boustany, Daniela Calina, Ismael R Campos-Nonato, Kumar Chattu Vijay, Sheng-Chia Chung, Daniela Contreras, Sandra Cortés, Omar B Da'ar, Omid Dadras, Xiaochen Dai, Bardia Danaei, Rupak Desai, Shirin Djalalinia, Deepa Dongarwar, Haneil Larson Dsouza, Temitope Cyrus Ekundayo, Iman El Sayed, Noha Mousaad Elemam, Mohamed A Elmonem, Aisha Elsharkawy, Sayeh Ezzikouri, Amr Farwati, Farshad Farzadfar, Ginenus Fekadu, Florian Fischer, Tushar Garg, Elena S George, Seyyed-Hadi Ghamari, Mohammad Ghasemi Nour, Amit Goel, Mahaveer Golechha, Pouya Goleij, Vivek Kumar Gupta, Parham Habibzadeh, Adel Hajj Ali, Saeed S Hamid, Harapan Harapan, Sanam Hariri, Maryam Hashemian, Abbas M Hassan, Mohammed Bheser Hassen, Simon I Hay, Yuta Hiraike, Reza Homayounfar, Mohammad-Salar Hosseini, Sedighe Hosseini Shabanan, Soodabeh Hoveidamanesh, Vivian Chia-Rong Hsieh, Junjie Huang, Salman Hussain, Segun Emmanuel Ibitoye, Olayinka Stephen Ilesanmi, Nahlah Elkudssiah Ismail, Chidozie Cd Iwu, J Linda Merin, Elham Jamshidi, Umesh Jayarajah, Shubha Jayaram, Bijay ghMukesh Jeswani, Jost B Jonas, Abel Joseph, Charity Ehimwenma Joshua, Jacek Jerzy Jozwiak, Ali Kabir, Vidya Kadashetti, Tesfaye K Kanko, Rami S Kantar, Nitin Kapoor, Ibraheem M Karaye, Joonas H Kauppila, Mohammad Keykhaei, Moien A B Khan, Min Seo Kim, Hamid Reza Koohestani, Ambily Kuttikkattu, Carlo La Vecchia, Bagher Larijani, Sang-Woong Lee, Yeong Yeh Lee, Lee-Ling Lim, Stephen S Lim, Chun-Han Lo, Stefan Lorkowski, Jamal Majidpoor, Mohammad-Reza Malekpour, Yasaman Mansoori, Miquel Martorell, Sahar Masoudi, Alexios-Fotios A Mentis, Tuomo J Meretoja, Tomislav Mestrovic, Erkin M Mirrakhimov, Awoke Misganaw, Abdollah Mohammadian-Hafshejani, Ali H Mokdad, Jibran Sualeh Muhammad, Efrén Murillo-Zamora, Christopher J L Murray, Mukhammad David Naimzada, Sreenivas Narasimha Swamy, Hasan Nassereldine, Zuhair S Natto, Robina Khan Niazi, Virginia Nuñez-Samudio, Bogdan Oancea, In-Hwan Oh, Olubunmi Omotola Oladunjoye, Antonio Olivas-Martinez, Jagadish Rao Padubidri, Beng Seoyeon Park, Harsh K Patel, Ronit Patnaik Patnaik, Venkata Suresh Patthipati, Gayatri Pemmasani, Simone Perna, Vivek Podder, Akram Pourshams, Akila Prashant, Pradhum Ram, Indu Ramachandra Rao, Sina Rashedi, Mohammad-Mahdi Rashidi, Negar Rezaei, Jefferson Antonio Buendia Rodriguez, Leonardo Roever, Gholamreza Roshandel, Bahar Saberzadeh-Ardestani, Umar Saeed, Sher Zaman Safi, Amirhossein Sahebkar, Soumya Swaroop Sahoo, Mohammad Amin Salehi, Abdallah M Samy, Senthilkumar Sankararaman, Chinmoy Sarkar, Danish Iltaf Satti, Allen Seylani, Pritik A Shah, Elaheh Shaker, Ali Shamekh, Parnian Shobeiri, Seyed Afshin Shorofi, Jasvinder A Singh, Paramdeep Singh, Md Shahjahan Siraj, Anna Aleksandrovna Skryabina, Amir Ali Sohrabpour, Keita Suzuki, Majid Taheri, Ker-Kan Tan, Samar Tharwat, Nikhil Kenny Thomas, Bereket M Tigabu, Marco Vacante, Seyed Mohammad Vahabi, Rohollah Valizadeh, Tommi Juhani Vasankari, Theo Vos, C |
|
|
|
|
|
|
|
|
|
|
192. | An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography |
|
J Hepatol. 2023 Sep;79(3):592-604. doi: 10.1016/j.jhep.2023.04.025.Epub 2023 Apr 29.
Jia-Xu Liang 1, Javier Ampuero 2, Hao Niu 3, Kento Imajo 4, Mazen Noureddin 5, Jaideep Behari 6, Dae Ho Lee 7, Richard L Ehman 8, Fredrik Rorsman 9, Johan Vessby 9, Juan R Lacalle 10, Ferenc E Mózes 11, Michael Pavlides 12, Quentin M Anstee 13, Stephen A Harrison 11, Javier Castell 14, Rohit Loomba 15, Manuel Romero-Gómez 16; LITMUS Consortium Investigators
|
|
|
|
|
194. | A global research priority agenda to advance public health responses to fatty liver disease |
|
J Hepatol. 2023 Sep;79(3):618-634. doi: 10.1016/j.jhep.2023.04.035. Epub 2023 Jun 20.
Jeffrey V Lazarus 1, Henry E Mark 2, Alina M Allen 3, Juan Pablo Arab 4, Patrizia Carrieri 5, Mazen Noureddin 6, William Alazawi 7, Naim Alkhouri 8, Saleh A Alqahtani 9, Marco Arrese 10, Ramon Bataller 11, Thomas Berg 12, Paul N Brennan 13, Patrizia Burra 14, Graciela E Castro-Narro 15, Helena Cortez-Pinto 16, Kenneth Cusi 17, Nikos Dedes 18, Ajay Duseja 19, Sven M Francque 20, Hannes Hagström 21, Terry T-K Huang 22, Dana Ivancovsky Wajcman 23, Achim Kautz 24, Christopher J Kopka 25, Aleksander Krag 26, Veronica Miller 27, Philip N Newsome 28, Mary E Rinella 29, Diana Romero 30, Shiv Kumar Sarin 31, Marcelo Silva 32, C Wendy Spearman 33, Emmanuel A Tsochatzis 34, Luca Valenti 35, Marcela Villota-Rivas 23, Shira Zelber-Sagi 36, Jörn M Schattenberg 37, Vincent Wai-Sun Wong 38, Zobair M Younossi 39; Healthy Livers, Healthy Lives Collaborators
Collaborators
- Healthy Livers, Healthy Lives Collaborators:
Jeffrey V Lazarus, Henry E Mark, Alina M Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A Alqahtani, Marco Arrese, Ramon Bataller, Thomas Berg, Paul N Brennan, Patrizia Burra, Graciela E Castro-Narro, Helena Cortez-Pinto, Kenneth Cusi, Nikos Dedes, Ajay Duseja, Sven M Francque, Hannes Hagström, Terry T-K Huang, Dana Ivancovsky Wajcman, Achim Kautz, Christopher J Kopka, Aleksander Krag, Veronica Miller, Philip N Newsome, Mary E Rinella, Diana Romero, Shiv Kumar Sarin, Marcelo Silva, C Wendy Spearman, Emmanuel A Tsochatzis, Luca Valenti, Marcela Villota-Rivas, Shira Zelber-Sagi, Jörn M Schattenberg, Vincent Wai-Sun Wong, Zobair M Younossi, Fredrik Aberg, Leon Adams, Khalid Al-Naamani, Reda M Albadawy, Zinaida Alexa, Michael Allison, Faisal A Alnaser, Khalid Alswat, Mario Reis Alvares-da-Silva, Domenico Alvaro, Michele Alves-Bezerra, Raul J Andrade, Quentin M Anstee, Yaw Asante Awuku, Oidov Baatarkhuu, Gyorgy Baffy, Shokhista Bakieva, Meena B Bansal, Robert Barouki, Rachel L Batterham, Cynthia Behling, Renata Belfort-DeAguiar, Annalisa Berzigotti, Michael Betel, Cristiana Bianco, Emanuele Bosi, Jerome Boursier, Elizabeth M Brunt, Elisabetta Bugianesi, Christopher J Byrne, Maria Cecilia Cabrera Cabrejos, Stephen Caldwell, Rotonya Carr, Marlen Ivón Castellanos Fernández, Laurent Castera, Maria Gabriela Castillo-López, Cyrielle Caussy, Eira Cerda-Reyes, Antonio Ceriello, Wah-Kheong Chan, Yoosoo Chang, Phunchai Charatcharoenwitthaya, Norberto Chavez-Tapia, Raymond T Chung, Massimo Colombo, Kirsten Coppell, Helma P Cotrim, Antonio Craxi, Javier Crespo, Anuradha Dassanayake, Nicholas O Davidson, Robert De Knegt, Victor de Ledinghen, Münevver Demir, Hailemichael Desalegn, Moises Diago, John F Dillon, Bruce Dimmig, M Ashworth Dirac, Melisa Dirchwolf, Jean-François Dufour, Karel Dvorak, Mattias Ekstedt, Mohamed El-Kassas, Osama M Elsanousi, Ahmed M Elsharkawy, Reda Elwakil, Wayne Eskridge, Mohammed Eslam, Gamal Esmat, Jian-Gao Fan, Maria Lucia Ferraz, Robert Flisiak, Davide Fortin, Yasser Fouad, Scott L Freidman, Michael Fuchs, Adrian Gadano, Amalia Gastaldelli, Anja Geerts, Andreas Geier, Jacob George, Lynn H Gerber, Hasmik Ghazinyan, Liana Gheorghe, Denise Giangola Kile, Marcos Girala, George Goh Boon Bee, Nicolas Goossens, Isabel Graupera, Henning Grønbæk, Saeed Hamid, Vanessa Hebditch, Zachary Henry, Ingrid J Hickman, L Ansley Hobbs, Samantha L Hocking, Wolf Peter Hofmann, Ramazan Idilman, Paula Iruzubieta, Scott Isaacs, Vasily A Isakov, Mona H Ismail, Mohammad H Jamal, Helen Jarvis, Peter Jepsen, François Jornayvaz, K C Sudhamshu, Satoru Kakizaki, Saul Karpen, Takumi Kawaguchi, Shelley E Keating, Yousef Khader, Seung Up Kim, Won Kim, David E Kleiner, Ger Koek, Narcisse Patrice Joseph Komas, Loreta A Kondili, Bart G Koot, Marko Korenjak, Eleni Kotsiliti, Yiannoula Koulla, Carina Kugelmas, Marcelo Kugelmas, Asma Labidi, Naomi F Lange, Joel E Lavine, Mariana Lazo, Nathalie Leite, Han-Chieh Lin, Undram Lkhagvaa, Michelle T Long, Patricio Lopez-Jaramillo, Adelina Lozano, Maria Paula Macedo, Reza Malekzadeh, Giulio Marchesini, Sebastian Marciano, Kim Martinez, Sophia E Martínez Vázquez, Lyudmila Mateva, José M Mato, Charles Mbendi Nlombi, Alexis Gorden McCary, Jeff McIntyre, Martin McKee, Juan M Mendive, Ivana Mikolasevic, Pamela S Miller, Tamara Milovanovic, Terri Milton, Rosalba Moreno-Alcantar, Timothy R Morgan, Ayesha Motala, Jean Muris, Carla Musso, Edna J Nava-González, Francesco Negro, Alexander V Nersesov, Brent A Neuschwander-Tetri, Dafina Nikolova, Suzanne Norris, Katja Novak, Ponsiano Ocama, Janus P Ong, Arlinking Ong-Go, Charles Onyekwere, Martin Padilla, Raluca Pais, Calvin Pan, Arturo Panduro, Manas K Panigrahi, Georgios Papatheodoridis, Imran Paruk, Keyur Patel, Carlos Penha Gonçalves, Marlene Pérez Figueroa, Juanita Pérez-Escobar, Juan M Pericàs, Gianluca Perseghin, Mário Guimarães Pessoa, Salvatore Petta, Claudia Pinto Marques Souza de Oliveira, Dorairaj Prabhakaran, Nikolaos Pyrsopoulous, Atoosa Rabiee, Alnoor Ramji, Vlad Ratziu, Natarajan Ravendhran, Katrina Ray, Michael Roden, Stefano Romeo, Manuel Romero-Gómez, Yaron Rotman, Samir Rouabhia, Ian A Rowe, Shakhlo Sadirova, Maryam Salem Alkhatry, Riina Salupere, Sanjaya K Satapathy, Jeffrey B Schwimmer, Giada Sebastiani, Lynn Seim, Yosuke Seki, Abdel Karim Serme, David Shapiro, Lali Sharvadze, Jonathan E Shaw, Isaac Thom Shawa, Thrivikrama Shenoy, Oren Shibolet, Yusuke Shimakawa, Jay H Shubrook, Shivaram Prasad Singh, Edford Sinkala, Lubomir Skladany, Igor Skrypnyk, Myeong Jun Song, Silvia Sookoian, Kannan Sridharan, Norbert Stefan, Jonathan G Stine, Nikolaos Stratakis, Dhastagir Sultan Sheriff, Shikha S Sundaram, Gianluca Svegliati-Baroni, Mark G Swain, Frank Tacke, Shahrad Taheri, Soek-Siam Tan, Elliot B Tapper, Giovanni Targher, Eugen Tcaciuc, Maja Thiele, Dina Tiniakos, Ieva Tolmane, Aldo Torre, Esther A Torres, Sombat Treeprasertsuk, Michael Trenell, Svetlana Turcan, Adela Turcanu, Jonas Valantinas, Laurens A van Kleef, Jose Antonio Velarde Ruiz Velasco, Mette Vesterhus, Eduardo Vilar-Gomez, Imam Waked, Julia Wattacheril, Heiner Wedemeyer, Fonda Wilkins, José Willemse, Robert J Wong, Yusuf Yilmaz, Hannele Yki-Järvinen, Ming-Lung Yu, Volkan Yumuk, Müjdat Zeybel, Kenneth I Zheng, Ming-Hua Zheng
|
|
|
195. | Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization |
|
Cancer Epidemiol Biomarkers Prev. 2023 Sep 1;32(9):1265-1269.doi: 10.1158/1055-9965.EPI-23-0453.
Sontoria D King # 1, Swathi Veliginti # 2, Martijn C G J Brouwers 3 4, Zhewen Ren 3 4, Wei Zheng 5, Veronica W Setiawan 6, Lynne R Wilkens 7, Xiao-Ou Shu 5, Alan A Arslan 8, Laura E Beane Freeman 9, Paige M Bracci 10, Federico Canzian 11, Mengmeng Du 12, Steven J Gallinger 13 14, Graham G Giles 15 16 17, Phyllis J Goodman 18, Christopher A Haiman 6, Manolis Kogevinas 19, Charles Kooperberg 20, Loic LeMarchand 7 7, Rachel E Neale 21, Kala Visvanathan 22 23, Emily White 24, Demetrius Albanes 9, Gabriella Andreotti 9, Ana Babic 25, Sonja I Berndt 9, Lauren K Brais 25, Paul Brennan 26, Julie E Buring 27 28, Kari G Rabe 29, William R Bamlet 29, Stephen J Chanock 9, Charles S Fuchs 30 31 32, J Michael Gaziano 28 33, Edward L Giovannucci 27 34 35, Thilo Hackert 36, Manal M Hassan 37, Verena Katzke 38, Robert C Kurtz 39, I-Min Lee 27 28, Núria Malats 40, Neil Murphy 41, Ann L Oberg 29, Irene Orlow 12, Miquel Porta 42, Francisco X Real 43, Nathaniel Rothman 9, Howard D Sesso 27 28, Debra T Silverman 9, Ian M Thompson 44, Jean Wactawski-Wende 45, Xiaoliang Wang 24, Nicolas Wentzensen 9, Herbert Yu 7, Anne Zeleniuch-Jacquotte 46, Kai Yu 9, Brian M Wolpin 25, Eric J Duell 47, Donghui Li 37, Rayjean J Hung 48, Sandra Perdomo 26, Marjorie L McCullough 49, Neal D Freedman 9, Alpa V Patel 49, Ulrike Peters 20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
202. | A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials |
|
J Hepatol. 2023 Sep;79(3):829-841. doi: 10.1016/j.jhep.2023.03.014.Epub 2023 Mar 29.
Raluca Pais 1, Bertrand Cariou 2, Mazen Noureddin 3, Sven Francque 4, Jörn M Schattenberg 5, Manal F Abdelmalek 6, Gadi Lalazar 7, Sharat Varma 8, Julie Dietrich 9, Veronica Miller 10, Arun Sanyal 11, Vlad Ratziu 12; Liver Forum NAFLD-Associated Comorbidities Working Group
|
|
|
|
|
204. | NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study |
|
Hepatol. 2023 Sep;79(3):758-767. doi: 10.1016/j.jhep.2023.04.031. Epub 2023 May 22.
Stephen A Harrison 1, Vlad Ratziu 2, Jeremy Magnanensi 3, Yacine Hajji 4, Sylvie Deledicque 4, Zouher Majd 4, Christian Rosenquist 4, Dean W Hum 4, Bart Staels 5, Quentin M Anstee 6, Arun J Sanyal 7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
211. | Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons |
|
Hepatol. 2023 Aug;79(2):287-295. doi: 10.1016/j.jhep.2023.03.040.Epub 2023 Apr 9.
Michael H Le 1, David M Le 2, Thomas C Baez 2, Yuankai Wu 3, Takanori Ito 4, Eunice Y Lee 5, KeeSeok Lee 6, Christopher D Stave 7, Linda Henry 5, Scott D Barnett 5, Ramsey Cheung 8, Mindie H Nguyen 9
|
|
|
|
|
|
|
|
|
|
|
216. | Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH |
|
N Engl J Med. 2023 Sep 14;389(11):998-1008. doi: 10.1056/NEJMoa2304286.Epub 2023 Jun 24.
Rohit Loomba 1, Arun J Sanyal 1, Kris V Kowdley 1, Deepak L Bhatt 1, Naim Alkhouri 1, Juan P Frias 1, Pierre Bedossa 1, Stephen A Harrison 1, Donald Lazas 1, Robert Barish 1, Mildred D Gottwald 1, Shibao Feng 1, Germaine D Agollah 1, Cynthia L Hartsfield 1, Hank Mansbach 1, Maya Margalit 1, Manal F Abdelmalek 1
|
|
|
217. | Dissecting the role of cadmium, lead, arsenic, and mercury in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
|
Environ Res. 2023 Sep 13;238(Pt 1):117134. doi: 10.1016/j.envres.2023.117134.Online ahead of print.
Alexey A Tinkov 1, Michael Aschner 2, Abel Santamaria 3, Alfred R Bogdanov 4, Yousef Tizabi 5, Miriam B Virgolini 6, Ji-Chang Zhou 7, Anatoly V Skalny 8
|
|
|
|
|
|
|
|
|
|
|
|
|
223. | HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia |
|
J Hepatol. 2023 Aug;79(2):378-393. doi: 10.1016/j.jhep.2023.03.041. Epub 2023 Apr 13.
Davide Povero 1, Yongbin Chen 2, Scott M Johnson 2, Cailin E McMahon 2, Meixia Pan 3, Hanmei Bao 3, Xuan-Mai T Petterson 4, Emily Blake 5, Kimberly P Lauer 5, Daniel R O'Brien 5, Yue Yu 5, Rondell P Graham 6, Timucin Taner 7, Xianlin Han 8, Gina L Razidlo 9, Jun Liu 10
|
|
|
|
|
|
|
|
|
227. | Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease |
|
PLoS One. 2023 Jul 14;18(7):e0288598.doi: 10.1371/journal.pone.0288598. eCollection 2023.
Daniel Bradshaw 1, Iga Abramowicz 2, Stephen Bremner 2 3, Sumita Verma 3, Yvonne Gilleece 1, Sarah Kirk 1, Mark Nelson 4, Rosalie Housman 4, Helena Miras 5, Chloe Orkin 5, Ashini Fox 6, Michael Curnock 6, Louise Jennings 7, Mark Gompels 7, Emily Clarke 8, Rachel Robinson 8, Pauline Lambert 9, David Chadwick 9, Nicky Perry 2
|
|
|
|
|
|
|
230. | Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study |
|
Lancet Gastroenterol Hepatol. 2023 Aug;8(8):714-725.doi: 10.1016/S2468-1253(23)00017-1. Epub 2023 Mar 21.
Yasaman Vali 1, Jenny Lee 1, Jerome Boursier 2, Salvatore Petta 3, Kristy Wonders 4, Dina Tiniakos 5, Pierre Bedossa 4, Andreas Geier 6, Sven Francque 7, Mike Allison 8, Georgios Papatheodoridis 9, Helena Cortez-Pinto 10, Raluca Pais 11, Jean-Francois Dufour 12, Diana Julie Leeming 13, Stephen A Harrison 14, Yu Chen 15, Jeremy F Cobbold 16, Michael Pavlides 17, Adriaan G Holleboom 18, Hannele Yki-Jarvinen 19, Javier Crespo 20, Morten Karsdal 13, Rachel Ostroff 21, Mohammad Hadi Zafarmand 1, Richard Torstenson 22, Kevin Duffin 15, Carla Yunis 23, Clifford Brass 24, Mattias Ekstedt 25, Guruprasad P Aithal 26, Jörn M Schattenberg 27, Elisabetta Bugianesi 28, Manuel Romero-Gomez 29, Vlad Ratziu 11, Quentin M Anstee 30, Patrick M Bossuyt 1; Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators
|
|
|
|
|
232. | 100 years of glucagon and 100 more |
|
Diabetologia. 2023 Aug;66(8):1378-1394. doi: 10.1007/s00125-023-05947-y.Epub 2023 Jun 27.
Nicolai J Wewer Albrechtsen 1 2, Jens J Holst 3 4, Alan D Cherrington 5, Brian Finan 6, Lise Lotte Gluud 7 8, E Danielle Dean 5 9, Jonathan E Campbell 10 11 12, Stephen R Bloom 13, Tricia M-M Tan 13, Filip K Knop 7 14 15, Timo D Müller 16 17
|
|
|
233. | Non-Alcoholic fatty liver disease (NAFLD) and Cardiovascular Risk: Is Imaging helpful? |
|
Curr Probl Cardiol. 2023 Aug 29;102065. doi: 10.1016/j.cpcardiol.2023.102065.Online ahead of print.
Stavros A Doumas 1, Shalini Tripathi 2, Aditi Kashikar 3, Akhilesh Khuttan 2, Ashwin Kumar 1, Harjit Singh 1, Justin P Canakis 4, Kumar Ashish 2, Debashish Dey 5, Ian Oppenheim 1, Amit Kumar Dey 6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
245. | An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis |
|
J Pediatr Gastroenterol Nutr. 2023 Aug 1;77(2):160-165.doi: 10.1097/MPG.0000000000003796. Epub 2023 Apr 21.
Nidhi P Goyal 1 2, Ali Mencin 3, Kimberly P Newton 1 2, Janis Durelle 1, Carissa Carrier 1, Patricia Ugalde-Nicalo 1, Benoit Noel 1, Julie Mouton 1, Dawn Vargas 4, David Magrez 1, Bachirou Tadde 1, Pascal Birman 1, Brookie M Best 5 6, Carol Addy 4, Jeffrey B Schwimmer 1 2
|
|
|
246. | Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial |
|
Am J Gastroenterol. 2023 Aug 1;118(8):1365-1372.doi: 10.14309/ajg.0000000000002143. Epub 2022 Dec 14.
Masaya Sato 1 2, Masatoshi Akamatsu 3, Toshihide Shima 4, Tadashi Ikegami 5, Mikio Yanase 6, Shintaro Mikami 6, Jun Imamura 7, Takuma Nakatsuka 1, Ryosuke Tateishi 1, Naoko Yamauchi 8, Tetsuo Ushiku 8, Takeshi Okanoue 4, Mitsuhiro Fujishiro 1, Eisuke Hida 9, Kazuhiko Koike 1
|
|
|
247. | A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study |
|
Contemp Clin Trials. 2023 Jul;130:107176. doi: 10.1016/j.cct.2023.107176.Epub 2023 Apr 5.
Manal F Abdelmalek 1, Ayako Suzuki 2, Willian Sanchez 3, Eric Lawitz 4, Claudia Filozof 5, Hyungjin Cho 6, Eunhye Baek 6, JaeDuk Choi 6, Seungjae Baek 6
|
|
|
248. | Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis |
|
Clin Gastroenterol Hepatol. 2023 Jul;21(7):1750-1760.e12.doi: 10.1016/j.cgh.2022.06.029. Epub 2022 Jul 19.
Ansel Tang 1, Cheng Han Ng 2, Poh Hui Phang 1, Kai En Chan 1, Yip Han Chin 1, Clarissa Elysia Fu 1, Rebecca Wenling Zeng 1, Jieling Xiao 1, Darren Jun Hao Tan 1, Jingxuan Quek 1, Wen Hui Lim 1, Lung Yi Mak 3, Jiong-Wei Wang 4, Nicholas W S Chew 5, Nicholas Syn 1, Daniel Q Huang 6, Mohammad Shadab Siddiqui 7, Arun Sanyal 7, Mark Muthiah 6, Mazen Noureddin 8
|
|
|
249. | Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease |
|
J Hepatol. 2023 Aug;79(2):277-286. doi: 10.1016/j.jhep.2023.04.002.Epub 2023 Apr 21.
Maria Kjaergaard 1, Katrine Prier Lindvig 1, Katrine Holtz Thorhauge 1, Peter Andersen 2, Johanne Kragh Hansen 1, Nanna Kastrup 3, Jane Møller Jensen 2, Camilla Dalby Hansen 1, Stine Johansen 1, Mads Israelsen 2, Nikolaj Torp 1, Morten Beck Trelle 4, Shan Shan 5, Sönke Detlefsen 6, Steen Antonsen 7, Jørgen Ellegaard Andersen 8, Isabel Graupera 9, Pere Ginés 9, Maja Thiele 10, Aleksander Krag 11
|
|
|
|
|
|
|
|
|
|
|
|
|
255. | Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States |
|
Metabolism. 2023 Sep;146:155642. doi: 10.1016/j.metabol.2023.155642. Epub 2023 Jun 26.
Pegah Golabi 1, James M Paik 1, Ameeta Kumar 2, Reem Al Shabeeb 2, Kathrine E Eberly 2, Kenneth Cusi 3, Nagashree GunduRao 4, Zobair M Younossi 5
|
|
|
|
|
|
|
258. | Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis |
|
Lancet Gastroenterol Hepatol. 2023 Aug;8(8):704-713.doi: 10.1016/S2468-1253(23)00141-3. Epub 2023 Jun 5.
Ferenc E Mózes 1, Jenny A Lee 2, Yasaman Vali 2, Osama Alzoubi 3, Katharina Staufer 4, Michael Trauner 5, Rafael Paternostro 5, Rudolf E Stauber 6, Adriaan G Holleboom 7, Anne-Marieke van Dijk 7, Anne Linde Mak 7, Jérôme Boursier 8, Marc de Saint Loup 9, Toshihide Shima 10, Elisabetta Bugianesi 11, Silvia Gaia 11, Angelo Armandi 11, Shalimar 12, Monica Lup?or-Platon 13, Vincent Wai-Sun Wong 14, Guanlin Li 14, Grace Lai-Hung Wong 14, Jeremy Cobbold 15, Thomas Karlas 16, Johannes Wiegand 16, Giada Sebastiani 17, Emmanuel Tsochatzis 18, Antonio Liguori 19, Masato Yoneda 20, Atsushi Nakajima 20, Hannes Hagström 21, Camilla Akbari 22, Masashi Hirooka 23, Wah-Kheong Chan 24, Sanjiv Mahadeva 24, Ruveena Rajaram 24, Ming-Hua Zheng 25, Jacob George 26, Mohammed Eslam 26, Salvatore Petta 27, Grazia Pennisi 27, Mauro Viganò 28, Sofia Ridolfo 29, Guruprasad Padur Aithal 30, Naaventhan Palaniyappan 30, Dae Ho Lee 31, Mattias Ekstedt 32, Patrik Nasr 32, Christophe Cassinotto 33, Victor de Lédinghen 34, Annalisa Berzigotti 35, Yuly P Mendoza 36, Mazen Noureddin 37, Emily Truong 38, Céline Fournier-Poizat 39, Andreas Geier 40, Miljen Martic 41, Theresa Tuthill 42, Quentin M Anstee 43, Stephen A Harrison 1, Patrick M Bossuyt
|
|
|
|
|
|
|
|
|
262. | Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study |
|
Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000439. Online ahead of print.
Quentin M Anstee 1, Kathryn J Lucas 2, Sven Francque 3 4 5, Manal F Abdelmalek 6, Arun J Sanyal 7, Vlad Ratziu 8, Adrian C Gadano 9, Mary Rinella 10, Michael Charlton 11, Rohit Loomba 12, Edward Mena 13, Jörn M Schattenberg 14, Mazen Noureddin 15, Donald Lazas 16, George Bb Goh 17, Shiv Kumar Sarin 18, Yusuf Yilmaz 19 20, Miljen Martic 21, Rowan Stringer 21, Jossy Kochuparampil 21, Li Chen 22, Gerardo Rodriguez-Araujo 23, Elaine Chng 24, Nikolai V Naoumov 21, Clifford Brass 22, Marcos C Pedrosa 21
|
|
|
|
|
|
|
|
|
266. | Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL) |
|
Mol Metab. 2023 Jul;73:101728. doi: 10.1016/j.molmet.2023.101728. Epub 2023 Apr 19.
Gabriele Mocciaro 1, Michael Allison 2, Benjamin Jenkins 3, Vian Azzu 4, Isabel Huang-Doran 2, Luis Vicente Herrera-Marcos 5, Zoe Hall 6, Antonio Murgia 7, Davies Susan 2, Mattia Frontini 8, Antonio Vidal-Puig 3, Albert Koulman 9, Julian L Griffin 10, Michele Vacca 11
|
|
|
|
|
|
|
|
|
270. | High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold |
|
Diabetes Care. 2023 Jul 1;46(7):1354-1362. doi: 10.2337/dc22-2048.
Laurent Castera 1 2, Cédric Laouenan 3 4, Anaïs Vallet-Pichard 5, Tiphaine Vidal-Trécan 6, Pauline Manchon 4, Valérie Paradis 1 7, Dominique Roulot 8 9, Nathalie Gault 4, Christian Boitard 10 11, Benoit Terris 10 12, Hélène Bihan 13 14, Jean-Baptiste Julla 6 15, Alina Radu 16, Thierry Poynard 17 18 19, Angélique Brzustowsky 20, Etienne Larger 10 11, Sébastien Czernichow 16 21, Stanislas Pol 5 10, Pierre Bedossa 1 22, Dominique Valla 1 2, Jean-François Gautier 6 15; QUID-NASH investigators
Collaborators
Christophe Junot, Bernard Van Beers, Christian Boitard, Nathalie de Préville, Isabelle Durand Zaleski, Pierre-Emmanuel Rautou, Marco Dioguardi, Valérie Vilgrain, Jean-Pierre Riveline
|
|
|
|
|
|
|
|
|
274. | Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes |
|
Hepatology. 2023 Jul 1;78(1):195-211. doi: 10.1097/HEP.0000000000000351.Epub 2023 Mar 17.
Grazia Pennisi 1, Marco Enea 1, Vincenzo Falco 2, Guruprasad P Aithal 3 4, Naaventhan Palaniyappan 3 4, Yusuf Yilmaz 5, Jerome Boursier 6 7, Christophe Cassinotto 8, Victor de Lédinghen 9, Wah Kheong Chan 10, Sanjiv Mahadeva 10, Peter Eddowes 3 4, Philip Newsome 3 4, Thomas Karlas 11, Johannes Wiegand 11, Vincent Wai-Sun Wong 12, Jörn M Schattenberg 13 14, Christian Labenz 13 14, Won Kim 15, Myoung Seok Lee 15, Monica Lupsor-Platon 16, Jeremy F L Cobbold 17, Jian-Gao Fan 18, Feng Shen 18, Katharina Staufer 19 20, Michael Trauner 19, Rudolf Stauber 21, Atsushi Nakajima 22, Masato Yoneda 22, Elisabetta Bugianesi 23, Ramy Younes 23, Silvia Gaia 23, Ming-Hua Zheng 24 25, Calogero Cammà 1 2, Quentin M Anstee 26 27, Ferenc E Mózes 28, Michael Pavlides 17 28, Salvatore Petta 1 2
|
|
|
275. | US Quantification of Liver Fat: Past, Present, and Future |
|
Radiographics. 2023 Jul;43(7):e220178. doi: 10.1148/rg.220178.
David T Fetzer 1, Theodore T Pierce 1, Michelle L Robbin 1, Guy Cloutier 1, Arjmand Mufti 1, Timothy J Hall 1, Anil Chauhan 1, Reinhard Kubale 1, An Tang 1
|
|
|
|
|
277. | Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence |
|
Hepatol Int. 2023 Jun;17(3):584-594. doi: 10.1007/s12072-022-10469-7. Epub 2023 Feb 3.
Phillip E Melton 1 2, M A Burton 3, K A Lillycrop 4 5, K M Godfrey 5 6, S Rauschert 7, D Anderson 7, G C Burdge 8, T A Mori 9, L J Beilin 9, O T Ayonrinde 9 10, J M Craig 11 12, J K Olynyk 10 13, J D Holbrook 6, C E Pennell 14, W H Oddy 15, E K Moses 15 16, L A Adams 9, R C Huang 7
|
|
|
278. | Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study |
|
BMJ Open. 2023 Jul 3;13(7):e070431.doi: 10.1136/bmjopen-2022-070431.
Willy B Theel 1 2 3, Bianca M Boxma-de Klerk 4 5, Femme Dirksmeier-Harinck 6, Elisabeth Fc van Rossum 2 3, Danny A Kanhai 7, Jan A Apers 8, Bas M van Dalen 9, Robert J De Knegt 10, Bojou Neecke 11, Ellen M van der Zwan 12, Diederick E Grobbee 13, Thomas Hankemeier 14, Janneke Wiebolt 2, Manuel Castro Cabezas 3 15
|
|
|
279. | A multi-society Delphi consensus statement on new fatty liver disease nomenclature |
|
J Hepatol. 2023 Jun 20;S0168-8278(23)00418-X. doi: 10.1016/j.jhep.2023.06.003.Online ahead of print.
Mary E Rinella 1, Jeffrey V Lazarus 2, Vlad Ratziu 3, Sven M Francque 4, Arun J Sanyal 5, Fasiha Kanwal 6, Diana Romero 7, Manal F Abdelmalek 8, Quentin M Anstee 9, Juan Pablo Arab 10, Marco Arrese 11, Ramon Bataller 12, Ulrich Beuers 13, Jerome Boursier 14, Elisabetta Bugianesi 15, Christopher Byrne 16, Graciela E Castro Narro 17, Abhijit Chowdhury 18, Helena Cortez-Pinto 19, Donna Cryer 20, Kenneth Cusi 21, Mohamed El-Kassas 22, Samuel Klein 23, Wayne Eskridge 24, Jiangao Fan 25, Samer Gawrieh 26, Cynthia D Guy 27, Stephen A Harrison 28, Seung Up Kim 29, Bart Koot 30, Marko Korenjak 31, Kris Kowdley 32, Florence Lacaille 33, Rohit Loomba 34, Robert Mitchell-Thain 35, Timothy R Morgan 36, Elisabeth Powell 37, Michael Roden 38, Manuel Romero-Gómez 39, Marcelo Silva 40, Shivaram Prasad Singh 41, Silvia C Sookoian 42, C Wendy Spearman 43, Dina Tiniakos 44, Luca Valenti 45, Miriam B Vos 46, Vincent Wai-Sun Wong 47, Stavra Xanthakos 48, Yusuf Yilmaz 49, Zobair Younossi 50, Ansley Hobbs 7, Marcela Villota-Rivas 51, Philip N Newsome 52; NAFLD Nomenclature consensus group
Collaborators
NAFLD Nomenclature consensus group:
Veeral Ajmeral, William Alazawi, Maryam Alkhatry, Naim Alkhouri, Alina Allen, Michael Allison, Khalid Alswat, Mario R Alvares-da-Silva, Michele Alves-Bezerra, Matthew J Armstrong, Diego Arufe, Pablo Aschner, Gyorgy Baffy, Meena Bansal, Pierre Bedossa, Renata Belfort, Thomas Berg, Annalisa Berzigotti, Michael Betel, Cristiana Bianco, Clifford Brass, Carol L Brosgart< |
|
|
280. | Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study |
|
Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000470. Online ahead of print.
Beom Kyung Kim 1 2, Jaclyn Bergstrom 1, Rohan Loomba 1, Nobuharu Tamaki 1 3, Namiki Izumi 3, Atsushi Nakajima 4, Ramazan Idilman 5, Mesut Gumussoy 5, Digdem Kuru Oz 6, Ayse Erden 6, Emily Truong 7, Ju Dong Yang 7, Mazen Noureddin 7, Alina M Allen 8, Rohit Loomba 1 9, Veeral Ajmera 1
|
|
|
|
|
|
|
|
|
|
|
285. | The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study |
|
Hepatology. 2023 Jun 1;77(6):2063-2072. doi: 10.1097/HEP.0000000000000286.Epub 2023 Jan 19.
Heidi S Ahmed 1, Na Wang 2, J Jeffrey Carr 3, Jingzhong Ding 4, James G Terry 3, Lisa B VanWagner 5 6, Lifang Hou 6, Yuankai Huo 7, Joseph Palmisano 2, Yinan Zheng 6, Emelia J Benjamin 8, Michelle T Long 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
292. | Fibro-Scope V1.0.1: an artificial intelligence/neural network system for staging of nonalcoholic steatohepatitis |
|
Hepatol Int. 2023 Jun;17(3):573-583. doi: 10.1007/s12072-022-10454-0. Epub 2022 Dec 21.
Kanji Yamaguchi 1, Toshihide Shima 2, Yasuhide Mitsumoto 2, Yuya Seko 1, Atsushi Umemura 3, Yoshito Itoh 1, Atsushi Nakajima 4, Shuichi Kaneko 5, Kenichi Harada 6, Timothy Watkins 7, Takeshi Okanoue 8
|
|
|
|
|
|
|
|
|
|
|
|
|
298. | Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis |
|
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1523-1532.e1. doi: 10.1016/j.cgh.2022.03.044.Epub 2022 Apr 11.
Federica Tavaglione 1, Oveis Jamialahmadi 2, Antonio De Vincentis 3, Sami Qadri 4, Mohammad Erfan Mowlaei 5, Rosellina Margherita Mancina 2, Ester Ciociola 2, Simone Carotti 6, Giuseppe Perrone 7, Vincenzo Bruni 8, Ida Francesca Gallo 8, Dario Tuccinardi 9, Cristiana Bianco 10, Daniele Prati 10, Silvia Manfrini 9, Paolo Pozzilli 9, Antonio Picardi 11, Marco Caricato 12, Hannele Yki-Järvinen 4, Luca Valenti 13, Umberto Vespasiani-Gentilucci 14, Stefano Romeo 15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
309. | Does the Mediterranean Diet Have Any Effect on Lipid Profile, Central Obesity and Liver Enzymes in Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects? A Systematic Review and Meta-Analysis of Randomized Control Trials |
|
Nutrients. 2023 May 9;15(10):2250. doi: 10.3390/nu15102250.
Cristian Del Bo' 1, Simone Perna 1, Sabika Allehdan 2, Ayesha Rafique 2, Sara Saad 2, Fahad AlGhareeb 2, Mariangela Rondanelli 3 4, Reema F Tayyem 5, Mirko Marino 1, Daniela Martini 1, Patrizia Riso 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
316. | AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD |
|
Clin Gastroenterol Hepatol. 2023 May;21(5):1293-1302.e5. doi: 10.1016/j.cgh.2022.06.013.Epub 2022 Jul 14.
Grazia Pennisi 1, Marco Enea 1, Alessandra Pandolfo 1, Ciro Celsa 1, Michela Antonucci 2, Carlo Ciccioli 1, Giuseppe Infantino 1, Claudia La Mantia 1, Stefanie Parisi 1, Adele Tulone 1, Vito Di Marco 1, Antonio Craxì 1, Calogero Cammà 1, Salvatore Petta 3
|
|
|
|
|
|
|
|
|
320. | Physicians' Use of Digital Health Interventions in the Management of Nonalcoholic Fatty Liver Disease |
|
Clin Liver Dis. 2023 May;27(2):515-533. doi: 10.1016/j.cld.2023.01.021.
Jeffrey V Lazarus 1, Marcela Villota-Rivas 2, Carolina Jiménez-González 3, Alvaro Santos-Laso 3, Paula Iruzubieta 3, María Teresa Arias-Loste 3, Lisa Rice-Duek 4, Simon Leigh 5, Christopher J Kopka 6, Juan Turnes 7, José Luis Calleja 8, Javier Crespo 3
|
|
|
|
|
|
|
|
|
|
|
325. | Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study |
|
J Diabetes Complications. 2023 Jun;37(6):108475.doi: 10.1016/j.jdiacomp.2023.108475. Epub 2023 Apr 12.
Karen D Corbin 1, Anastassios G Pittas 2, Cyrus Desouza 3, Kristine K Grdinovac 4, Karl-Heinz Herzig 5, Sangeeta R Kashyap 6, Sun H Kim 7, Jason Nelson 2, Neda Rasouli 8, Ellen M Vickery 2, William C Knowler 9, Richard E Pratley 1
|
|
|
|
|
|
|
328. | Diet and Exercise Exert a Differential Effect on Glucose Metabolism Markers According to the Degree of NAFLD Severity |
|
Nutrients. 2023 May 10;15(10):2252. doi: 10.3390/nu15102252.
Antonella Bianco 1, Isabella Franco 1, Ritanna Curci 1, Caterina Bonfiglio 1, Angelo Campanella 1, Antonella Mirizzi 1, Fabio Fucilli 2, Giuseppe Di Giovanni 2, Nicola Giampaolo 2, Pasqua Letizia Pesole 3, Alberto Ruben Osella 1
|
|
|
|
|
330. | Rising NAFLD and metabolic severity during the Sars-CoV-2 pandemic among children with obesity in the United States |
|
Obesity (Silver Spring). 2023 May;31(5):1383-1391. doi: 10.1002/oby.23728.
Aaron L Slusher 1, Pamela Hu 1, Stephanie Samuels 1, Fuyuze Tokoglu 2, Jessica Lat 1, Zhongyao Li 1, Michele Alguard 1, Jordan Strober 3, Daniel Vatner 3, Veronika Shabanova 1, Sonia Caprio 1
|
|
|
|
|
332. | Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1) |
|
J Hepatol. 2023 May;78(5):914-925. doi: 10.1016/j.jhep.2023.02.004.Epub 2023 Feb 18.
Stephen A Harrison 1, Carole Thang 2, Sébastien Bolze 2, Sheila Dewitt 3, Sophie Hallakou-Bozec 4, Julie Dubourg 2, Pierre Bedossa 5, Kenneth Cusi 6, Vlad Ratziu 7, Jean-Marie Grouin 8, David E Moller 2, Pascale Fouqueray 2
|
|
|
333. | Postprandial dysfunction in fatty liver disease |
|
Physiol Rep. 2023 Apr;11(8):e15653. doi: 10.14814/phy2.15653.
Josephine Grandt 1 2, Anne-Sofie H Jensen 1 2, Mikkel P Werge 1, Elias B Rashu 1, Andreas Møller 1, Anders E Junker 1, Lise Hobolth 1, Christian Mortensen 1, Christian D Johansen 2 3, Mogens Vyberg 4 5, Reza Rafiolsadat Serizawa 4, Søren Møller 6 7, Lise Lotte Gluud 1 7, Nicolai J Wewer Albrechtsen 2 3
|
|
|
|
|
335. | Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial |
|
Lancet. 2023 May 27;401(10390):1786-1797.doi: 10.1016/S0140-6736(23)00634-7. Epub 2023 Apr 21.
Ornella Verrastro 1, Simona Panunzi 2, Lidia Castagneto-Gissey 3, Andrea De Gaetano 2, Erminia Lembo 1, Esmeralda Capristo 4, Caterina Guidone 5, Giulia Angelini 1, Francesco Pennestrì 5, Luca Sessa 5, Fabio Maria Vecchio 6, Laura Riccardi 4, Maria Assunta Zocco 4, Ivo Boskoski 4, James R Casella-Mariolo 7, Pierluigi Marini 7, Maurizio Pompili 4, Giovanni Casella 5, Enrico Fiori 3, Francesco Rubino 8, Stefan R Bornstein 9, Marco Raffaelli 4, Geltrude Mingrone 10
|
|
|
|
|
|
|
|
|
|
|
340. | Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH |
|
Cell Rep Med. 2023 Apr 18;4(4):101016. doi: 10.1016/j.xcrm.2023.101016.
Jake Conway 1, Maryam Pouryahya 1, Yevgeniy Gindin 2, David Z Pan 2, Oscar M Carrasco-Zevallos 1, Victoria Mountain 1, G Mani Subramanian 3, Michael C Montalto 1, Murray Resnick 1, Andrew H Beck 1, Ryan S Huss 3, Robert P Myers 3, Amaro Taylor-Weiner 1, Ilan Wapinski 4, Chuhan Chung 5
|
|
|
341. | Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis |
|
Hepatology. 2023 Apr 1;77(4):1348-1365. doi: 10.1002/hep.32731. Epub 2022 Sep 16.
Dimitri Loureiro 1 2, Issam Tout 1 2, Stéphanie Narguet 1 2, Cheikh Mohamed Bed 1 2, Morgane Roinard 1 2, Ahmad Sleiman 1 2, Nathalie Boyer 1 2, Nathalie Pons-Kerjean 3, Corinne Castelnau 1 2, Nathalie Giuly 1 2, Dorothy Tonui 1 2, Vassili Soumelis 4 5, Jamel El Benna 1, Patrick Soussan 6, Richard Moreau 1 2, Valérie Paradis 1 2, Abdellah Mansouri 1 2, Tarik Asselah 1 2
|
|
|
342. | Research Priorities for Precision Medicine in NAFLD |
|
Clin Liver Dis. 2023 May;27(2):535-551. doi: 10.1016/j.cld.2023.01.016.Epub 2023 Feb 26.
Paula Iruzubieta 1, Ramon Bataller 2, María Teresa Arias-Loste 1, Marco Arrese 3, José Luis Calleja 4, Graciela Castro-Narro 5, Kenneth Cusi 6, John F Dillon 7, María Luz Martínez-Chantar 8, Miguel Mateo 9, Antonio Pérez 10, Mary E Rinella 11, Manuel Romero-Gómez 12, Jörn M Schattenberg 13, Shira Zelber-Sagi 14, Javier Crespo 15, Jeffrey V Lazarus 16
|
|
|
|
|
344. | Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography |
|
Ultraschall Med. 2023 Apr;44(2):169-178. doi: 10.1055/a-1724-7289.Epub 2022 Feb 28.
David Jm Bauer 1 2, Vladimir Matic 3, Ruxandra Mare 4, Laura Maiocchi 5, David Chromy 1 2, Theresa Müllner-Bucsics 1 2, Mattias Mandorfer 1 2, Sandra Mustapic 3, Ioan Sporea 6, Giovanna Ferraioli 5, Ivica Grgurevic 3, Thomas Reiberger 1 2 7
|
|
|
|
|
|
|
347. | Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis |
|
Gut. 2023 Mar;72(3):581-589. doi: 10.1136/gutjnl-2022-327777. Epub 2022 Sep 9.
Rohit Loomba 1 2, Daniel Q Huang 2 3 4, Arun J Sanyal 5, Quentin Mark Anstee 6, Michael Trauner 7, Eric J Lawitz 8, Dora Ding 9, Lily Ma 9, Catherine Jia 9, Andrew Billin 9, Ryan S Huss 9, Chuhan Chung 9, Zachary Goodman 10, Vincent Wai-Sun Wong 11, Takeshi Okanoue 12, Manuel Romero-Gómez 13, Manal F Abdelmalek 14, Andrew Muir 15, Nezam Afdhal 16, Jaime Bosch 17, Stephen Harrison 18 19, Zobair M Younossi 20, Robert P Myers 9
|
|
|
348. | Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants |
|
Am J Gastroenterol. 2023 Apr 1;118(4):645-653.doi: 10.14309/ajg.0000000000002042. Epub 2022 Sep 30.
Phoebe Wen Lin Tay 1, Cheng Han Ng 1, Snow Yunni Lin 1, Yip Han Chin 1, Jieling Xiao 1, Wen Hui Lim 1, Sze Yinn Lim 1, Clarissa Elysia Fu 1, Kai En Chan 1, Jingxuan Quek 1, Darren Jun Hao Tan 1, Nicholas Chew 2, Nicholas Syn 1, Taisei Keitoku 3, Nobuharu Tamaki 3, Mohammad Shadab Siddiqui 4, Mazen Noureddin 5, Mark Muthiah 1 6 7, Daniel Q Huang 1 6 7, Rohit Loomba 8
|
|
|
|
|
|
|
|
|
|
|
353. | Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants |
|
BMC Med. 2023 Apr 3;21(1):123. doi: 10.1186/s12916-023-02793-y.
Fanny Petermann-Rocha 1 2, Michael D Wirth 3 4, Jirapitcha Boonpor 1 5, Solange Parra-Soto 1 6, Ziyi Zhou 7, John C Mathers 8, Katherine Livingstone 9, Ewan Forrest 10, Jill P Pell 7, Frederick K Ho 7, James R Hébert 4, Carlos Celis-Morales 11 12
|
|
|
|
|
|
|
|
|
357. | Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial |
|
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):511-522.doi: 10.1016/S2468-1253(23)00068-7. Epub 2023 Mar 16.
Rohit Loomba 1, Manal F Abdelmalek 2, Matthew J Armstrong 3, Maximilian Jara 4, Mette Skalshøi Kjær 4, Niels Krarup 4, Eric Lawitz 5, Vlad Ratziu 6, Arun J Sanyal 7, Jörn M Schattenberg 8, Philip N Newsome 3; NN9931-4492 investigators
|
|
|
|
|
359. | American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease |
|
Hepatol Commun. 2023 Mar 30;7(4):e0108. doi: 10.1097/HC9.0000000000000108.eCollection 2023 Apr 1.
Jonathan G Stine 1 2, Michelle T Long 3, Kathleen E Corey 4, Robert E Sallis 5, Alina M Allen 6, Matthew J Armstrong 7, David E Conroy 8, Daniel J Cuthbertson 9, Andres Duarte-Rojo 10, Kate Hallsworth 11, Ingrid J Hickman 12, Matthew R Kappus 13, Shelley E Keating 14, Christopher J A Pugh 15, Yaron Rotman 16, Tracey G Simon 4, Eduardo Vilar-Gomez 17, Vincent Wai-Sun Wong 18, Kathryn H Schmitz 2
|
|
|
|
|
361. | Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease |
|
J Hepatol. 2023 Apr;78(4):693-703. doi: 10.1016/j.jhep.2022.11.029.Epub 2022 Dec 14.
Arun J Sanyal 1, Stephen A Williams 2, Joel E Lavine 3, Brent A Neuschwander-Tetri 4, Leigh Alexander 5, Rachel Ostroff 2, Hannah Biegel 5, Kris V Kowdley 6, Naga Chalasani 7, Srinivasan Dasarathy 8, Anna Mae Diehl 9, Rohit Loomba 10, Bilal Hameed 11, Cynthia Behling 10, David E Kleiner 12, Saul J Karpen 13, Jessica Williams 14, Yi Jia 2, Katherine P Yates 15, James Tonascia 15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
369. | NAFLD and NASH Biomarker Qualification in the LITMUS consortium - Lessons learned |
|
Hepatol. 2022 Dec 13;S0168-8278(22)03325-6. doi: 10.1016/j.jhep.2022.11.028.Online ahead of print.
Daniel Guldager Kring Rasmussen 1, Quentin M Anstee 2, Richard Torstenson 3, Bruno Golding 4, Scott D Patterson 5, Clifford Brass 6, Paresh Thakker 7, Stephen Harrison 8, Andrew N Billin 5, Detlef Schuppan 9, Jean-François Dufour 10, Anneli Andersson 11, Ioan Wigley 11, Elizabeth Shumbayawonda 11, Andrea Dennis 11, Corinna Schoelch 12, Vlad Ratziu 13, Carla Yunis 14, Patrick Bossuyt 15, Morten Asser Karsdal 16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
378. | The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance |
|
Hepatol Commun. 2023 Feb 1;7(2):e0033. doi: 10.1097/HC9.0000000000000033.
Ryan M Gill 1, Daniela Allende 2, Patricia H Belt 3, Cynthia A Behling 4, Oscar W Cummings 5, Cynthia D Guy 6, Daniela Carpenter 7, Brent A Neuschwander-Tetri 8, Arun J Sanyal 9, James Tonascia 3, Mark L Van Natta 3, Laura A Wilson 3, Goro Yamada 3, Matthew Yeh 10, David E Kleiner 11; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
|
|
|
|
|
|
|
|
|
382. | The Effects of Eight Weeks' Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity |
|
Nutrients. 2023 Feb 6;15(4):825. doi: 10.3390/nu15040825.
Roberta Rinaldi 1, Sara De Nucci 1, Fabio Castellana 2, Martina Di Chito 1, Vito Giannuzzi 3, Endrit Shahini 3, Roberta Zupo 2, Luisa Lampignano 2, Giuseppina Piazzolla 4, Vincenzo Triggiani 4, Raffaele Cozzolongo 3, Gianluigi Giannelli 5, Giovanni De Pergola 1
|
|
|
|
|
|
|
|
|
|
|
387. | Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trials |
|
Aliment Pharmacol Ther. 2023 May;57(9):948-961. doi: 10.1111/apt.17456.Epub 2023 Mar 14.
Juan M Pericàs 1, Nicholas A Di Prospero 2, Quentin M Anstee 3 4, Peter Mesenbrinck 5, Mette S Kjaer 6, Jesús Rivera-Esteban 1, Franz Koenig 7, Elena Sena 1, Raluca Pais 8, Ramiro Manzano 1, Joan Genescà 1, Frank Tacke 9, Vlad Ratziu 8; EU-PEARL NASH Investigators
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
402. | Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis |
|
Hepatology. 2023 Feb 1;77(2):546-557. doi: 10.1002/hep.32655. Epub 2022 Aug 9.
Devon Chang 1, Emily Truong 2, Edward A Mena 3, Fabiana Pacheco 3, Micaela Wong 3, Maha Guindi 4, Tsuyoshi T Todo 5, Nabil Noureddin 6, Walid Ayoub 2 5 7, Ju Dong Yang 2 5 7, Irene K Kim 5, Anita Kohli 8, Naim Alkhouri 8, Stephen Harrison 9, Mazen Noureddin 2 5 7
|
|
|
|
|
404. | Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores |
|
J Hepatol. 2023 Feb;78(2):247-259. doi: 10.1016/j.jhep.2022.10.034. Epub 2022 Nov 12.
Arun J Sanyal 1, Julie Foucquier 2, Zobair M Younossi 3, Stephen A Harrison 4, Philip N Newsome 5, Wah-Kheong Chan 6, Yusuf Yilmaz 7, Victor De Ledinghen 8, Charlotte Costentin 9, Ming-Hua Zheng 10, Vincent Wai-Sun Wong 11, Magdy Elkhashab 12, Ryan S Huss 13, Robert P Myers 13, Marine Roux 14, Aymeric Labourdette 2, Marie Destro 2, Céline Fournier-Poizat 15, Véronique Miette 2, Laurent Sandrin 2, Jérôme Boursier 16
|
|
|
405. | A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes |
|
J Hepatol. 2023 Mar;78(3):471-478. doi: 10.1016/j.jhep.2022.11.010. Epub 2022 Nov 19.
Veeral Ajmera 1, Sandra Cepin 2, Kaleb Tesfai 2, Heather Hofflich 3, Karen Cadman 4, Scarlett Lopez 2, Egbert Madamba 2, Ricki Bettencourt 2, Lisa Richards 2, Cynthia Behling 5, Claude B Sirlin 6, Rohit Loomba 7
|
|
|
406. | Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial |
|
Nat Med. 2023 Feb;29(2):392-400. doi: 10.1038/s41591-022-02200-8.Epub 2023 Feb 16.
Arun J Sanyal 1, Patricia Lopez 2, Eric J Lawitz 3, Kathryn J Lucas 4, Juergen Loeffler 2, Won Kim 5, George B B Goh 6, Jee-Fu Huang 7, Carla Serra 8, Pietro Andreone 9 10, Yi-Cheng Chen 11, Stanley H Hsia 12, Vlad Ratziu 13, Diego Aizenberg 14, Hiroshi Tobita 15, Aasim M Sheikh 16, John M Vierling 17, Yoon Jun Kim 18, Hideyuki Hyogo 19 20, Dean Tai 21, Zachary Goodman 22, Felicity Schaefer 23, Ian R I Carbarns 2, Sophie Lamle 2, Miljen Martic 2, Nikolai V Naoumov 2, Clifford A Brass 23
|
|
|
407. | Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH |
|
Hepatol Commun. 2023 Mar 17;7(4):e0052.doi: 10.1097/HC9.0000000000000052. eCollection 2023 Apr 1.
Jonathan G Stine 1 2 3 4, Gloriany Rivas 1, Breianna Hummer 1, Andres Duarte-Rojo 5, Christine N May 6, Nathaniel Geyer 2, Vernon M Chinchilli 2, David E Conroy 7, Ellen Siobhan Mitchell 6, Meaghan McCallum 6, Andreas Michealides 6, Kathryn H Schmitz 4 7 8
|
|
|
|
|
409. | Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis |
|
J Hepatol. 2023 Feb;78(2):238-246.doi: 10.1016/j.jhep.2022.10.027. Epub 2022 Nov 8.
Wei Shen 1, Michael S Middleton 2, Guilherme M Cunha 3, Timoteo I Delgado 2, Tanya Wolfson 4, Anthony Gamst 5, Kathryn J Fowler 2, Adina Alazraki 6, Andrew T Trout 7, Michael A Ohliger 8, Shetal N Shah 9, Mustafa R Bashir 10, David E Kleiner 11, Rohit Loomba 12, Brent A Neuschwander-Tetri 13, Arun J Sanyal 14, Jane Zhou 15, Claude B Sirlin 2, Joel E Lavine 16
|
|
|
|
|
411. | A prolonged fast improves overnight substrate oxidation without modulating hepatic glycogen in adults with and without nonalcoholic fatty liver: A randomized crossover trial |
|
Obesity (Silver Spring). 2023 Mar;31(3):757-767.doi: 10.1002/oby.23676. Epub 2023 Feb 9.
Kay H M Roumans 1, Anna Veelen 1, Charlotte Andriessen 1, Julian Mevenkamp 1 2, Esther Kornips 1, Pandichelvam Veeraiah 1 2, Bas Havekes 1 3, Harry P F Peters 4, Lucas Lindeboom 1 2, Patrick Schrauwen 1, Vera B Schrauwen-Hinderling 1 2 5
|
|
|
412. | An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD |
|
Clin Gastroenterol Hepatol. 2023 Mar;21(3):619-629.e7.doi: 10.1016/j.cgh.2021.11.038. Epub 2021 Dec 4.
Grace En Hui Lim 1, Ansel Tang 2, Cheng Han Ng 2, Yip Han Chin 2, Wen Hui Lim 2, Darren Jun Hao Tan 2, Jie Ning Yong 2, Jieling Xiao 2, Chloe Wen-Min Lee 2, Mark Chan 3, Nicholas Ws Chew 4, Eunice Xiang Xuan Tan 5, Mohammad Shadab Siddiqui 6, Daniel Huang 5, Mazen Noureddin 7, Arun J Sanyal 6, Mark D Muthiah 8
|
|
|
|
|
414. | Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP) |
|
Pharmacol Res. 2023 Mar;189:106679. doi: 10.1016/j.phrs.2023.106679.Epub 2023 Feb 8.
Manfredi Rizzo 1, Alessandro Colletti 2, Peter E Penson 3, Niki Katsiki 4, Dimitri P Mikhailidis 5, Peter P Toth 6, Ioanna Gouni-Berthold 7, John Mancini 8, David Marais 9, Patrick Moriarty 10, Massimiliano Ruscica 11, Amirhossein Sahebkar 12, Dragos Vinereanu 13, Arrigo Francesco Giuseppe Cicero 14, Maciej Banach 15; International Lipid Expert Panel (ILEP)
|
|
|
|
|
|
|
|
|
|
|
419. | Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium |
|
Clin Gastroenterol Hepatol. 2023 Feb;21(2):445-455.e2. doi: 10.1016/j.cgh.2022.02.028.Epub 2022 Feb 18.
Mary E Rinella 1, Sanjaya K Satapathy 2, Danielle Brandman 3, Coleman Smith 4, Sal Elwir 5, Jonathan Xia 6, Meg Gibson 6, Carlos Figueredo 7, Mounika Angirekula 8, Jason M Vanatta 9, Raiya Sarwar 10, Yu Jiang 9, Dyanna Gregory 6, Tandy Agostini 4, JimIn Ko 4, Pradeep Podila 11, Grace Gallo 6, Kymberly D Watt 8, Mohammad S Siddiqui 12
|
|
|
|
|
421. | Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies |
|
Oncologist. 2023 Feb 10;oyac251. doi: 10.1093/oncolo/oyac251. Online ahead of print.
Surendra Pal Chaudhary 1, Stephanie Reyes 2, Matthew L Chase 3, Aparna Govindan 4, Lei Zhao 5, Jay Luther 6, Irun Bhan 6, Emily Bethea 6, Joseph W Franses 1, Elizabeth Paige Walsh 1, Leigh Anne Dageford 7, Shoko Kimura 7, Nahel Elias 7, Heidi Yeh 7, James Markman 7, Adel Bozorgzadeh 7, Kenneth Tanabe 8, Cristina Ferrone 8, Andrew X Zhu 9, Karin Andersson 6, Michael Thiim 6, Onofrio Antonio Catalano 10, Avinash Kambadakone 10, Parsia A Vagefi 11, Motaz Qadan 8, Daniel Pratt 6, Nikroo Hashemi 12, Kathleen E Corey 6, Joseph Misdraji 13, Lipika Goyal 1, Jeffrey W Clark 1
|
|
|
422. | Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis |
|
Curr Probl Cardiol. 2023 Feb 10;48(6):101643. doi: 10.1016/j.cpcardiol.2023.101643.Online ahead of print.
Giandomenico Bisaccia 1, Fabrizio Ricci 2, Mohammed Y Khanji 3, Anna Sorella 1, Eugenia Melchiorre 1, Giovanni Iannetti 1, Kristian Galanti 1, Cesare Mantini 1, Andrea Delli Pizzi 4, Claudio Tana 5, Giulia Renda 1, Artur Fedorowski 6, Raffaele De Caterina 7, Sabina Gallina 1
|
|
|
|
|
|
|
425. | Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature |
|
J Gastroenterol Hepatol. 2023 Feb;38(2):269-273. doi: 10.1111/jgh.16049.Epub 2022 Nov 16.
Ashraf Almomani 1, Prabhat Kumar 1, Somtochukwu Onwuzo 1, Antoine Boustany 1, Eduard Krishtopaytis 1, Asif Hitawala 2, Dana Alshaikh 3, Almaza Albakri 4, Leen Hussein 5, Ebrahim Hussein 5, Imad Asaad 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
433. | Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat |
|
Clin Gastroenterol Hepatol. 2023 Jan;21(1):143-152.e3.doi: 10.1016/j.cgh.2021.12.044. Epub 2022 Jan 6.
Eric J Lawitz 1, Bal Raj Bhandari 2, Peter J Ruane 3, Anita Kohli 4, Eliza Harting 5, Dora Ding 5, Jen-Chieh Chuang 5, Ryan S Huss 5, Chuhan Chung 5, Robert P Myers 5, Rohit Loomba 6
|
|
|
|
|
|
|
|
|
437. | A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis |
|
JHEP Rep. 2022 Aug 23;5(1):100563. doi: 10.1016/j.jhepr.2022.100563. eCollection 2023 Jan.
Stephen A Harrison 1, Peter J Ruane 2, Bradley Freilich 3, Guy Neff 4, Rashmee Patil 5, Cynthia Behling 6, Chen Hu 7, Reshma Shringarpure 8, Brittany de Temple 8, Erica Fong 8, Erik J Tillman 8, Timothy Rolph 8, Andrew Cheng 8, Kitty Yale 8
|
|
|
|
|
439. | A multistakeholder approach to innovations in NAFLD care |
|
Commun Med (Lond)\. 2023 Jan 3;3(1):1. doi: 10.1038/s43856-022-00228-y.
Jörn M Schattenberg 1, Alina M Allen 2, Helen Jarvis 3, Shira Zelber-Sagi 4 5, Ken Cusi 6, John F Dillon 7, Cyrielle Caussy 8 9, Sven M Francque 10 11, Zobair Younossi 12, Naim Alkhouri 13, Jeffrey V Lazarus 14 15 16
|
|
|
440. | Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis |
|
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30.doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16.
Jingxuan Quek 1, Kai En Chan 1, Zhen Yu Wong 2, Caitlyn Tan 1, Bryan Tan 1, Wen Hui Lim 1, Darren Jun Hao Tan 1, Ansel Shao Pin Tang 1, Phoebe Tay 1, Jieling Xiao 1, Jie Ning Yong 1, Rebecca Wenling Zeng 1, Nicholas W S Chew 3, Benjamin Nah 4, Anand Kulkarni 5, Mohammad Shadab Siddiqui 6, Yock Young Dan 7, Vincent Wai-Sun Wong 8, Arun J Sanyal 6, Mazen Noureddin 9, Mark Muthiah 10, Cheng Han Ng 1
|
|
|
|
|
|
|
443. | Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials |
|
Clin Gastroenterol Hepatol. 2023 Jan;21(1):90-102.e6.doi: 10.1016/j.cgh.2022.01.015. Epub 2022 Jan 22.
Vincent Wai-Sun Wong 1, Won Young Tak 2, George Boon Bee Goh 3, Pin-Nan Cheng 4, Eric J Lawitz 5, Zobair M Younossi 6, Raj Vuppalanchi 7, Ziad Younes 8, Naim Alkhouri 9, Lulu Wang 10, Jialuo Liu 10, Kathryn Kersey 10, Robert P Myers 10, Stephen A Harrison 11, Zachary Goodman 6, Michael Trauner 12, Manuel Romero-Gomez 13, Quentin M Anstee 14, Mindie H Nguyen 15, Takeshi Okanoue 16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455. | High-Intensity Interval Training is Safe, Feasible and Efficacious in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial |
|
Dig Dis Sci. 2022 Dec 20;1-17. doi: 10.1007/s10620-022-07779-z. Online ahead of print.
Shelley E Keating 1, Ilaria Croci 2 3 4, Matthew P Wallen 5 6, Emily R Cox 7, Moe Thuzar 8 9, Uyen Pham 10 11 12, Gregore I Mielke 13, Jeff S Coombes 2, Graeme A Macdonald 12 14, Ingrid J Hickman 12 15
|
|
|
456. | A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis |
|
Aliment Pharmacol Ther. 2023 Feb;57(3):304-312. doi: 10.1111/apt.17346. Epub 2022 Dec 13.
Zobair Younossi 1 2 3, Naim Alkhouri 4, Ken Cusi 5, Scott Isaacs 6, Fasiha Kanwal 7, Mazen Noureddin 8, Rohit Loomba 9, Natarajan Ravendhran 10, Brian Lam 2 3, Khalil Nader 11 12, Andrei Racila 2 3 12, Fatema Nader 12, Linda Henry 2 3 12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
464. | Upper gut heat shock proteins HSP70 and GRP78 promote insulin resistance, hyperglycemia, and non-alcoholic steatohepatitis |
|
Nat Commun. 2022 Dec 13;13(1):7715. doi: 10.1038/s41467-022-35310-5.
Giulia Angelini 1 2, Lidia Castagneto-Gissey 3, Serenella Salinari 4, Alessandro Bertuzzi 5, Danila Anello 1, Meenakshi Pradhan 6, Marlen Zschätzsch 7 8, Paul Ritter 9, Carel W Le Roux 10, Francesco Rubino 11, Nicola Basso 3, Giovanni Casella 3, Stefan R Bornstein 12 13, Valentina Tremaroli 6, Geltrude Mingrone 14 15 16
|
|
|
|
|
|
|
|
|
|
|
469. | Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis |
|
Clin Pharmacol Ther. 2022 Dec;112(6):1271-1279. doi: 10.1002/cpt.2745.Epub 2022 Sep 27.
Atoosa Rabiee # 1, Martha D Gay # 2, Narayan Shivapurkar 2, Hong Cao 2, Sandeep Nadella 3, Coleman I Smith 3, James H Lewis 3, Sunil Bansal 2, Amrita Cheema 2, John Kwagyan 4, Jill P Smith 1 2
|
|
|
|
|
471. | Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment |
|
J Clin Transl Hepatol. 2023 Apr 28;11(2):502-515. doi: 10.14218/JCTH.2022.00204.Epub 2022 Dec 23.
Ankoor H Patel 1 2, Dhiraj Peddu 1 2, Sahil Amin 1 2, Mohamed I Elsaid 3 4, Carlos D Minacapelli 1 2, Toni-Marie Chandler 1 2, Carolyn Catalano 1 2, Vinod K Rustgi 1 2
|
|
|
472. | Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey |
|
Curr Probl Cardiol. 2022 Dec;47(12):101333. doi: 10.1016/j.cpcardiol.2022.101333.Epub 2022 Jul 25.
Abdul Mannan Khan Minhas 1, Vardhmaan Jain 2, Muhammad Haisum Maqsood 3, Ambarish Pandey 4, Sadiya S Khan 5, Marat Fudim 6, Gregg C Fonarow 7, Javed Butler 8, Muhammad Shahzeb Khan 9
|
|
|
473. | Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial |
|
Ann Intern Med. 2023 Jan;176(1):10-21. doi: 10.7326/M22-1787.Epub 2022 Dec 13.
Camilla Dalby Hansen 1, Eva-Marie Gram-Kampmann 2, Johanne Kragh Hansen 3, Mie Balle Hugger 1, Bjørn Stæhr Madsen 3, Jane Møller Jensen 3, Sara Olesen 3, Nikolaj Torp 1, Ditlev Nytoft Rasmussen 3, Maria Kjærgaard 1, Stine Johansen 1, Katrine Prier Lindvig 4, Peter Andersen 3, Katrine Holtz Thorhauge 1, Jan Christian Brønd 5, Pernille Hermann 6, Henning Beck-Nielsen 2, Sönke Detlefsen 7, Torben Hansen 8, Kurt Højlund 2, Maja Sofie Thiele 1, Mads Israelsen 3, Aleksander Krag 9
|
|
|
474. | SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum |
|
J Gastroenterol. 2022 Dec 5;1-19. doi: 10.1007/s00535-022-01932-1.Online ahead of print.
Yoshihiro Kamada 1, Takahiro Nakamura 2, Satoko Isobe 3, Kumiko Hosono 4, Yukiko Suama 5, Yukie Ohtakaki 6, Arihito Nauchi 7, Naoto Yasuda 8, Soh Mitsuta 3, Kouichi Miura 9, Takuma Yamamoto 10, Tatsunori Hosono 11, Akihiro Yoshida 12, Ippei Kawanishi 13, Hideaki Fukushima 14, Masao Kinoshita 15, Atsushi Umeda 16, Yuichi Kinoshita 17, Kana Fukami 18, Toshio Miyawaki 5, Hideki Fujii 19, Yuichi Yoshida 20, Miwa Kawanaka 21, Hideyuki Hyogo 22 23, Asahiro Morishita 24, Hideki Hayashi 25, Hiroshi Tobita 26, Kengo Tomita 27, Tadashi Ikegami 28, Hirokazu Takahashi 29, Masato Yoneda 30, Dae Won Jun 31, Yoshio Sumida 32, Takeshi Okanoue 33, Atsushi Nakajima 30; JANIT Forum
|
|
|
|
|
|
|
477. | Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study |
|
Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132.doi: 10.1016/S2468-1253(22)00347-8. Epub 2022 Dec 12.
Rohit Loomba 1, Eric J Lawitz 2, Juan Pablo Frias 3, Grisell Ortiz-Lasanta 4, Lars Johansson 5, Bridgette Boggess Franey 6, Linda Morrow 7, Moti Rosenstock 8, Cynthia L Hartsfield 9, Chao-Yin Chen 9, Leo Tseng 9, R Will Charlton 9, Hank Mansbach 9, Maya Margalit 10
|
|
|
478. | Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial |
|
Cell Metab. 2023 Jan 3;35(1):56-70.e3.doi: 10.1016/j.cmet.2022.12.001. Epub 2022 Dec 21.
Mark Ezpeleta 1, Kelsey Gabel 1, Sofia Cienfuegos 1, Faiza Kalam 1, Shuhao Lin 1, Vasiliki Pavlou 1, Zhenyuan Song 1, Jacob M Haus 2, Sean Koppe 3, Shaina J Alexandria 4, Lisa Tussing-Humphreys 1, Krista A Varady 5
|
|
|
|
|
480. | A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers |
|
Panminerva Med. 2022 Dec;64(4):485-496.doi: 10.23736/S0031-0808.22.04590-6. Epub 2022 Apr 19.
Nuria Perez-Diaz-Del-Campo 1, Jose I Riezu-Boj 1 2, Bertha A Marin-Alejandre 1, J Ignacio Monreal 2 3, Mariana Elorz 2 4, José I Herrero 2 5 6, Alberto Benito-Boillos 2 4, Fermín I Milagro 1 2 7, Elisabetta Bugianesi 8, Josep A Tur 7 9, J Alfredo Martinez 10 2 7, Itziar Abete 1 2 7, M Angeles Zulet 1 2 7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
496. | NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity? |
|
Semin Liver Dis. 2022 Nov;42(4):465-474. doi: 10.1055/s-0042-1757712.Epub 2022 Oct 14.
Bing Chen 1, W H Wilson Tang 2, Mario Rodriguez 3, Kathleen E Corey 4, Arun J Sanyal 5, Patrick S Kamath 6, Biykem Bozkurt 7, Hafeez Ul Hassan Virk 8, Gregg S Pressman 9, Jeffrey V Lazarus 10 11, Hashem B El-Serag 12 13, Chayakrit Krittanawong 14
|
|
|
|
|
|
|
499. | Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization |
|
Radiology. 2022 Nov;305(2):265-276. doi: 10.1148/radiol.212808.Epub 2022 Sep 13.
David T Fetzer # 1, Ivan M Rosado-Mendez # 1, Michael Wang 1, Michelle L Robbin 1, Arinc Ozturk 1, Keith A Wear 1, Juvenal Ormachea 1, Timothy A Stiles 1, J Brian Fowlkes 1, Timothy J Hall 1, Anthony E Samir 1
|
|
|
|
|
501. | Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis |
|
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2451-2461.e3.doi: 10.1016/j.cgh.2021.09.041. Epub 2021 Oct 7.
Anneli Andersson 1, Matt Kelly 1, Kento Imajo 2, Atsushi Nakajima 2, Jonathan A Fallowfield 3, Gideon Hirschfield 4, Michael Pavlides 5, Arun J Sanyal 6, Mazen Noureddin 7, Rajarshi Banerjee 1, Andrea Dennis 8, Stephen Harrison 9
|
|
|
|
|
|
|
|
|
505. | Multiomics study of nonalcoholic fatty liver disease |
|
Nat Genet. 2022 Nov;54(11):1652-1663. doi: 10.1038/s41588-022-01199-5. Epub 2022 Oct 24.
Gardar Sveinbjornsson # 1, Magnus O Ulfarsson # 2 3, Rosa B Thorolfsdottir 2, Benedikt A Jonsson 2, Eythor Einarsson 2, Gylfi Gunnlaugsson 2, Solvi Rognvaldsson 2, David O Arnar 2 4 5, Magnus Baldvinsson 6, Ragnar G Bjarnason 4 7, DBDS Genomic consortium; Thjodbjorg Eiriksdottir 2, Christian Erikstrup 8, Egil Ferkingstad 2, Gisli H Halldorsson 2, Hannes Helgason 2, Anna Helgadottir 2, Lotte Hindhede 8, Grimur Hjorleifsson 2, David Jones 9, Kirk U Knowlton 10, Sigrun H Lund 2, Pall Melsted 2 11, Kristjan Norland 2, Isleifur Olafsson 12, Sigurdur Olafsson 5, Gudjon R Oskarsson 2, Sisse Rye Ostrowski 13 14, Ole Birger Pedersen 14 15, Auðunn S Snaebjarnarson 2, Emil Sigurdsson 16 17, Valgerdur Steinthorsdottir 2, Michael Schwinn 13, Gudmundur Thorgeirsson 2 5, Gudmar Thorleifsson 2, Ingileif Jonsdottir 2 4, Henning Bundgaard 14 18, Lincoln Nadauld 9, Einar S Bjornsson 4 5, Ingrid C Rulifson 19, Thorunn Rafnar 2, Gudmundur L Norddahl 2, Unnur Thorsteinsdottir 2 4, Patrick Sulem 2, Daniel F Gudbjartsson 2 3 20, Hilma Holm 2, Kari Stefansson 21 22
|
|
|
506. | Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease |
|
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2276-2286.e6.doi: 10.1016/j.cgh.2021.10.023. Epub 2021 Oct 21.
Octavi Bassegoda 1, Pol Olivas 2, Laura Turco 3, Mattias Mandorfer 4, Miquel Serra-Burriel 5, Luis Tellez 6, Wilhelmus Kwanten 7, Alexia Laroyenne 8, Oana Farcau 9, Edilmar Alvarado 10, Lucile Moga 11, Elise Vuille-Lessard 12, Jose Ignacio Fortea 13, Luis Ibañez 14, Giulia Tosetti 15, Thomas Vanwolleghem 7, Hélène Larrue 8, Diego Burgos-Santamaría 16, Horia Stefanescu 9, Rafael Paternostro 4, Annalisa Cippitelli 3, Sabela Lens 1, Salvador Augustin 17, Elba Llop 18, Wim Laleman 19, Jonel Trebicka 20, Johannes Chang 21, Helena Masnou 22, Alexander Zipprich 23, Francesca Miceli 3, Georg Semmler 4, Xavier Forns 1, Massimo Primignani 15, Rafael Bañares 14, Angela Puente 13, Annalisa Berzigotti 12, Pierre Emmanuel Rautou 11, Candid Villanueva 10, Pere Ginès 1, J C Garcia-Pagan 2, Bogdan Procopet 9, Cristophe Bureau 8, Agustin Albillos 6, Sven Francque 7, Thomas Reiberger 4, Filippo Schepis 3, Isabel Graupera 24, Virginia Hernandez-Gea 25
|
|
|
|
|
508. | Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH |
|
Hepatol Commun. 2022 Oct 22. doi: 10.1002/hep4.2100. Online ahead of print.
Stephen A Harrison 1, Patrick R Mayo 2, Todd M Hobbs 3, Carlos Canizares 3, Erin P Foster 2, Caroline Zhao 2, Daren R Ure 2, Daniel J Trepanier 2, Jill A Greytok 3, Robert T Foster 2
|
|
|
509. | Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort |
|
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2393-2395.e4.doi: 10.1016/j.cgh.2021.01.023. Epub 2021 Jan 21.
Miguel H Malespin 1, Alfred Sidney Barritt 4th 2, Stephanie E Watkins 3, Cheryl Schoen 3, Monica A Tincopa 4, Karen D Corbin 5, Andrea R Mospan 3, Breda Munoz 3, Huy N Trinh 6, L Michael Weiss 7, K Rajender Reddy 8, Rohit Loomba 9, Nyingi Kemmer 1, Anna S Lok 10
|
|
|
|
|
511. | Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality |
|
Front Med (Lausanne). 2022 Oct 6;9:985803. doi: 10.3389/fmed.2022.985803.eCollection 2022.
Cheng Han Ng 1, Jieling Xiao 1, Nicholas W S Chew 1 2, Yip Han Chin 1, Kai En Chan 1, Jingxuan Quek 1, Wen Hui Lim 1, Darren Jun Hao Tan 1, Ryan Wai Keong Loke 1, Caitlyn Tan 1, Ansel Shao Pin Tang 1, Xin Lei Goh 1, Benjamin Nah 3, Nicholas Syn 1, Dan Yock Young 1 3 4, Nobuharu Tamaki 5, Daniel Q Huang 1 3 4, Mohammad Shadab Siddiqui 6, Mazen Noureddin 7, Arun Sanyal 6, Mark Muthiah 1 3 4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
518. | A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease |
|
Endocr Pract. 2022 Oct 20;S1530-891X(22)00648-6. doi: 10.1016/j.eprac.2022.10.007.Online ahead of print.
Clarissa Elysia Fu 1, Cheng Han Ng 2, Jie Ning Yong 1, Kai En Chan 1, Jieling Xiao 1, Benjamin Nah 3, Shirley Huey Shin Bong 4, Khin Maung Win 5, Aung Hlaing Bwa 5, Wen Hui Lim 1, Darren Jun Hao Tan 1, Rebecca Wenling Zeng 1, Nicholas Chew 6, Margaret L P Teng 3, Mohammad Shadab Siddiqui 7, Jude A Oben 8, Arun J Sanyal 7, Vincent Wai-Sun Wong 9, Mazen Noureddin 10, Mark Muthiah 11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
532. | Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent |
|
World J Surg. 2022 Oct 20. doi: 10.1007/s00268-022-06781-w. Online ahead of print.
John V Reynolds 1, Noel E Donlon 2, Jessie A Elliott 2, Brendan Moran 2, Hugo Temperley 2, Tim S Nugent 2, Maria Davern 2, Sinead King 2, Melissa Conroy 2, Joanne Lysaght 2, Narayanasamy Ravi 2, Carmel Ryan 3, Stephen Finn 3, Suzanne Norris 4, Clare L Donohoe 2
|
|
|
533. | Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles |
|
Hepatology. 2022 Oct;76(4):1121-1134. doi: 10.1002/hep.32427. Epub 2022 Mar 17.
Ibon Martínez-Arranz 1, Chiara Bruzzone 2, Mazen Noureddin 3, Ruben Gil-Redondo 2, Itziar Mincholé 1, Maider Bizkarguenaga 2, Enara Arretxe 1, Marta Iruarrizaga-Lejarreta 1, David Fernández-Ramos 2, Fernando Lopitz-Otsoa 2, Rebeca Mayo 1, Nieves Embade 2, Elizabeth Newberry 4, Bettina Mittendorf 5, Laura Izquierdo-Sánchez 6, Vaclav Smid 7, Jorge Arnold 8, Paula Iruzubieta 9, Ylenia Pérez Castaño 10, Marcin Krawczyk 11 12, Urko M Marigorta 2, Martine C Morrison 13, Robert Kleemann 13, Antonio Martín-Duce 14, Liat Hayardeny 15, Libor Vitek 7, Radan Bruha 7, Rocío Aller de la Fuente 16, Javier Crespo 9, Manuel Romero-Gomez 17, Jesus M Banales 6 18, Marco Arrese 8 19, Kenneth Cusi 20, Elisabetta Bugianesi 21, Samuel Klein 5, Shelly C Lu 3, Quentin M Anstee 22 23, Oscar Millet 2, Nicholas O Davidson 4, Cristina Alonso 1, José M Mato 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
547. | Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis |
|
Nutr Metab Cardiovasc Dis. 2022 Oct;32(10):2279-2288.doi: 10.1016/j.numecd.2022.07.001. Epub 2022 Jul 16.
Grazia Pennisi 1, Ciro Celsa 1, Marco Enea 2, Marco Vaccaro 2, Vito Di Marco 1, Carlo Ciccioli 1, Giuseppe Infantino 1, Claudia La Mantia 1, Stefanie Parisi 1, Federica Vernuccio 3, Antonio Craxì 1, Calogero Cammà 1, Salvatore Petta 4
|
|
|
|
|
549. | The Impact of Bariatric-Surgery-Induced Weight Loss on Patients Undergoing Liver Transplant: A Focus on Metabolism, Pathophysiological Changes, and Outcome in Obese Patients Suffering NAFLD-Related Cirrhosis |
|
J Clin Med. 2022 Sep 8;11(18):5293. doi: 10.3390/jcm11185293.
Gerardo Sarno 1, Luigi Schiavo 2 3, Pietro Calabrese 2 3, Ludwig Álvarez Córdova 4, Evelyn Frias-Toral 5 6, Gabriela Cucalón 7, Eloisa Garcia-Velasquez 8, Vanessa Fuchs-Tarlovsky 9, Vincenzo Pilone 2 3
|
|
|
|
|
551. | Combination Treatment with Hydroxytyrosol and Vitamin E Improves NAFLD-Related Fibrosis |
|
Nutrients. 2022 Sep 14;14(18):3791.
Nadia Panera 1, Maria Rita Braghini 1, Annalisa Crudele 1, Antonella Smeriglio 2, Marzia Bianchi 1, Angelo Giuseppe Condorelli 3, Rebecca Nobili 3, Libenzio Adrian Conti 4, Cristiano De Stefanis 4, Gessica Lioci 5, Fabio Gurrado 5, Donatella Comparcola 6, Antonella Mosca 6, Maria Rita Sartorelli 6, Vittorio Scoppola 1, Gianluca Svegliati-Baroni 7 8, Domenico Trombetta 2, Anna Alisi 1
|
|
|
|
|
553. | Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes |
|
Diabetes Metab. 2022 Sep;48(5):101363. doi: 10.1016/j.diabet.2022.101363. Epub 2022 Jun 24.
Erminia Lembo 1, Maria Francesca Russo 1, Ornella Verrastro 1, Danila Anello 1, Giulia Angelini 1, Amerigo Iaconelli 1, Caterina Guidone 1, Gianluigi Stefanizzi 1, Luigi Ciccoritti 1, Francesco Greco 1, Luca Sessa 1, Laura Riccardi 1, Maurizio Pompili 1, Marco Raffaelli 1, Fabio Maria Vecchio 1, Stefan R Bornstein 2, Geltrude Mingrone 3, Amalia Gastaldelli 4, Esmeralda Capristo 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
566. | Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies |
|
Clin Gastroenterol Hepatol. 2022 Aug 4;S1542-3565(22)00733-9.doi: 10.1016/j.cgh.2022.07.033. Online ahead of print.
Phuc Le 1, Julia Yang Payne 2, Lu Zhang 3, Abhishek Deshpande 4, Michael B Rothberg 4, Naim Alkhouri 5, William Herman 6, Adrian V Hernandez 7, Mary Schleicher 8, Wen Ye 9, Srinivasan Dasarathy 10
|
|
|
567. | Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD |
|
Semin Liver Dis. 2022 Aug;42(3):233-249. doi: 10.1055/s-0042-1755316.Epub 2022 Aug 24.
Raquel Carvalho-Gontijo # 1 2, Cuijuan Han # 1 2, Lei Zhang 1 2, Vivian Zhang 1 2, Mojgan Hosseini 3, Kristin Mekeel 2, Bernd Schnabl 1, Rohit Loomba 1, Michael Karin 4, David A Brenner 1, Tatiana Kisseleva 2
|
|
|
568. | Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis |
|
Clin Gastroenterol Hepatol. 2022 Sep;20(9):2050-2058.e12.doi: 10.1016/j.cgh.2021.07.020. Epub 2021 Jul 15.
Zobair M Younossi 1, Maria Stepanova 2, Fatema Nader 2, Rohit Loomba 3, Quentin M Anstee 4, Vlad Ratziu 5, Stephen Harrison 6, Arun J Sanyal 7, Jörn M Schattenberg 8, A Sidney Barritt 9, Mazen Noureddin 10, Martin Bonacci 11, Gail Cawkwell 11, Bruce Wong 11, Mary Rinella 12, RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid TreatmEnt (REGENERATE) Study Investigators
|
|
|
569. | Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial |
|
J Hepatol. 2022 Sep;77(3):607-618.doi: 10.1016/j.jhep.2022.04.003.Epub 2022 Apr 16.
Naim Alkhouri 1, Robert Herring 2, Heidi Kabler 3, Zeid Kayali 4, Tarek Hassanein 5, Anita Kohli 6, Ryan S Huss 7, Yanni Zhu 7, Andrew N Billin 7, Lars Holm Damgaard 8, Kristine Buchholtz 8, Mette Skalshøi Kjær 8, Clare Balendran 8, Robert P Myers 7, Rohit Loomba 9, Mazen Noureddin 10
|
|
|
|
|
|
|
|
|
573. | Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis |
|
Clin Gastroenterol Hepatol. 2022 Jul;20(7):1561-1569.e4. doi: 10.1016/j.cgh.2021.06.012.Epub 2021 Jun 10.
Haley Schoenberger 1, Nicolas Chong 1, David T Fetzer 2, Nicole E Rich 1, Takeshi Yokoo 2, Gaurav Khatri 2, Jocelyn Olivares 3, Neehar D Parikh 4, Adam C Yopp 5, Jorge A Marrero 3, Amit G Singal 6
|
|
|
574. | Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients |
|
J Lipid Res. 2022 Jul 11;63(9):100250. doi: 10.1016/j.jlr.2022.100250. Online ahead of print.
Eric J Lawitz 1, Kelvin W Li 2, Edna Nyangau 2, Tyler John Field 2, Jen-Chieh Chuang 3, Andrew Billin 3, Lulu Wang 3, Ya Wang 3, Ryan S Huss 3, Chuhan Chung 3, G Mani Subramanian 3, Robert P Myers 3, Marc K Hellerstein 4
|
|
|
|
|
|
|
|
|
|
|
579. | NASH Presence is Associated with a Lower Weight Loss One and 2 Years After Bariatric Surgery in Women with Severe Obesity |
|
Obes Surg. 2022 Jul 6. doi: 10.1007/s11695-022-06175-w. Online ahead of print.
Fàtima Sabench # 1 2, Laia Bertran # 2, Margarita Vives 1, Marta París 1, Carmen Aguilar 2, Salomé Martínez 2, Jessica Binetti 2 3, Monica Real 3, Alja Alibalic 3, Cristóbal Richart 2, Daniel Del Castillo 1 2, Teresa Auguet 4 5
|
|
|
|
|
|
|
582. | Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD |
|
Radiology. 2022 Jul;304(1):75-82. doi: 10.1148/radiol.211131. Epub 2022 Mar 29.
Jinho Jung 1, Aiguo Han 1, Egbert Madamba 1, Ricki Bettencourt 1, Rohan R Loomba 1, Andrew S Boehringer 1, Michael P Andre 1, John W Erdman Jr 1, William D O'Brien Jr 1, Kathryn J Fowler 1, Claude B Sirlin 1, Rohit Loomba 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
593. | Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives |
|
Aliment Pharmacol Ther. 2022 Aug;56(4):570-579. doi: 10.1111/apt.17121.Epub 2022 Jul 6.
Cheng Han Ng 1, Wen Hui Lim 1, Yip Han Chin 1, Jie Ning Yong 1, Rebecca Wenling Zeng 1, Kai En Chan 1, Darren Jun Hao Tan 1, Clarissa Elysia Fu 1, Ansel Shao Pin Tang 1, Lay Hoon Goh 2, Kamala Devi 3, Nicholas W S Chew 1 4, Lung-Yi Loey Mak 5, Nobuharu Tamaki 6 7, Daniel Q Huang 1 8 9, Mazen Noureddin 10, Mohammad Shadab Siddiqui 11, Rohit Loomba 6, Arun J Sanyal 11, Mark Muthiah 1 8 9
|
|
|
|
|
|
|
596. | Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study |
|
Nat Med. 2022 Jul;28(7):1432-1438. doi: 10.1038/s41591-022-01861-9.Epub 2022 Jun 20
Stephen A Harrison 1, Federico Perez Manghi 2, William B Smith 3, Diana Alpenidze 4, Diego Aizenberg 5, Naomi Klarenbeek 6, Chi-Yi Chen 7, Eli Zuckerman 8, Eric Ravussin 9, Phunchai Charatcharoenwitthaya 10, Pin-Nan Cheng 11, Helena Katchman 12, Samuel Klein 13, Ziv Ben-Ari 14, Anisha E Mendonza 15, Yiming Zhang 16, Miljen Martic 17, Shenglin Ma 15, Sheena Kao 18, Sandra Tanner 17, Alok Pachori 15, Michael K Badman 15, YanLing He 15, Chinweike Ukomadu 15, Eric Sicard 19
|
|
|
|
|
|
|
599. | Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials |
|
Nutrients. 2022 Jul 12;14(14):2846. doi: 10.3390/nu14142846.
Danielle Lee 1 2, Laura Chiavaroli 1 2, Sabrina Ayoub-Charette 1 2, Tauseef A Khan 1 2, Andreea Zurbau 1 2 3, Fei Au-Yeung 1 2 3, Annette Cheung 1 2, Qi Liu 1 2, Xinye Qi 1 2, Amna Ahmed 1 2, Vivian L Choo 1 2 4, Sonia Blanco Mejia 1 2, Vasanti S Malik 1 5, Ahmed El-Sohemy 1, Russell J de Souza 1 2 6 7, Thomas M S Wolever 1 3 8, Lawrence A Leiter 1 2 8 9 10, Cyril W C Kendall 1 2 11, David J A Jenkins 1 2 8 9 10, John L Sievenpiper 1 2 8 9 10
|
|
|
600. | The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis |
|
Kans J Med. 2022 Jul 21;15:241-246. doi: 10.17161/kjm.vol15.16522. eCollection 2022.
Umar Hayat 1, Muhammad Zubair Ashfaq 2, Luke Johnson 1, Ryan Ford 1, Chelsea Wuthnow 1, Kevin Kadado 1, Katia El Jurdi 1, Hayrettin Okut 3, William Ransom Kilgore 1 4, Maha Assi 1 5, Ali A Siddiqui 6
|
|
|
601. | Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals |
|
Endocr Pract. 2022 Jul;28(7):667-672. doi: 10.1016/j.eprac.2022.03.016.Epub 2022 Mar 29.
Jingxuan Quek 1, Cheng Han Ng 2, Ansel Shao Pin Tang 1, Nicholas Chew 3, Mark Chan 3, Chin Meng Khoo 4, Chen Poh Wei 1, Yip Han Chin 1, Phoebe Tay 1, Grace Lim 5, Darren Jun Hao Tan 1, Wen Hui Lim 1, Kai En Chan 1, Margaret Teng 6, Eunice Tan 7, Nobuharu Tamaki 8, Daniel Q Huang 7, Mohammad Shadab Siddiqui 9, Dan Yock Young 6, Mazen Noureddin 10, Mark D Muthiah 11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
609. | American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) |
|
Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.
Kenneth Cusi 1, Scott Isaacs 2, Diana Barb 3, Rita Basu 4, Sonia Caprio 5, W Timothy Garvey 6, Sangeeta Kashyap 7, Jeffrey I Mechanick 8, Marialena Mouzaki 9, Karl Nadolsky 10, Mary E Rinella 11, Miriam B Vos 12, Zobair Younossi 13
|
|
|
|
|
|
|
|
|
|
|
|
|
615. | Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques |
|
Obes Rev. 2022 Jun 12. doi: 10.1111/obr.13481. Online ahead of print.
Willy Theel 1 2, Bianca M Boxma-de Klerk 3, Femme Dirksmeier-Harinck 4, Elisabeth F C van Rossum 2 5, Danny A Kanhai 6, Jan Apers 7, Bas M van Dalen 8, Robert J de Knegt 9, Anthony G Holleboom 10, Maarten E Tushuizen 11, Diederick E Grobbee 12 13, Janneke Wiebolt 1 2, Manuel Castro Cabezas 1 5 13
|
|
|
616. | The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population-A Review |
|
Life (Basel). 2022 Jun 5;12(6):839. doi: 10.3390/life12060839.
Thomas Pixner 1 2, Nathalie Stummer 2 3, Anna Maria Schneider 2 3, Andreas Lukas 1 2, Karin Gramlinger 1, Valérie Julian 4, David Thivel 5, Katharina Mörwald 2 3, Katharina Maruszczak 2 3, Harald Mangge 6, Julian Gomahr 2 3, Daniel Weghuber 2 3, Dieter Furthner 1 2
|
|
|
|
|
|
|
619. | Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease |
|
Cureus. 2022 May 30;14(5):e25495. doi: 10.7759/cureus.25495.eCollection 2022 May.
Gashaw Hassen 1 2 3 4, Abhishek Singh 5, Gizeshwork Belete 6, Nidhi Jain 7 8 9, Ivonne De la Hoz 10, Genesis P Camacho-Leon 11 12, Nitsuh K Dargie 13, Keila G Carrera 14, Tadesse Alemu 15, Sharan Jhaveri 16, Nebiyou Solomon 15
|
|
|
|
|
|
|
|
|
|
|
|
|
625. | Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants |
|
Gastroenterology. 2022 Jul 1;S0016-5085(22)00735-1. doi: 10.1053/j.gastro.2022.06.073.Online ahead of print.
Veeral Ajmera 1, Beom Kyung Kim 2, Kun Yang 3, Abdul M Majzoub 4, Tarek Nayfeh 5, Nobuharu Tamaki 6, Namiki Izumi 7, Atsushi Nakajima 8, Ramazan Idilman 9, Mesut Gumussoy 9, Digdem Kuru Oz 10, Ayse Erden 10, Natalie E Quach 3, Xin Tu 3, Xinlian Zhang 3, Mazen Noureddin 11, Alina M Allen 12, Rohit Loomba 13
|
|
|
|
|
|
|
|
|
|
|
630. | Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial |
|
Nutrients. 2022 May 23;14(10):2178. doi: 10.3390/nu14102178.
Giuseppina Costabile 1 2, Giuseppe Della Pepa 1, Dominic Salamone 1, Delia Luongo 3, Daniele Naviglio 4, Valentina Brancato 5, Carlo Cavaliere 5, Marco Salvatore 5, Paola Cipriano 1, Marilena Vitale 1, Alessandra Corrado 1, Angela Albarosa Rivellese 1 2, Giovanni Annuzzi 1 2, Lutgarda Bozzetto 1 2
|
|
|
|
|
|
|
|
|
634. | Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease |
|
JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.
Aidan J McGlinchey 1, Olivier Govaere 2, Dawei Geng 3, Vlad Ratziu 4, Michael Allison 5, Jerome Bousier 6, Salvatore Petta 7, Claudia de Oliviera 8, Elisabetta Bugianesi 9, Jörn M Schattenberg 10, Ann K Daly 2, Tuulia Hyötyläinen 3, Quentin M Anstee 2 11, Matej Orešic 1 12
|
|
|
|
|
636. | Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association |
|
Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185.doi: 10.1161/ATV.0000000000000153. Epub 2022 Apr 14.
P Barton Duell, Francine K Welty, Michael Miller, Alan Chait, Gmerice Hammond, Zahid Ahmad, David E Cohen, Jay D Horton, Gregg S Pressman, Peter P Toth, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
643. | Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group |
|
Lancet Gastroenterol Hepatol. 2022 Apr 28;S2468-1253(22)00061-9.doi: 10.1016/S2468-1253(22)00061-9. Online ahead of print.
Stuart McPherson 1, Matthew J Armstrong 2, Jeremy F Cobbold 3, Lynsey Corless 4, Quentin M Anstee 5, Richard J Aspinall 6, Stephen T Barclay 7, Paul N Brennan 8, Tessa M Cacciottolo 9, Robert D Goldin 10, Kate Hallsworth 5, Vanessa Hebditch 11, Kathryn Jack 12, Helen Jarvis 13, Jill Johnson 14, Wenhao Li 15, Dina Mansour 16, Mary McCallum 17, Ashis Mukhopadhya 17, Richard Parker 18, Valerie Ross 15, Ian A Rowe 19, Ankur Srivastava 20, Prarthana Thiagarajan 12, Alexandra I Thompson 21, Jeremy Tomlinson 22, Emmanuel A Tsochatzis 23, Andrew Yeoman 24, William Alazawi 15
|
|
|
|
|
|
|
646. | Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science |
|
J Clin Transl Hepatol. 2022 Apr 28;10(2):374-382. doi: 10.14218/JCTH.2021.00408.Epub 2021 Oct 22.
Yasser Fouad 1, Melissa Palmer 2 3, Minjun Chen 4, Arie Regev 5, Rajarshi Banerjee 6, Rob Myers 7, Robert Riccio 8, Richard Torstenson 9, Ramy Younes 10, Puneet S Arora 11, Henrik Landgren 12, Morten A Karsdal 13, Martin Blake 14, David A Shapiro 15, Hans-Juergen Gruss 8, Muhammad Y Sheikh 16, Dina Attia 17, Steven Bollipo 18 19, Alastair D Smith 8, Bradley Freilich 20, Robert G Gish 21, Detlef Schuppan 22 23
|
|
|
647. | A Low Glycemic Index Mediterranean Diet Combined with Aerobic Physical Activity Rearranges the Gut Microbiota Signature in NAFLD Patients |
|
Nutrients. 2022 Apr 23;14(9):1773. doi: 10.3390/nu14091773.
Francesco Maria Calabrese 1, Vittoria Disciglio 2, Isabella Franco 2, Paolo Sorino 2, Caterina Bonfiglio 2, Antonella Bianco 2, Angelo Campanella 2, Tamara Lippolis 2, Pasqua Letizia Pesole 2, Maurizio Polignano 2, Mirco Vacca 1, Giusy Rita Caponio 2, Gianluigi Giannelli 2, Maria De Angelis 1, Alberto Ruben Osella 2
|
|
|
648. | Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases |
|
Hepatology. 2022 Jan;75(1):219-228. doi: 10.1002/hep.32163. Epub 2021 Dec 10.
Pere Ginès 1 2 3 4, Laurent Castera 5 6 7, Frank Lammert 8 9 10, Isabel Graupera 1 2 3 4, Miquel Serra-Burriel 11, Alina M Allen 12, Vincent Wai-Sun Wong 13, Phillipp Hartmann 14, Maja Thiele 15, Llorenç Caballeria 16, Robert J de Knegt 17, Ivica Grgurevic 18, Salvador Augustin 3 19 20, Emmanuel A Tsochatzis 21, Jörn M Schattenberg 22, Indra Neil Guha 23, Andrea Martini 24, Rosa M Morillas 3 20 25, Montserrat Garcia-Retortillo 26, Harry J de Koning 27, Núria Fabrellas 2 28, Judit Pich 29, Ann T Ma 1 2 4, M Alba Diaz 30, Dominique Roulot 31, Philip N Newsome 32 33, Michael Manns 8, Patrick S Kamath 12, Aleksander Krag 15, LiverScreen Consortium Investigators
|
|
|
|
|
|
|
|
|
|
|
653. | Advancing the global public health agenda for NAFLD: a consensus statement |
|
Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78.doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27.
Jeffrey V Lazarus 1 2, Henry E Mark 3, Quentin M Anstee 4 5, Juan Pablo Arab 6, Rachel L Batterham 7, Laurent Castera 8, Helena Cortez-Pinto 9, Javier Crespo 10, Kenneth Cusi 11, M Ashworth Dirac 12, Sven Francque 13 14, Jacob George 15, Hannes Hagström 16, Terry T-K Huang 17, Mona H Ismail 18, Achim Kautz 19, Shiv Kumar Sarin 20, Rohit Loomba 21 22, Veronica Miller 23, Philip N Newsome 24, Michael Ninburg 25, Ponsiano Ocama 26, Vlad Ratziu 27, Mary Rinella 28, Diana Romero 29, Manuel Romero-Gómez 30, Jörn M Schattenberg 31, Emmanuel A Tsochatzis 32 33, Luca Valenti 34 35, Vincent Wai-Sun Wong 36, Yusuf Yilmaz 37 38, Zobair M Younossi 39, Shira Zelber-Sagi 40 41, NAFLD Consensus Consortium
Collaborators, Affiliations collapse
- NAFLD Consensus Consortium:
Fredrik Åberg, Leon Adams, Maryam Salem Al Khatry, Khalid Al Naamani, Omar Alfaro Murillo, Alina M Allen, Faisal Alnaser, Saleh A Alqahtani, Khalid Alswat, Domenico Alvaro, Raúl J Andrade, Marco Arrese, Yaw Asante Awuku, Motala Ayesha, Oidov Baatarkhuu, Shokhista Bakieva, Rita Basu, Ramon Bataller, Shahinaz Bedri, Emanuele Bosi, Marc Bourliere, Radan Bruha, Elisabetta Bugianesi, Patrizia Burra, Maria Buti, Christopher D Byrne, Jose Luis Calleja, Patrizia Carrieri, Flloyd Carter, Marlen Ivon Castellanos Fernandez, Gabriela Castillo-Lopez, Graciela E Castro-Narro, Henry Lik Yuen Chan, Wah-Kheong Chan, Yoosoo Chang, Massimo Colombo, Kirsten J Coppell, Kathleen Corey, Antonio Craxi, Donna Cryer, Anuradha Dassanayake, Antonieta de Ascenção Soares Martins, Victor de Ledinghen, Stefano DelPrato, Alessandro Demaio, Hailemichael Desalegn, John Dillon, Ajay Duseja, Prabhakaran Dorairaj, Mattias Ekstedt, Mohamed El Kassas, Osama M Elsanousi, Gamal Esmat, Jian-Gao Fan, Nathalie Farpour-Lambert, Robert Flisiak, Yasser Fouad, Michael Fuchs, Rino A Gani, Lynn Gerber, Hasmik Ghazinyan, Liana Gheorghe, George Boon-Bee Goh, Henning Grønbæk, Aghayeva Gulnara, Saeed Hamid, Vanessa Hebditch, Ingrid J Hickman, Samantha L Hocking, Bela Hunyady, Ramazan Idilman, Vasily A Isakov, Mohammad H Jamal, Peter Jepsen, Natacha Jreige Iskandar, Myeong Jun Song, K C Sudhamshu, Satoru Kakizaki, George Kalamitsis, Fasiha Kanwal, Jia-Horng Kao, Lee Kaplan, Takumi Kawaguchi, Yousef Khader, Seung Up Kim, Nicolas Kodjoh, Ger Koek, Kazuhiko Koike, Narcisse Patrice Komas, Marko Korenjak, Marcelo Kugelmas, Asma Labidi, Naomi F Lange, Joel E Lavine, Mariana Lazo, Nancy Lee, Cosmas Rinaldi A Lesmana, Chun-Jen Liu, Michelle T Long, Patricio Lopez-Jaramillo, Reza Malekzadeh, Mamun Al Mahtab, Giulio Marchesini, Rui Marinho, Sophia E Martínez Vázquez, Lyudmila Mateva, Charles Mbendi Nlombi, Pascal Melin, Ivana Mikolasevic, Tamara Milovanovic, Carla Musso, Atsushi Nakajima, Edna Nava, Alexander V Nersesov, Dafina Nikolova, Suzanne Norris, Katja Novak, Jude Oben, Janus P Ong, Charles Onyekwere, George Papatheodoridis, Imran Paruk, Keyur Patel, M Paula Macedo, Carlos Penha-Gonçalves, Marlene Pérez Figueroa, Wolf Peter Hofmann, Salvatore Petta, Claudia Pinto Marques Souza de Oliveira, Puneet Puri, Calvin Q Pan, Marek Rac, Johanna Ralston, Alnoor Ramji, Homie Razavi, Mario Reis Alvares-da-Silva, Stuart Roberts, Michael Roden, Tamsin Rose, Samir Rouabhia, Patrizia Rovere-Querini, Ian A Rowe, Shakhlo Sadirova, Riina Salupere, Tobokalova Saparbu, Raymond Sayegh, Giada Sebastiani, Yosuke Seki, Josefina Selmo,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
661. | Inhibition of 11ß-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study |
|
Diabetes Obes Metab. 2022 May;24(5):881-890.doi: 10.1111/dom.14646.Epub 2022 Jan 25.
Yogesh Yadav 1, Kelly Dunagan 2, Rachita Khot 3, Sudhakar K Venkatesh 2, John Port 2, Alfonso Galderisi 4, Claudio Cobelli 4, Craig Wegner 5, Ananda Basu 1, Rickey Carter 6, Rita Basu 1
|
|
|
|
|
|
|
664. | Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis |
|
Gut. 2022 May;71(5):1006-1019. doi: 10.1136/gutjnl-2021-324243.Epub 2021 May 17.
Ferenc Emil Mózes 1, Jenny A Lee 2, Emmanuel Anandraj Selvaraj 1 3 4, Arjun Narayan Ajmer Jayaswal 1, Michael Trauner 5, Jerome Boursier 6 7, Céline Fournier 8, Katharina Staufer 5 9 10, Rudolf E Stauber 11, Elisabetta Bugianesi 12, Ramy Younes 13, Silvia Gaia 12, Monica Lup?or-Platon 14, Salvatore Petta 15, Toshihide Shima 16, Takeshi Okanoue 16, Sanjiv Mahadeva 17, Wah-Kheong Chan 17, Peter J Eddowes 18 19, Gideon M Hirschfield 20, Philip Noel Newsome 18 21 22, Vincent Wai-Sun Wong 23, Victor de Ledinghen 24 25, Jiangao Fan 26, Feng Shen 26, Jeremy F Cobbold 3 4, Yoshio Sumida 27, Akira Okajima 28, Jörn M Schattenberg 29, Christian Labenz 29, Won Kim 30, Myoung Seok Lee 31, Johannes Wiegand 32, Thomas Karlas 32, Yusuf Yilmaz 33 34, Guruprasad Padur Aithal 19 35, Naaventhan Palaniyappan 19 35, Christophe Cassinotto 36, Sandeep Aggarwal 37, Harshit Garg 37, Geraldine J Ooi 38, Atsushi Nakajima 39, Masato Yoneda 39, Marianne Ziol 40, Nathalie Barget 41, Andreas Geier 42, Theresa Tuthill 43, M Julia Brosnan 43, Quentin Mark Anstee 44, Stefan Neubauer 1, Stephen A Harrison 1, Patrick M Bossuyt 2, Michael Pavlides 45 3 4, LITMUS Investigators
|
|
|
|
|
666. | Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool |
|
Sci Rep. 2022 Apr 20;12(1):6485.doi: 10.1038/s41598-022-10481-9.
Ambrin Farizah Babu # 1 2, Susanne Csader # 1, Ville Männistö 3, Milla-Maria Tauriainen 1 3, Heikki Pentikäinen 4, Kai Savonen 4 5, Anton Klåvus 2, Ville Koistinen 1 2 6, Kati Hanhineva 1 2 6, Ursula Schwab 7 8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
674. | Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease |
|
Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049.Epub 2021 Sep 20.
Fasiha Kanwal 1, Jay H Shubrook 2, Leon A Adams 3, Kim Pfotenhauer 4, Vincent Wai-Sun Wong 5, Eugene Wright 6, Manal F Abdelmalek 6, Stephen A Harrison 7, Rohit Loomba 8, Christos S Mantzoros 9, Elisabetta Bugianesi 10, Robert H Eckel 11, Lee M Kaplan 12, Hashem B El-Serag 1, Kenneth Cusi 13
|
|
|
|
|
|
|
|
|
|
|
679. | Validation of the accuracy of the FASTâ„¢ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms |
|
PLoS One. 2022 Apr 15;17(4):e0266859.doi: 10.1371/journal.pone.0266859. eCollection 2022.
Tinsay A Woreta 1, Mark L Van Natta 2, Mariana Lazo 3, Arunkumar Krishnan 1, Brent A Neuschwander-Tetri 4, Rohit Loomba 5, Anna Mae Diehl 6, Manal F Abdelmalek 6, Naga Chalasani 7, Samer Gawrieh 7, Srinivasan Dasarathy 8, Raj Vuppalanchi 7, Mohammad S Siddiqui 9, Kris V Kowdley 10, Arthur McCullough 8, Norah A Terrault 11, Cynthia Behling 5, David E Kleiner 12, Mark Fishbein 13, Paula Hertel 14, Laura A Wilson 2, Emily P Mitchell 2, Laura A Miriel 2, Jeanne M Clark 1, James Tonascia 2, Arun J Sanyal 9, NASH Clinical Research Network
|
|
|
|
|
|
|
|
|
683. | The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis |
|
J Clin Endocrinol Metab. 2022 Feb 17;107(3):862-881.doi: 10.1210/clinem/dgab795.
Angelo Sabag 1 2, Loren Barr 2, Mike Armour 1 3, Alex Armstrong 4, Callum J Baker 5, Stephen M Twigg 5 6, Dennis Chang 1, Daniel A Hackett 4, Shelley E Keating 7, Jacob George 8, Nathan A Johnson 4 9
|
|
|
684. | Genome-Wide Association Study of NAFLD Using Electronic Health Records |
|
Hepatol Commun. 2022 Feb;6(2):297-308. doi: 10.1002/hep4.1805.Epub 2021 Sep 17.
Cameron J Fairfield 1, Thomas M Drake 1, Riinu Pius 1, Andrew D Bretherick 2, Archie Campbell 1 3 4, David W Clark 5, Jonathan A Fallowfield 6, Caroline Hayward 2, Neil C Henderson 6, Peter K Joshi 5, Nicholas L Mills 7, David J Porteous 3, Prakash Ramachandran 6, Robert K Semple 7, Catherine A Shaw 1, Cathie L M Sudlow 1, Paul R H J Timmers 2 5, James F Wilson 2 5, Stephen J Wigmore 8, Ewen M Harrison # 1 8, Athina Spiliopoulou # 5
|
|
|
|
|
|
|
687. | A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach |
|
Aliment Pharmacol Ther. 2022 Jan;55(2):234-243. doi: 10.1111/apt.16720. Epub 2021 Dec 5.
Jeffrey V Lazarus 1 2, Henry E Mark 2, Massimo Colombo 2 3, Sandro Demaio 4, John F Dillon 5, Jacob George 6, Hannes Hagström 7, Samantha Hocking 6, Nancy Lee 8, Mark J Nieuwenhuijsen 1, Mary E Rinella 9, Manuel Romero-Gomez 10, Joan B Soriano 11, Jörn M Schattenberg 12, Frank Tacke 13, Emmanuel A Tsochatzis 14, Luca Valenti 3, Shira Zelber-Sagi 15 16, M Ashworth Dirac 17, Terry T-K Huang 18
|
|
|
|
|
689. | Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease |
|
Children (Basel). 2022 Mar 8;9(3):374. doi: 10.3390/children9030374.
Eduardo Castillo-Leon 1 2, Heather L Morris 3, Cheryl Schoen 3, Jacob Bilhartz 4, Patrick McKiernan 5, Tamir Miloh 6, Sirish Palle 7, Mohammad Nasser Kabbany 8, Breda Munoz 3, Andrea R Mospan 3, Bryan Rudolph 9, Stavra A Xanthakos 10, Miriam B Vos 11, Target-Nash Investigators
|
|
|
690. | Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis |
|
Aliment Pharmacol Ther. 2021 Dec;54(11-12):1405-1415. doi: 10.1111/apt.16664.Epub 2021 Oct 20.
Rifaat Safadi 1, Marius Braun 2, Adi Francis 3, Yael Milgrom 1, Muhammad Massarwa 1, David Hakimian 1, Wadi Hazou 1, Assaf Issachar 2, Zivit Harpaz 4, Motti Farbstein 4, Inbal Itzhak 4, Naama Lev-Cohain 5, Avital Bareket-Samish 6, Michael H Silverman 4, Pnina Fishman 4
|
|
|
691. | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis |
|
Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7.
Arun J Sanyal 1, Quentin M Anstee 2, Michael Trauner 3, Eric J Lawitz 4, Manal F Abdelmalek 5 6, Dora Ding 7, Ling Han 7, Catherine Jia 7, Ryan S Huss 7, Chuhan Chung 7, Vincent Wai-Sun Wong 8, Takeshi Okanoue 9, Manuel Romero-Gomez 10, Andrew J Muir 5 6, Nezam H Afdhal 11, Jaime Bosch 12 13, Zachary Goodman 14, Stephen A Harrison 15, Zobair M Younossi 14, Robert P Myers 7
|
|
|
|
|
693. | Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease |
|
Am J Gastroenterol. 2021 Dec 1;116(12):2399-2409.doi: 10.14309/ajg.0000000000001375.
Stephen A Harrison 1, Seth J Baum 2, Nadege T Gunn 3, Ziad H Younes 4, Anita Kohli 5, Rashmee Patil 6, Margaret J Koziel 7, Harinder Chera 7, Jeff Zhao 7, Manu V Chakravarthy 7
|
|
|
|
|
|
|
696. | Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study |
|
Clin Gastroenterol Hepatol. 2022 Feb;20(2):458-460.e4. doi: 10.1016/j.cgh.2021.03.031.Epub 2021 Mar 26.
Mary J Thomson 1, Marina Serper 2, Vandana Khungar 2, L Michael Weiss 3, Huy Trinh 4, Roberto Firpi-Morell 5, Michael Roden 6, Rohit Loomba 7, A Sidney Barritt 4th 8, Derek Gazis 9, Andrea R Mospan 9, Michael W Fried 9, K Rajender Reddy 2, Anna S Lok 10
|
|
|
697. | The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? |
|
J Hepatol. 2022 Apr;76(4):771-780. doi: 10.1016/j.jhep.2021.10.025. Epub 2021 Dec 9.
Jeffrey V Lazarus 1, Henry E Mark 2, Marcela Villota-Rivas 3, Adam Palayew 4, Patrizia Carrieri 5, Massimo Colombo 6, Mattias Ekstedt 7, Gamal Esmat 8, Jacob George 9, Giulio Marchesini 10, Katja Novak 11, Ponsiano Ocama 12, Vlad Ratziu 13, Homie Razavi 14, Manuel Romero-Gómez 15, Marcelo Silva 16, C Wendy Spearman 17, Frank Tacke 18, Emmanuel A Tsochatzis 19, Yusuf Yilmaz 20, Zobair M Younossi 21, Vincent W-S Wong 22, Shira Zelber-Sagi 23,
Helena Cortez-Pinto 24, Quentin M Anstee 25, NAFLD policy review collaborators
Collaborators
- NAFLD policy review collaborators:
Samir Rouabhia
26
, Hasmik Ghazinyan
27,
Natacha Jreige Iskandar
28, Michael Trauner
29,
Gulnara Aghayeva
30, Flloyd Carter
31, Kannan Sridharan
32, Mamun Al Mahtab
33, Sven Francque
34, Nicolas Kodjoh
35,
Ruben Muñoz Camacho
36, Motswedi Anderson
37,
Claudia Pinto Marques Souza de Oliveira
38,
Lyudmila Mateva
39, Abdel Karim Serme
40,
Antonieta A Soares Martins
41,
Mark G Swain
42,
Narcisse Patrice Komas
43, Ming-Hua Zheng
44, Patricio Lopez Jaramillo
45, Omar Alfaro Murillo
46,
Ivana Mikolasevic
47, Emmelia Vounou
48, Radan Bruha
49, Charles Mbendi Nlombi
50, Maja Thiele
51, Marlene Perez
52, Juan José
Suárez M
53,
Imam Waked
54, Riina Salupere
55, Hailemichael Desalegn
56, Hannele Yki-Järvinen 57, Tengiz Tsertsvadze 58, Lali Sharvadze 58, Maia Butsashvili 58, Yaw Asante Awuku 59, Georgios Papatheodoridis 60, Bela Hunyady 61, Einar Stefan Bjornsson 62, Ajay Duseja 63, Cosmas Rinaldi A Lesmana 64, Reza Malekzadeh 65, Suzanne Norris 66, Kazuhiko Koike 67, Alexander V Nersesov 68, Missiani Ochwoto 69, Mohammad Jamal 70, Tobokalova Saparbu 71, Ieva Tolmane 72, Raymond Sayegh 73, Dhastagir Sultan Sheriff 74, Jonas Valantinas 75, Joseph Weber 76, Isaac Thom Shawa 77, Soek-Siam Tan 78, Sophia E Martínez Vázquez 79, Oidov Baatarkhuu 80, Undram Lkhagvaa 80, Tsolmon Jadamba 80, Tahiri Mohammed 81, K C Sudhamshu 82, Kirsten Coppell 83
, Charles Onyekwere 84,&nbs |
|
|
698. | Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study |
|
BMJ Open. 2022 Mar 30;12(3):e056159. doi: 10.1136/bmjopen-2021-056159.
Neeta B Amin 1, Amanda Darekar 2, Quentin M Anstee 3, Vincent Wai-Sun Wong 4, Frank Tacke 5, Manoli Vourvahis 6, Douglas S Lee 7, Michael Charlton 8, Naim Alkhouri 9, Atsushi Nakajima 10, Carla Yunis 6
|
|
|
|
|
|
|
|
|
702. | Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score |
|
Hepatology. 2022 Mar 25. doi: 10.1002/hep.32475. Online ahead of print.
Rish K Pai 1, Vipul Jairath 2 3 4, Malcolm Hogan 3, Guangyong Zou 3 4 5, Oyedele A Adeyi 6, Quentin M Anstee 7 8, Bashar A Aqel 9, Cynthia Behling 10 11, Elizabeth J Carey 9, Andrew D Clouston 12, Kathleen Corey 13 14, Brian G Feagan 2 3 4, David E Kleiner 15, Christopher Ma 3 16 17, Stefanie C McFarlane 3, Mazen Noureddin 18, Vlad Ratziu 19, Mark A Valasek 20, Zobair M Younossi 21 22, Stephen A Harrison 23 24, Rohit Loomba 25
|
|
|
|
|
704. | Bariatric Surgery in NAFLD |
|
Dig Dis Sci. 2022 Feb;67(2):408-422. doi: 10.1007/s10620-021-07317-3.Epub 2022 Jan 4.
Mahak Chauhan 1, Kuldeep Singh 1, Paul J Thuluvath 2 3
|
|
|
|
|
|
|
|
|
|
|
|
|
710. | Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography |
|
Ultraschall Med. 2022 Feb 28. doi: 10.1055/a-1724-7289. Online ahead of print.
David Jm Bauer 1 2, Vladimir Matic 3, Ruxandra Mare 4, Laura Maiocchi 5, David Chromy 1 2, Theresa Müllner-Bucsics 1 2, Mattias Mandorfer 1 2, Sandra Mustapic 3, Ioan Sporea 6, Giovanna Ferraioli 5, Ivica Grgurevic 3, Thomas Reiberger 1 2 7
|
|
|
|
|
712. | Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial |
|
Lancet Gastroenterol Hepatol. 2022 Mar 21;S2468-1253(22)00017-6.doi: 10.1016/S2468-1253(22)00017-6. Online ahead of print.
Stephen A Harrison 1, Manal F Abdelmalek 2, Guy Neff 3, Nadege Gunn 4, Cynthia D Guy 5, Naim Alkhouri 6, Mustafa R Bashir 7, Bradley Freilich 8, Anita Kohli 9, Arun Khazanchi 10, Muhammad Y Sheikh 11, Mark Leibowitz 12, Mary E Rinella 13, Mohammad S Siddiqui 14, Mark Kipnes 15, Sam E Moussa 16, Ziad H Younes 17, Meena Bansal 18, Seth J Baum 19, Brian Borg 20, Peter J Ruane 21, Paul J Thuluvath 22, Mildred Gottwald 23, Mujib Khan 23, Charles Chen 23, Liza Melchor-Khan 23, William Chang 23, Alex M DePaoli 23, Lei Ling 24, Hsiao D Lieu 23
|
|
|
|
|
|
|
|
|
716. | The fecal mycobiome in non-alcoholic fatty liver disease |
|
J Hepatol. 2022 Apr;76(4):788-799. doi: 10.1016/j.jhep.2021.11.029. Epub 2021 Dec 10.
Münevver Demir 1, Sonja Lang 2, Phillipp Hartmann 3, Yi Duan 4, Anna Martin 5, Yukiko Miyamoto 4, Marina Bondareva 6, Xinlian Zhang 7, Yanhan Wang 4, Philipp Kasper 5, Corinna Bang 8, Christoph Roderburg 9, Frank Tacke 1, Hans-Michael Steffen 5, Tobias Goeser 5, Andrey Kruglov 6, Lars Eckmann 4, Peter Stärkel 10, Derrick E Fouts 11, Bernd Schnabl 12
|
|
|
717. | Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? |
|
Gut. 2022 Feb;71(2):382-390. doi: 10.1136/gutjnl-2020-322564. Epub 2021 Feb 4.
Ramy Younes 1 2 3, Olivier Govaere 1, Salvatore Petta 4, Luca Miele 5 6, Dina Tiniakos 1 7, Alastair Burt 1, Ezio David 3, Fabio Maria Vecchio 5 8, Marco Maggioni 9, Daniela Cabibi 10, Duncan McLeod 11, Maria Jesus Pareja 12, Anna Ludovica Fracanzani 13, Rocio Aller 14, Chiara Rosso 3, Javier Ampuero 15, Rocío Gallego-Durán 15, Angelo Armandi 3, Gian Paolo Caviglia 3, Marco Y W Zaki 1 16, Antonio Liguori 5, Paolo Francione 13, Grazia Pennisi 4, Antonio Grieco 5 6, Giovanni Birolo 3, Piero Fariselli 3, Mohammed Eslam 17, Luca Valenti 18, Jacob George 17, Manuel Romero-Gómez 15, Quentin Mark Anstee 19 20, Elisabetta Bugianesi 21
|
|
|
718. | Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease |
|
J Clin Invest. 2021 Dec 15;131(24):e150996. doi: 10.1172/JCI150996.
Catherine C Cohen 1 2, Kelvin W Li 3, Adina L Alazraki 4 5, Carine Beysen 6, Carissa A Carrier 7, Rebecca L Cleeton 1, Mohamad Dandan 3, Janet Figueroa 1, Jack Knight-Scott 5, Cynthia J Knott 8, Kimberly P Newton 7 9, Edna M Nyangau 3, Claude B Sirlin 10, Patricia A Ugalde-Nicalo 7 9, Jean A Welsh 1 11, Marc K Hellerstein 3, Jeffrey B Schwimmer 7 9, Miriam B Vos 1 11
|
|
|
719. | Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control |
|
Nat Commun. 2022 Mar 10;13(1):1259. doi: 10.1038/s41467-022-28889-2.
Magdalene K Montgomery 1, Jacqueline Bayliss 2, Shuai Nie 3, William De Nardo 2, Stacey N Keenan 2, Paula M Miotto 2, Hamzeh Karimkhanloo 2 4, Cheng Huang 5, Ralf B Schittenhelm 5, Anthony S Don 6, Andrew Ryan 7, Nicholas A Williamson 3, Geraldine J Ooi 8, Wendy A Brown 8, Paul R Burton 8, Benjamin L Parker 2, Matthew J Watt 9
|
|
|
|
|
|
|
722. | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD |
|
J Hepatol. 2022 Jan 25;S0168-8278(22)00024-1. doi: 10.1016/j.jhep.2022.01.011.Online ahead of print.
Elizabeth M Brunt 1, Andrew D Clouston 2, Zachary Goodman 3, Cynthia Guy 4, David E Kleiner 5, Carolin Lackner 6, Dina G Tiniakos 7, Aileen Wee 8, Matthew Yeh 9, Wei Qiang Leow 10, Elaine Chng 11, Yayun Ren 11, George Goh Boon Bee 12, Elizabeth E Powell 13, Mary Rinella 14, Arun J Sanyal 15, Brent Neuschwander-Tetri 16, Zobair Younossi 17, Michael Charlton 18, Vlad Ratziu 19, Stephen A Harrison 20, Dean Tai 21, Quentin M Anstee 22
|
|
|
|
|
|
|
|
|
|
|
|
|
728. | Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD |
|
Hepatol Commun. 2022 Mar 15. doi: 10.1002/hep4.1932. Online ahead of print.
Theresia M Schnurr 1 2, Sophia Figueroa Katz 1 3, Johanne M Justesen 1 2, Jack W O'Sullivan 1, Peter Saliba-Gustafsson 1 4, Themistocles L Assimes 1 5, Ivan Carcamo-Orive 1 6, Aijaz Ahmed 7, Euan A Ashley 1 8 9, Torben Hansen 2, Joshua W Knowles 1 6 10
|
|
|
729. | Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD) |
|
Aliment Pharmacol Ther. 2022 Mar 17. doi: 10.1111/apt.16874. Online ahead of print.
Danielle Brandman 1, Marie Boyle 2 3, Stuart McPherson 2 3, Mark L Van Natta 4, Arun J Sanyal 5, Kris Kowdley 6, Brent Neuschwander-Tetri 7, Naga Chalasani 8, Manal F Abdelmalek 9, Norah A Terrault 10, Art McCullough 11, Ricki Bettencourt 12, Cyrielle Caussy 12, David E Kleiner 13, Cynthia Behling 14, James Tonascia 4, Quentin M Anstee 2, Rohit Loomba 12, Members of the Nonalcoholic Steatohepatitis Clinical Research Network
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
740. | Factors impacting survival in those transplanted for NASH cirrhosis: Data from the NailNASH Consortium |
|
Clin Gastroenterol Hepatol. 2022 Feb 18;S1542-3565(22)00184-7.doi: 10.1016/j.cgh.2022.02.028. Online ahead of print.
Mary E Rinella, Sanjaya K Satapathy, Danielle Brandman, Coleman Smith, Sal Elwir, Jonathan Xia, Meg Gibson, Carlos Figueredo, Mounika Angirekula, Jason M Vanatta, Raiya Sarwar, Yu Jiang, Dyanna Gregory, Tandy Agostini, JimIn Ko, Pradeep Podila, Grace Gallo, Kymberly D Watt, Mohammad S Siddiqui
|
|
|
|
|
742. | Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-ß and Tau Pathology in Middle-Aged Adults: The Framingham Study |
|
J Alzheimers Dis. 2022 Feb 21. doi: 10.3233/JAD-215409. Online ahead of print.
Galit Weinstein 1, Adrienne O'Donnell 2 3, Kendra Davis-Plourde 2 3, Shira Zelber-Sagi 1 4, Saptaparni Ghosh 3 5, Charles S DeCarli 6, Emma G Thibault 7, Reisa A Sperling 7 8, Keith A Johnson 7 8, Alexa S Beiser 2 3 5, Sudha Seshadri 3 5 9
|
|
|
743. | Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study |
|
J Pediatr Gastroenterol Nutr. 2022 Feb 21. doi: 10.1097/MPG.0000000000003418.Online ahead of print.
Jake P Mann 1, Benjamin Jenkins, Samuel Furse, Stuart G Snowden, Anna Alisi, Laura G Draijer, Kylie Karnebeek, Deirdre A Kelly, Bart G Koot, Antonella Mosca, Camilla Salvestrini, Indra van Mourik, Anita Vreugdenhil, Matthias Zilbauer, Albert Koulman, EU-PNAFLD investigators^
|
|
|
744. | Clinical Intervention to Reduce Dietary Sugar does not Impact Liver Fat in Latino Youth, Regardless of PNPLA3 Genotype: A Randomized Controlled Trial |
|
J Nutr. 2022 Feb 26;nxac046. doi: 10.1093/jn/nxac046. Online ahead of print.
Kelsey A Schmidt 1, Roshonda B Jones 1, Claudia Rios 1, Yesica Corona 1, Paige K Berger 1, Jasmine F Plows 1, Tanya L Alderete 2, Jennifer Fogel 1, Hailey Hampson 1 3, Jaana A Hartiala 4, Zhiheng Cai 5, Hooman Allayee 5 4, Krishna S Nayak 6 7, Frank R Sinatra 3, Gregory Harlan 3, Trevor A Pickering 4, Sarah-Jeanne Salvy 8, Wendy Mack 4, Rohit Kohli 9, Michael I Goran 1
|
|
|
|
|
746. | Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery |
|
Hepatology. 2022 Jan 25. doi: 10.1002/hep.32358. Online ahead of print.
Raluca Pais 1 2 3 4, Judith Aron-Wisnewsky 1 2 5, Pierre Bedossa 6, Maharajah Ponnaiah 3, Jean-Michel Oppert 1 2, Jean-Michel Siksik 1, Laurent Genser 1 2 5, Frederic Charlotte 1 2, Dominique Thabut 1 2 4, Karine Clement 1 2 5, Vlad Ratziu 1 2 3 6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
755. | Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat |
|
Clin Gastroenterol Hepatol. 2022 Jan 6;S1542-3565(22)00002-7. doi: 10.1016/j.cgh.2021.12.044.Online ahead of print.
Eric J Lawitz 1, Bal Raj Bhandari 2, Peter J Ruane 3, Anita Kohli 4, Eliza Harting 5, Dora Ding 5, Jen-Chieh Chuang 5, Ryan S Huss 5, Chuhan Chung 5, Robert P Myers 6, Rohit Loomba 7
|
|
|
|
|
757. | Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD |
|
Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324. Online ahead of print.
Mary P Moore 1 2, Rory P Cunningham 1 2, Grace M Meers 1 2, Sarah A Johnson 1 3, Andrew A Wheeler 4, Rama R Ganga 4, Nicole M Spencer 4, James B Pitt 4, Alberto Diaz-Arias 5, Ahmed I A Swi 3, Ghassan M Hammoud 3, Jamal A Ibdah 1 2 3, Elizabeth J Parks 2 3, R Scott Rector 1 2 3
|
|
|
|
|
|
|
760. | Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease |
|
J Clin Med. 2022 Feb 8;11(3):890. doi: 10.3390/jcm11030890.
Peter Lemmer 1 2, Paul Manka 1, Jan Best 1, Alisan Kahraman 3, Julia Kälsch 3, Ramiro Vilchez-Vargas 2, Alexander Link 2, Hsin Chiang 3, Guido Gerken 3, Ali Canbay 1, Lars P Bechmann 1, Svenja Sydor 1
|
|
|
|
|
|
|
763. | The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint |
|
Liver Int. 2022 Feb 7. doi: 10.1111/liv.15188. Online ahead of print.
Taghreed M Farahat 1, Mehmet Ungan 2, Josep Vilaseca 3, Jacqueline Ponzo 4, Pramendra Prasad Gupta 5, Andrew D Schreiner 6, Wadeia Al Sharief 7, Kelly Casler 8, Tafat Abdelkader 9, Ludovico Abenavoli 10, Fatima-Zohra Mchich Alami 11, Mattias Ekstedt 12, Muntadar Saad Jabir 13, Matthew J Armstrong 14, Mona Osman El Hage 15, Johannes Wiegand 16, Dina Attia 17, Veronique Verhoeven 18, Ashraf Abdul Qayoum Amir 19, Nagwa Nashat 1, Emmanuel A Tsochatzis 20, Yasser Fouad 21, Helena Cortez-Pinto 22
|
|
|
|
|
|
|
|
|
767. | NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH |
|
Hepatology. 2021 Dec 10. doi: 10.1002/hep.32274. Online ahead of print.
Jonathan G Stine 1 2 3 4, Ian R Schreibman 1 3, Alison J Faust 1 3, Jessica Dahmus 1, Benjamin Stern 1, Christopher Soriano 1, Gloriany Rivas 1, Breianna Hummer 1, Scot R Kimball 5, Nate R Geyer 2, Vernon M Chinchilli 2, Rohit Loomba 6 7, Kathryn Schmitz 2 4 8 9, Christopher Sciamanna 2 4 10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
781. | Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease |
|
Hepatol Commun. 2021 Sep 2. doi: 10.1002/hep4.1818. Online ahead of print.
Ashwini Arvind 1 2, Jacqueline B Henson 1 3, Stephanie A Osganian 2, Cheryl Nath 2, Lara M Steinhagen 2, Zoe N Memel 1 3, Arley Donovan 2, Oluwafemi Balogun 2, Raymond T Chung 1 2 4, Tracey G Simon 1 2 4, Kathleen E Corey 1 2 4
|
|
|
|
|
783. | Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry |
|
Clin Gastroenterol Hepatol. 2021 Nov 9;S1542-3565(21)01183-6.doi: 10.1016/j.cgh.2021.11.004.Online ahead of print.
Zobair M Younossi 1, Yusuf Yilmaz 2, Ming-Lung Yu 3, Vincent Wai-Sun Wong 4, Marlen Castellanos Fernandez 5, Vasily A Isakov 6, Ajay K Duseja 7, Nahum Mendez-Sanchez 8, Yuichiro Eguchi 9, Elisabetta Bugianesi 10, Patrizia Burra 11, Jacob George 12, Jian-Gao Fan 13, George V Papatheodoridis 14, Wah Kheong Chan 15, Khalid Alswat 16, Hamid S Saeed 17, Ashwani K Singal 18, Manuel Romero-Gomez 19, Stuart C Gordon 20, Stuart K Roberts 21, Mohamed El Kassas 22, Marcelo Kugelmas 23, Janus P Ong 24, Saleh Alqahtani 25, Mariam Ziayee 26, Brian Lam 27, Issah Younossi 28, Andrei Racila 27, Linda Henry 29, Maria Stepanova 29, Global NASH Council
|
|
|
784. | Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects |
|
J Gastrointestin Liver Dis. 2021 Sep 21;30(3):366-373. doi: 10.15403/jgld-3622.
Alexandra Feldman 1, Bernhard Wernly 2, Georg Strebinger 3, Sebastian Karl Eder 4, Stephan Zandanell 5, David Niederseer 6, Michael Strasser 7, Heike Haufe 8, Karl Sotlar 9, Bernhard Paulweber 10, Christian Datz 11, Elmar Aigner 12
|
|
|
|
|
|
|
|
|
|
|
|
|
790. | Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease |
|
Clin Infect Dis. 2021 Jun 15;72(12):2087-2094.doi: 10.1093/cid/ciaa382.
Lindsay T Fourman 1, Takara L Stanley 1, Isabel Zheng 1, Chelsea S Pan 1, Meghan N Feldpausch 1, Julia Purdy 2, Julia Aepfelbacher 2, Colleen Buckless 3, Andrew Tsao 3, Kathleen E Corey 4, Raymond T Chung 4, Martin Torriani 3, David E Kleiner 5, Colleen M Hadigan 2, Steven K Grinspoon 1
|
|
|
|
|
792. | Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease |
|
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1480-1488.e14. doi: 10.1016/j.cgh.2020.07.030.Epub 2020 Jul 21.
Nandini M Meyersohn 1, Thomas Mayrhofer 2, Kathleen E Corey 3, Daniel O Bittner 4, Pedro V Staziaki 5, Balint Szilveszter 5, Travis Hallett 5, Michael T Lu 5, Stefan B Puchner 6, Tracey G Simon 3, Borek Foldyna 5, Deepak Voora 7, Geoffrey S Ginsburg 7, Pamela S Douglas 8, Udo Hoffmann 5, Maros Ferencik 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
804. | Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study |
|
Eur J Nutr. 2021 Jun;60(4):1769-1780. doi: 10.1007/s00394-020-02370-6. Epub 2020 Aug 28.
Cristina Galarregui 1, Irene Cantero 1, Bertha Araceli Marin-Alejandre 1, J Ignacio Monreal 2 3, Mariana Elorz 2 4, Alberto Benito-Boillos 2 4, José Ignacio Herrero 2 5 6, Víctor de la O 2 7, Miguel Ruiz-Canela 2 7 8, Helen Hermana M Hermsdorff 9, Josefina Bressan 9, Josep A Tur 8 10, J Alfredo Martínez 1 2 8, M Angeles Zulet # 11 12 13, Itziar Abete # 14 15 16
|
|
|
|
|
|
|
|
|
808. | Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD |
|
Clin Gastroenterol Hepatol. 2021 Sep;19(9):1915-1924.e6. doi: 10.1016/j.cgh.2020.09.044.Epub 2020 Sep 30.
Tolga Gidener 1, Omar T Ahmed 1, Joseph J Larson 2, Kristin C Mara 2, Terry M Therneau 2, Sudhakar K Venkatesh 3, Richard L Ehman 3, Meng Yin 3, Alina M Allen 4
|
|
|
809. | Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD |
|
Dig Liver Dis. 2021 Sep;53(9):1154-1158. doi: 10.1016/j.dld.2020.09.021. Epub 2020 Oct 13.
Antonella Mosca 1, Annalisa Crudele 2, Antonella Smeriglio 3, Maria Rita Braghini 2, Nadia Panera 2, Donatella Comparcola 4, Arianna Alterio 4, Maria Rita Sartorelli 4, Giulia Tozzi 1, Massimiliano Raponi 5, Domenico Trombetta 3, Anna Alisi 6
|
|
|
|
|
|
|
|
|
|
|
814. | Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19 |
|
Dig Dis Sci. 2021 Sep;66(9):3192-3198. doi: 10.1007/s10620-020-06618-3. Epub 2020 Sep 27.
Vincent L Chen 1, Fadi Hawa 2, Jeffrey A Berinstein 3, Chanakyaram A Reddy 3, Ihab Kassab 4, Kevin D Platt 3, Chia-Yang Hsu 3, Calen A Steiner 3, Jeremy Louissaint 3, Naresh T Gunaratnam 5, Pratima Sharma 3
|
|
|
815. | ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis |
|
Hepatology. 2021 Jun;73(6):2238-2250. doi: 10.1002/hep.31576. Epub 2021 Apr 19.
Luis Calzadilla-Bertot 1, Eduardo Vilar-Gomez 2 3, Vincent Wai-Sun Wong 4, Manuel Romero-Gomez 3, Rocio Aller-de la Fuente 5, Grace Lai-Hung Wong 4, Marlen Castellanos 6, Mohammed Eslam 7, Archita P Desai 2, Gary P Jeffrey 1 8, Jacob George 7, Naga Chalasani 2, Leon A Adams 1 8
|
|
|
816. | Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard |
|
Clin Infect Dis. 2021 Jun 15;72(12):2124-2131. doi: 10.1093/cid/ciaa429.
Veeral H Ajmera 1 2, Edward R Cachay 3, Christian B Ramers 4, Shirin Bassirian 1, Seema Singh 1, Richele Bettencourt 1, Lisa Richards 1, Gavin Hamilton 5, Michael Middleton 5, Katie Fowler 5, Claude Sirlin 5, Rohit Loomba 1 2 6
|
|
|
817. | Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease |
|
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2202-2204. doi: 10.1016/j.cgh.2020.09.039.Epub 2020 Sep 30.
Samarth Patel 1, Mohammad Bilal Siddiqui 2, Jose Hernandez Roman 3, Emily Zhang 4, Emily Lee 4, Steve Shen 4, Masoud Faridnia 3, Robert J Mintini 5, Sherry Boyett 5, Michael O Idowu 6, Arun J Sanyal 1, Velimir A Luketic 1, Mohammad Shadab Siddiqui 1
|
|
|
|
|
819. | NAFLD and cardiovascular diseases: a clinical review |
|
Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7.Epub 2020 Jul 21.
Philipp Kasper 1, Anna Martin 1, Sonja Lang 2, Fabian Kütting 1, Tobias Goeser 1, Münevver Demir 3, Hans-Michael Steffen 4 5
|
|
|
|
|
|
|
|
|
|
|
|
|
825. | Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection |
|
Clin Infect Dis. 2021 Oct 5;73(7):e2184-e2193. doi: 10.1093/cid/ciaa1302.
James B Maurice 1 2, Robert Goldin 3, Andrew Hall 4, Jennifer C Price 5, Giada Sebastiani 6 7, Caryn G Morse 8, Laura Iogna Prat 2, Hugo Perazzo 9, Lucy Garvey 10, Patrick Ingiliz 11, Giovanni Guaraldi 12, Emmanouil Tsochatzis 2 13, Maud Lemoine 1
|
|
|
826. | Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease |
|
Clin Infect Dis. 2021 Aug 16;73(4):621-630.doi: 10.1093/cid/ciab019.
Takara L Stanley 1, Lindsay T Fourman 1, Lai Ping Wong 2, Ruslan Sadreyev 2, James M Billingsley 3, Meghan N Feldpausch 1, Isabel Zheng 1, Chelsea S Pan 1, Autumn Boutin 1, Hang Lee 4, Kathleen E Corey 5, Martin Torriani 6, David E Kleiner 7, Raymond T Chung 5, Colleen M Hadigan 8, Steven K Grinspoon 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
836. | Preparing for the NASH epidemic: A call to action |
|
Obesity (Silver Spring). 2021 Sep;29(9):1401-1412. doi: 10.1002/oby.23250.Epub 2021 Aug 8.
Fasiha Kanwal 1, Jay H Shubrook 2, Zobair Younossi 3, Yamini Natarajan 4, Elisabetta Bugianesi 5, Mary E Rinella 6, Stephen A Harrison 7, Christos Mantzoros 8, Kim Pfotenhauer 9, Samuel Klein 10, Robert H Eckel 11, Davida Kruger 12, Hashem El-Serag 4, Kenneth Cusi 13
|
|
|
837. | A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis |
|
Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087. Online ahead of print.
Jaime Bosch 1 2, Chuhan Chung 3, Oscar M Carrasco-Zevallos 4, Stephen A Harrison 5, Manal F Abdelmalek 6, Mitchell L Shiffman 7, Don C Rockey 8, Zahil Shanis 4, Dinkar Juyal 4, Harsha Pokkalla 4, Quang Huy Le 4, Murray Resnick 4, Michael Montalto 4, Andrew H Beck 4, Ilan Wapinski 4, Ling Han 3, Catherine Jia 3, Zachary Goodman 9, Nezam Afdhal 10, Robert P Myers 3, Arun J Sanyal 11
|
|
|
|
|
839. | Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes |
|
Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2685-2692. doi: 10.1016/j.numecd.2021.05.027.Epub 2021 Jun 6.
Francesco Vadini 1, Paola G Simeone 2, Giovambattista Desideri 3, Rossella Liani 2, Romina Tripaldi 2, Sonia Ciotti 2, Armando Tartaro 4, Maria T Guagnano 2, Augusto Di Castelnuovo 5, Francesco Cipollone 2, Agostino Consoli 2, Francesca Santilli 6
|
|
|
|
|
|
|
842. | Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease |
|
Gastroenterology. 2021 Sep;161(3):968-981.e12. doi: 10.1053/j.gastro.2021.05.008.Epub 2021 May 15.
Anja Fuchs 1, Dmitri Samovski 2, Gordon I Smith 2, Vincenza Cifarelli 2, Sarah S Farabi 2, Jun Yoshino 2, Terri Pietka 2, Shin-Wen Chang 1, Sarbani Ghosh 1, Terence M Myckatyn 1, Samuel Klein 3
|
|
|
843. | A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease |
|
Clin Gastroenterol Hepatol. 2021 Jul 3;S1542-3565(21)00719-9.
doi: 10.1016/j.cgh.2021.06.048.Online ahead of print.
Zobair M Younossi 1, Janus P Ong 2, Hirokazu Takahashi 3, Yusuf Yilmaz 4, Yuichiro Eguchi 5, Mohamed El Kassas 6, Maria Buti 7, Moisés Diago 8, Ming-Hua Zheng 9, Jian-Gao Fan 10, Ming-Lung Yu 11, Vincent Wai-Sun Wong 12, Khalid Alswat 13, Wah-Kheong Chan 14, Nahum Mendez-Sanchez 15, Patrizia Burra 16, Elisabetta Bugianesi 17, Ajay K Duseja 18, Jacob George 19, George V Papatheodoridis 20, Hamid Saeed 21, Laurent Castera 22, Marco Arrese 23, Marcelo Kugelmas 24, Manuel Romero-Gomez 25, Saleh Alqahtani 26, Mariam Ziayee 27, Brian Lam 28, Issah Younossi 27, Andrei Racila 28, Linda Henry 27, Maria Stepanova 27, Global NASH Council
|
|
|
844. | Exercise Training Reverses Gut Dysbiosis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis: A Proof of Concept Study |
|
Clin Gastroenterol Hepatol. 2021 Aug;19(8):1723-1725. doi: 10.1016/j.cgh.2020.08.063.Epub 2020 Aug 31.
Alexa Hughes 1, Jessica Dahmus 2, Gloriany Rivas 2, Breianna Hummer 2, Jeremy R Chen See 3, Justin R Wright 3, Regina Lamendella 4, Kathryn H Schmitz 5, Christopher Sciamanna 6, Mack Ruffin 7, Andrew D Patterson 8, Rohit Loomba 9, Jonathan G Stine 10
|
|
|
845. | Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling |
|
Hepatology. 2021 Aug;74(2):704-722. doi: 10.1002/hep.31755.
Fanta Barrow # 1, Saad Khan # 2 3, Gavin Fredrickson 1, Haiguang Wang 1, Katrina Dietsche 1, Preethy Parthiban 1, Sacha Robert 1, Thomas Kaiser 4, Shawn Winer 2, Adam Herman 5, Oyedele Adeyi 6, Marialena Mouzaki 7, Alexander Khoruts 8 9, Kristin A Hogquist 6 9, Christopher Staley 4, Daniel A Winer 2 3 10, Xavier S Revelo 1 9
|
|
|
|
|
847. | Effect of exercise on cardiometabolic health of adults with overweight or obesity: Focus on blood pressure, insulin resistance, and intrahepatic fat-A systematic review and meta-analysis |
|
Obes Rev. 2021 Jul;22 Suppl 4(Suppl 4):e13269. doi: 10.1111/obr.13269. Epub 2021 May 6.
Francesca Battista 1, Andrea Ermolao 1, Marleen A van Baak 2, Kristine Beaulieu 3, John E Blundell 3, Luca Busetto 4 5, Eliana V Carraça 6, Jorge Encantado 7, Dror Dicker 4 8, Nathalie Farpour-Lambert 4 9, Adriyan Pramono 2, Alice Bellicha 10 11, Jean-Michel Oppert 12
|
|
|
|
|
849. | NAFLD and renal function in children: is there a genetic link? |
|
Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):975-984.doi: 10.1080/17474124.2021.1906649. Epub 2021 Apr 14.
Anna Di Sessa 1, Stefano Guarino 1, Antonio Paride Passaro 1, Laura Liguori 1, Giuseppina Rosaria Umano 1, Grazia Cirillo 1, Emanuele Miraglia Del Giudice 1, Pierluigi Marzuillo 1
|
|
|
|
|
|
|
|
|
|
|
|
|
855. | Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology |
|
J Hepatol. 2021 Jul 29;S0168-8278(21)01948-6. doi: 10.1016/j.jhep.2021.07.018.Online ahead of print.
Gennaro D'Amico 1, Luigi Maruzzelli 2, Aldo Airoldi 3, Ioannis Petridis 4, Giulia Tosetti 5, Antonio Rampoldi 6, Mario D'Amico 7, Roberto Miraglia 2, Stella De Nicola 3, Vincenzo La Mura 8, Marco Solcia 6, Riccardo Volpes 4, Giovanni Perricone 3, Cristiano Sgrazzutti 9, Angelo Vanzulli 9, Massimo Primignani 5, Angelo Luca 2, Giuseppe Malizia 10, Alessandro Federico 11, Marcello Dallio 11, Angelo Andriulli 12, Angelo Iacobellis 12, Luigi Addario 13, Matteo Garcovich 14, Antonio Gasbarrini 14, Luchino Chessa 15, Francesco Salerno 16, Giulia Gobbo 16, Manuela Merli 17, Lorenzo Ridola 18, Gianluca Svegliati Baroni 19, Giuseppe Tarantino 19, Nicola Caporaso 20, Filomena Morisco 20, Pietro Pozzoni 21, Agostino Colli 21, Luca Saverio Belli 3
|
|
|
|
|
|
|
|
|
|
|
860. | FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption |
|
Cell Metab. 2021 Aug 3;33(8):1671-1684.e4. doi: 10.1016/j.cmet.2021.06.012. Epub 2021 Jul 15.
Bethan L Clifford 1, Leslie R Sedgeman 1, Kevin J Williams 2, Pauline Morand 3, Angela Cheng 3, Kelsey E Jarrett 1, Alvin P Chan 1, Madelaine C Brearley-Sholto 1, Annika Wahlström 4, Julianne W Ashby 1, William Barshop 3, James Wohlschlegel 3, Anna C Calkin 5, Yingying Liu 6, Anders Thorell 7, Peter J Meikle 8, Brian G Drew 9, Julia J Mack 10, Hanns-Ulrich Marschall 4, Elizabeth J Tarling 11, Peter A Edwards 12, Thomas Q de Aguiar Vallim 13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
867. | The relationship between frailty and cirrhosis etiology: From the Functional Assessment in Liver Transplantation (FrAILT) Study |
|
Liver Int. 2021 Jul 5.doi: 10.1111/liv.15006. Online ahead of print.
Chelsea Q Xu 1, Yara Mohamad 1, Matthew R Kappus 2, Brian Boyarsky 3, Daniel R Ganger 4, Michael L Volk 5, Robert S Rahimi 6, Andres Duarte-Rojo 7, Mara McAdams-DeMarco 3 8, Dorry L Segev 3 8, Daniela P Ladner 9 10, Elizabeth C Verna 11, Joshua Grab 12, Monica Tincopa 13, Michael A Dunn 7, Jennifer C Lai 1
|
|
|
|
|
869. | Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study |
|
Diagnostics (Basel). 2021 Jun 13;11(6):1083. doi: 10.3390/diagnostics11061083.
Nuria Perez-Diaz-Del-Campo 1 2, Jose I Riezu-Boj 2 3, Bertha Araceli Marin-Alejandre 1 2, J Ignacio Monreal 3 4, Mariana Elorz 3 5, José Ignacio Herrero 3 6 7, Alberto Benito-Boillos 3 5, Fermín I Milagro 1 2 3 8, Josep A Tur 8 9, Itziar Abete 1 2 3 8, M Angeles Zulet 1 2 3 8, J Alfredo Martinez 1 2 3 8
|
|
|
|
|
|
|
|
|
|
|
874. | TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial |
|
Gastroenterology. 2021 Jul 20;S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.Online ahead of print.
Rohit Loomba 1, Rizwana Mohseni 2, K Jean Lucas 3, Julio A Gutierrez 4, Robert G Perry 5, James F Trotter 6, Robert S Rahimi 6, Stephen A Harrison 7, Veeral Ajmera 8, Jeffrey D Wayne 9, Marie O'Farrell 10, William McCulloch 10, Katharine Grimmer 10, Mary Rinella 11, Vincent Wai-Sun Wong 12, Vlad Ratziu 13, Gregory J Gores 14, Brent A Neuschwander-Tetri 15, George Kemble 10
|
|
|
875. | Preparing for the NASH epidemic: A call to action |
|
Metabolism. 2021 Jul 6;154822. doi: 10.1016/j.metabol.2021.154822. Online ahead of print.
Fasiha Kanwal 1, Jay H Shubrook 2, Zobair Younossi 3, Yamini Natarajan 4, Elisabetta Bugianesi 5, Mary E Rinella 6, Stephen A Harrison 7, Christos Mantzoros 8, Kim Pfotenhauer 9, Samuel Klein 10, Robert H Eckel 11, Davida Kruger 12, Hashem El-Serag 4, Kenneth Cusi 13
|
|
|
|
|
877. | Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm |
|
Rom J Morphol Embryol. Oct-Dec 2020;61(4):1023-1031. doi: 10.47162/RJME.61.4.04.
Laura Mihaela Trandafir 1, Otilia Elena Frasinariu, Maria Magdalena Leon-Constantin, Stefan Chiriac, Mioara Florentina Trandafirescu, Ingrith Crenguta Miron, Alina Costina Luca, Alin Constantin Iordache, Elena Cojocaru
|
|
|
878. | Conventional ultrasound for diagnosis of hepatic steatosis is better than believed |
|
Z Gastroenterol. 2021 Jun 25. doi: 10.1055/a-1491-1771. Online ahead of print.
Christoph F Dietrich 1, Long Shi 2, Axel Löwe 1, Yi Dong 3, Andrej Potthoff 4, Zeno Sparchez 5, Andreas Teufel 6, Sabine Guth 7, Jonas Koch 1, Richard G Barr 8, Xin-Wu Cui 9
|
|
|
879. | Defining comprehensive models of care for NAFLD |
|
Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.Online ahead of print.
Jeffrey V Lazarus 1 2, Quentin M Anstee 3 4, Hannes Hagström 5, Kenneth Cusi 6, Helena Cortez-Pinto 7, Henry E Mark 8, Michael Roden 9 10 11, Emmanuel A Tsochatzis 12 13, Vincent Wai-Sun Wong 14, Zobair M Younossi 15, Shira Zelber-Sagi 16 17, Manuel Romero-Gómez # 18, Jörn M Schattenberg # 19
|
|
|
|
|
|
|
882. | Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis |
|
Hepatol Commun. 2021 May 12;5(7):1201-1211. doi: 10.1002/hep4.1710. eCollection 2021 Jul.
Zobair M Younossi 1 2, Maria Stepanova 3, Mazen Noureddin 4, Kris V Kowdley 5, Simone I Strasser 6, Anita Kohli 7, Peter Ruane 8, Mitchell L Shiffman 9, Aasim Sheikh 10, Nadege Gunn 11, Stephen H Caldwell 12, Ryan S Huss 13, Robert P Myers 13, Vincent Wai-Sun Wong 14, Naim Alkhouri 15, Zachary Goodman 1 2, Rohit Loomba 4
|
|
|
883. | Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis |
|
Clin Gastroenterol Hepatol. 2021 Jul 15;S1542-3565(21)00751-5. doi: 10.1016/j.cgh.2021.07.020.Online ahead of print.
Zobair M Younossi 1, Maria Stepanova 2, Fatema Nader 2, Rohit Loomba 3, Quentin M Anstee 4, Vlad Ratziu 5, Stephen Harrison 6, Arun J Sanyal 7, Jörn M Schattenberg 8, A Sidney Barritt 9, Mazen Noureddin 10, Martin Bonacci 11, Gail Cawkwell 11, Bruce Wong 11, Mary Rinella 12, REGENERATE Study Investigators
|
|
|
884. | Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm |
|
Rom J Morphol Embryol. Oct-Dec 2020;61(4):1023-1031. doi: 10.47162/RJME.61.4.04.
Laura Mihaela Trandafir 1, Otilia Elena Frasinariu, Maria Magdalena Leon-Constantin, Stefan Chiriac, Mioara Florentina Trandafirescu, Ingrith Crenguta Miron, Alina Costina Luca, Alin Constantin Iordache, Elena Cojocaru
|
|
|
885. | Conventional ultrasound for diagnosis of hepatic steatosis is better than believed |
|
Z Gastroenterol. 2021 Jun 25. doi: 10.1055/a-1491-1771. Online ahead of print.
Christoph F Dietrich 1, Long Shi 2, Axel Löwe 1, Yi Dong 3, Andrej Potthoff 4, Zeno Sparchez 5, Andreas Teufel 6, Sabine Guth 7, Jonas Koch 1, Richard G Barr 8, Xin-Wu Cui 9
|
|
|
886. | Defining comprehensive models of care for NAFLD |
|
Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.Online ahead of print.
Jeffrey V Lazarus 1 2, Quentin M Anstee 3 4, Hannes Hagström 5, Kenneth Cusi 6, Helena Cortez-Pinto 7, Henry E Mark 8, Michael Roden 9 10 11, Emmanuel A Tsochatzis 12 13, Vincent Wai-Sun Wong 14, Zobair M Younossi 15, Shira Zelber-Sagi 16 17, Manuel Romero-Gómez # 18, Jörn M Schattenberg # 19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
893. | Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation |
|
Sci Rep. 2021 Jun 23;11(1):13159. doi: 10.1038/s41598-021-92264-2.
Victoria L Slaughter 1, John W Rumsey 2, Rachel Boone 1, Duaa Malik 1, Yunqing Cai 2, Narasimhan Narasimhan Sriram 2, Christopher J Long 2, Christopher W McAleer 2, Stephen Lambert 3, Michael L Shuler 2, J J Hickman 4 5
|
|
|
|
|
|
|
|
|
897. | PPAR-?-induced Changes in Visceral Fat and Adiponectin Levels are Associated with Improvement of Steatohepatitis in Patients with NASH |
|
Liver Int. 2021 Jul 5. doi: 10.1111/liv.15005. Online ahead of print.
Amalia Gastaldelli 1 2, Silvia Sabatini 2 3, Fabrizia Carli 2, Melania Gaggini 2, Fernando Bril 4, Renata Belfort-DeAguiar 5, Vincenzo Positano 6, Diana Barb 4, Sushma Kadiyala 4 7, Stephen Harrison 8, Kenneth Cusi 4 7
|
|
|
898. | Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial |
|
Nat Med. 2021 Jul;27(7):1262-1271. doi: 10.1038/s41591-021-01425-3. Epub 2021 Jul 8.
Stephen A Harrison 1, Peter J Ruane 2, Bradley L Freilich 3, Guy Neff 4, Rashmee Patil 5, Cynthia A Behling 6, Chen Hu 7, Erica Fong 8, Brittany de Temple 8, Erik J Tillman 8, Timothy P Rolph 8, Andrew Cheng 8, Kitty Yale 9
|
|
|
|
|
|
|
901. | Towards collaborative management of nonalcoholic fatty liver disease (TCM-NAFLD): a 'real-world' pathway for fibrosis risk assessment in primary care |
|
Intern Med J. 2021 Jun 17. doi: 10.1111/imj.15422. Online ahead of print.
Kelly L Hayward 1 2, Benjamin J McKillen 1 2, Leigh U Horsfall 1 2, Carolyn McIvor 3, Katerina Liew 3, Jo Sexton 3, Amy L Johnson 1 2, Katharine M Irvine 1 4, Patricia C Valery 1 5, Steven M McPhail 6 7, Laurence J Britton 2 8, William Rosenberg 9 10, Ingrid Weate 11, Sue Williams 12, Elizabeth E Powell 1 2
|
|
|
|
|
|
|
904. | Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives |
|
J Pers Med. 2021 Jun 2;11(6):499. doi: 10.3390/jpm11060499.
Michele Finotti 1, Maurizio Romano 1, Pasquale Auricchio 2, Michele Scopelliti 1, Marco Brizzolari 1, Ugo Grossi 1, Marco Piccino 1, Stefano Benvenuti 3, Giovanni Morana 4, Umberto Cillo 2, Giacomo Zanus 1
|
|
|
|
|
|
|
907. | Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease |
|
J Hepatol. 2021 Jun 11;S0168-8278(21)00402-5.doi: 10.1016/j.jhep.2021.05.029.Online ahead of print.
Carolin Lackner 1, Rudolf E Stauber 2, Susan Davies 3, Helmut Denk 4, Hans Peter Dienes 5, Viviane Gnemmi 6, Maria Guido 7, Rosa Miquel 8, Valerie Paradis 9, Peter Schirmacher 10, Luigi Terracciano 11, Andrea Berghold 12, Gudrun Pregartner 12, Lukas Binder 2, Philipp Douschan 2, Florian Rainer 2, Stephan Sygulla 4, Marion Jager 13, Pierre-Emmanuel Rautou 13, Andreea Bumbu 14, Adelina Horhat 14, Ioana Rusu 15, Horia Stefanescu 14, Sönke Detlefsen 16, Aleksander Krag 17, Maja Thiele 17, Helena Cortez-Pinto 18, Christophe Moreno 19, Annette S H Gouw 20, Dina G Tiniakos 21
|
|
|
|
|
|
|
|
|
|
|
912. | Current management of NAFLD/NASH |
|
Liver Int. 2021 Jun;41 Suppl 1:89-94. doi: 10.1111/liv.14869.
Ana Carolina Cardoso 1, Claudio de Figueiredo-Mendes 2, Cristiane A Villela-Nogueira 1
|
|
|
913. | New drugs for NASH |
|
Liver Int. 2021 Jun;41 Suppl 1:112-118. doi: 10.1111/liv.14844.
Somaya A M Albhaisi 1, Arun J Sanyal 2
|
|
|
|
|
915. | Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort |
|
Eur J Clin Invest. 2021 Jun 13;e13627. doi: 10.1111/eci.13627. Online ahead of print.
Adrian Post 1, Erwin Garcia 2, Eline H van den Berg 3, Jose L Flores-Guerrero 1, Eke G Gruppen 1, Dion Groothof 1, Berend Daan Westenbrink 4, Margery A Connelly 2, Stephan J L Bakker 1, Robin P F Dullaart 1
|
|
|
|
|
|
|
918. | Natural history of NASH |
|
Liver Int. 2021 Jun;41 Suppl 1:78-82. doi: 10.1111/liv.14910.
Angelo Armandi 1, Elisabetta Bugianesi 1
|
|
|
919. | Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study |
|
Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.
A Sidney Barritt 1, Stephanie Watkins 2, Norman Gitlin 3, Samuel Klein 4, Anna S Lok 5, Rohit Loomba 6, Cheryl Schoen 2, K Rajender Reddy 7, Huy Ngoc Trinh 8, Andrea R Mospan 2, Miriam B Vos 9, L Michael Weiss 10, Kenneth Cusi 11, Brent A Neuschwander-Tetri 12, Arun J Sanyal 13
|
|
|
920. | The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease |
|
Int J Mol Sci. 2021 May 15;22(10):5239. doi: 10.3390/ijms22105239.
Laia Bertran 1, Angela Pastor 1, Marta Portillo-Carrasquer 1, Jessica Binetti 2, Carmen Aguilar 1, Salomé Martínez 3, Margarita Vives 4, Fàtima Sabench 4, José Antonio Porras 2, David Riesco 2, Daniel Del Castillo 4, Cristóbal Richart 1 2, Teresa Auguet 1 2
|
|
|
921. | Animal Fat Intake Is Associated with Albuminuria in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome |
|
Nutrients. 2021 May 4;13(5):1548. doi: 10.3390/nu13051548.
Manuela Abbate 1 2, Catalina M Mascaró 1 2, Sofía Montemayor 1 2, María Barbería-Latasa 3, Miguel Casares 4, Cristina Gómez 5, Lucia Ugarriza 1 2 6, Silvia Tejada 1 2 7, Itziar Abete 7 8, María Ángeles Zulet 7 8, Antoni Sureda 1 2 7, J Alfredo Martínez 7 8 9, Josep A Tur 1 2 7
|
|
|
922. | Psoriasis and Liver Damage in HIV-Infected Patients |
|
Cells. 2021 May 4;10(5):1099. doi: 10.3390/cells10051099.
Carmen Busca Arenzana 1, Lucía Quintana Castanedo 2, Clara Chiloeches Fernández 2, Daniel Nieto Rodríguez 2, Pedro Herranz Pinto 2, Ana Belén Delgado Hierro 1, Antonio Olveira Martín 3, María Luisa Montes Ramírez 1
|
|
|
923. | Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease |
|
Cancers (Basel). 2021 May 11;13(10):2305. doi: 10.3390/cancers13102305.
Gian Paolo Caviglia 1, Angelo Armandi 1, Chiara Rosso 1, Silvia Gaia 2, Serena Aneli 1 3, Emanuela Rolle 2, Maria Lorena Abate 1, Antonella Olivero 1, Aurora Nicolosi 1, Marta Guariglia 1, Davide Giuseppe Ribaldone 1, Patrizia Carucci 2, Giorgio Maria Saracco 1 2, Elisabetta Bugianesi 1 2
|
|
|
924. | Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review |
|
Int J Mol Sci. 2021 May 1;22(9):4807. doi: 10.3390/ijms22094807.
Raquel Cano 1, José L Pérez 1, Lissé Angarita Dávila 2, Ángel Ortega 1, Yosselin Gómez 1, Nereida Josefina Valero-Cedeño 3, Heliana Parra 1, Alexander Manzano 1, Teresa Isabel Véliz Castro 3, María P Díaz Albornoz 1, Gabriel Cano 4, Joselyn Rojas-Quintero 5, Maricarmen Chacín 6, Valmore Bermúdez 6
|
|
|
|
|
926. | Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH |
|
Mol Metab. 2021 Jun 9;101270. doi: 10.1016/j.molmet.2021.101270. Online ahead of print.
Gavin Fredrickson 1, Fanta Barrow 1, Katrina Dietsche 1, Preethy Parthiban 1, Saad Khan 2, Sacha Robert 1, Maya Demirchian 1, Hailey Rhoades 1, Haiguang Wang 1, Oyedele Adeyi 3, Xavier S Revelo 4
|
|
|
|
|
928. | PNPLA3 Genotype, Arachidonic Acid Intake, and Unsaturated Fat Intake Influences Liver Fibrosis in Hispanic Youth with Obesity |
|
Nutrients. 2021 May 12;13(5):1621. doi: 10.3390/nu13051621.
Roshonda B Jones 1, Lide Arenaza 2, Claudia Rios 1, Jasmine F Plows 1, Paige K Berger 1, Tanya L Alderete 3, Jennifer L Fogel 1, Krishna Nayak 4, Passant Mohamed 5, Darryl Hwang 5, Suzanne Palmer 5, Frank Sinatra 1, Hooman Allayee 6, Rohit Kohli 1, Michael I Goran 1
|
|
|
|
|
|
|
|
|
932. | Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease |
|
J Hepatol. 2021 Jun 3;S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.Online ahead of print.
Ramy Younes 1, Gian Paolo Caviglia 2, Olivier Govaere 3, Chiara Rosso 2, Angelo Armandi 2, Tiziana Sanavia 2, Grazia Pennisi 4, Antonio Liguori 5, Paolo Francione 6, Rocío Gallego-Durán 7, Javier Ampuero 7, Maria J Garcia Blanco 8, Rocio Aller 9, Dina Tiniakos 10, Alastair Burt 3, Ezio David 11, Fabio M Vecchio 12, Marco Maggioni 13, Daniela Cabibi 14, María Jesús Pareja 15, Marco Y W Zaki 16, Antonio Grieco 17, Anna L Fracanzani 6, Luca Valenti 18, Luca Miele 17, Piero Fariselli 2, Salvatore Petta 4, Manuel Romero-Gomez 7, Quentin M Anstee 19, Elisabetta Bugianesi 20
|
|
|
|
|
934. | The role of elastography in non-alcoholic fatty liver disease |
|
Minerva Gastroenterol (Torino). 2021 Jun;67(2):164-170. doi: 10.23736/S2724-5985.21.02801-4.
Antonio Liguori 1, Maria E Ainora 1, Laura Riccardi 1, Nicoletta DE Matthaeis 1, Fabrizio Pizzolante 1, Antonio Gasbarrini 1 2, Maria A Zocco 1 2, Antonio Grieco 1 2, Gianludovico Rapaccini 1 2, Luca Miele 3 2
|
|
|
|
|
|
|
|
|
|
|
939. | Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis |
|
Cochrane Database Syst Rev. 2021 Jun 11;6:CD013156.doi: 10.1002/14651858.CD013156.pub2.
Elena Buzzetti 1, Audrey Linden 2, Lawrence Mj Best 2, Angela M Madden 3, Danielle Roberts 2, Thomas J G Chase 4, Suzanne C Freeman 5, Nicola J Cooper 5, Alex J Sutton 5, Dominic Fritche 6, Elisabeth Jane Milne 7, Kathy Wright 8, Chavdar S Pavlov 9, Brian R Davidson 2, Emmanuel Tsochatzis 1, Kurinchi Selvan Gurusamy 2 9
|
|
|
940. | Infections at the nexus of metabolic-associated fatty liver disease |
|
Arch Toxicol. 2021 May 24;1-19. doi: 10.1007/s00204-021-03069-1.Online ahead of print.
Joost Boeckmans 1 2, Matthias Rombaut 3, Thomas Demuyser 4 5, Baptist Declerck 4, Denis Piérard 4, Vera Rogiers 3, Joery De Kock 3, Luc Waumans 6, Koen Magerman 6 7, Reinoud Cartuyvels 6, Jean-Luc Rummens 6, Robim M Rodrigues # 8, Tamara Vanhaecke # 3
|
|
|
|
|
|
|
|
|
944. | The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age |
|
Hepatol Commun. 2021 Feb 6;5(5):891-905. doi: 10.1002/hep4.1681. eCollection 2021 May.
Patricia C Valery 1, Christina M Bernardes 1, Benjamin Mckillen 2 3, Samath Amarasena 4, Katherine A Stuart 2, Gunter Hartel 1, Paul J Clark 2 5, Richard Skoien 4, Tony Rahman 6, Leigh Horsfall 2 3, Kelly Hayward 2 3, Rohit Gupta 6, Andrew Lee 5, Leshni Pillay 7, Elizabeth E Powell 2 3
|
|
|
|
|
|
|
|
|
948. | coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment |
|
Hepatol Commun. 2021 Feb 12;5(5):774-785. doi: 10.1002/hep4.1678. eCollection 2021 May.
Elizabeth Clearfield 1, Veronica Miller 2, Joseph Nadglowski 3, Katherine Barradas 2, Jennifer Al Naber 1, Arun J Sanyal 4, Brent A Neuschwander-Tetri 5, Donna A Messner 1, coreNASH Panel
Collaborators,
Collaborators
William Baldyga, Maria-Magdalena Balp, Catherine Brun-Strang, Robyn Carson, Wayne Eskridge, Kurinchi Gurusamy, Lars Hansen, Morten Hansen, Katy Harrison, Andras Harsanyi, Anders Hvelplund, Zoltán Kaló, Marko Korenjak, E J Milne, Euan McLeod, Michelle Mocarski, Joachim Musaeus, Fady Ntanios, Mazen Noureddin, Daniel Ollendorf, Jan Oscarsson, Stephen Rossi, Vlad Ratziu, Yaron Rotman, Leonardo Ruiz-Casas, Lewis Sandy, Jörn M Schattenberg, Mohammad Shadab Siddiqui, Gregory Steinberg, Ethan Weiss, Keith White, José Willemse, Kathy Wright, Michael Zemel
|
|
|
|
|
950. | Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality |
|
J Clin Endocrinol Metab. 2021 May 13;dgab339. doi: 10.1210/clinem/dgab339.Online ahead of print.
Georg Semmler 1 2, Sarah Wernly 1, Sebastian Bachmayer 1, Isabella Leitner 1, Bernhard Wernly 3, Matthias Egger 1, Lena Schwenoha 1, Leonora Datz 1, Lorenz Balcar 1 2, Marie Semmler 1, Felix Stickel 4, David Niederseer 5, Elmar Aigner 6, Christian Datz 1
|
|
|
|
|
952. | Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) |
|
Liver Int. 2021 May 12. doi: 10.1111/liv.14943. Online ahead of print.
Patrizia Burra 1, Debora Bizzaro 1, Anna Gonta 1, Sarah Shalaby 1, Martina Gambato 1, Maria Cristina Morelli 2, Silvia Trapani 3, Annarosa Floreani 4 5, Fabio Marra 6, Maurizia Rossana Brunetto 7, Gloria Taliani 8, Erica Villa 9, Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF)
|
|
|
|
|
954. | Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors |
|
Exp Biol Med (Maywood). 2021 May 6;15353702211009228. doi: 10.1177/15353702211009228.Online ahead of print.
Manush Saydmohammed 1, Anupma Jha 1, Vineet Mahajan 1, Dillon Gavlock 1, Tong Ying Shun 1, Richard DeBiasio 1, Daniel Lefever 1, Xiang Li 1, Celeste Reese 1, Erin E Kershaw 2, Vijay Yechoor 2, Jaideep Behari 3 4, Alejandro Soto-Gutierrez 5 6, Larry Vernetti 1 7, Andrew Stern 1 7, Albert Gough 1 7, Mark T Miedel 1 7, D Lansing Taylor 1 6 7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
968. | Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease |
|
Liver Int. 2021 Apr 25. doi: 10.1111/liv.14899. Online ahead of print.
Sonja Lang 1 2, Anna Martin 1, Xinlian Zhang 3, Fedja Farowski 4 5 6, Hilmar Wisplinghoff 7 8 9, Maria J G T Vehreschild 4 5 6, Marcin Krawczyk 10 11, Angela Nowag 7 9, Anne Kretzschmar 7, Claus Scholz 7, Philipp Kasper 1, Christoph Roderburg 12, Raphael Mohr 13, Frank Lammert 10 14, Frank Tacke 13, Bernd Schnabl 2 15, Tobias Goeser 1, Hans-Michael Steffen 1, Münevver Demir 13
|
|
|
969. | Allele Specific Variation at APOE Increases Non-alcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction |
|
Hum Mol Genet. 2021 Apr 15;ddab096. doi: 10.1093/hmg/ddab096. Online ahead of print.
Nicholette D Palmer 1, Bratati Kahali 2 3, Annapurna Kuppa 3, Yanhua Chen 3, Xiaomeng Du 3, Mary F Feitosa 4, Lawrence F Bielak 5, Jeffrey R O'Connell 6, Solomon K Musani 7, Xiuqing Guo 8, Albert V Smith 9, Kathleen A Ryan 6, Gudny Eirksdottir 9, Matthew A Allison 10, Donald W Bowden 1, Matthew J Budoff 11, J Jeffrey Carr 12, Yii-Der I Chen 8, Kent D Taylor 8, Adolfo Correa 7, Breland F Crudup 7, Brian Halligan 3, Jian Yang 13, Sharon L R Kardia 5, Lenore J Launer 14, Yi-Ping Fu 15 16, Thomas H Mosley 7, Jill M Norris 17, James G Terry 12, Christopher J O'Donnell 1, Jerome I Rotter 8, Lynne E Wagenknecht 18, Vilmundur Gudnason 9 19, Michael A Province 4, Patricia A Peyser 5, Elizabeth K Speliotes 3
|
|
|
970. | Definite and indeterminate NASH share similar clinical features and prognosis: a longitudinal study of 1893 biopsy-proven NAFLD subjects |
|
Liver Int. 2021 Apr 25. doi: 10.1111/liv.14898. Online ahead of print.
Javier Ampuero 1 2 3, Rocío Aller 4, Rocío Gallego-Durán 2 3, Javier Crespo 5, Javier Abad 6, Águeda González-Rodríguez 7, Judith Gómez-Camarero 8, Joan Caballería 3 9, Oreste Lo Iacono 10, Luis Ibañez 3 11, Javier García-Samaniego 3 12, Rosa Martín-Mateos 3 13, Rubén Francés 3 14, Conrado Fernández-Rodríguez 15, Moisés Diago 16, Germán Soriano 3 17, Raúl J Andrade 3 18, Raquel Latorre 19, Francisco Jorquera 3 20, Rosa María Morillas 3 21, Desamparados Escudero 22, Pamela Estévez 23, Manuel Hernández Guerra 24, Salvador Augustín 25, María Jesús Pareja-Megia 26, Jesús M Banales 3 27, Patricia Aspichueta 28, Salvador Benlloch 3 29, José Miguel Rosales 30, Javier Salmerón 31, Juan Turnes 32, Manuel Romero Gómez 1 2 3, HEPAmet Registry
|
|
|
971. | Non-alcoholic fatty liver disease |
|
Lancet. 2021 Apr 21;S0140-6736(20)32511-3.doi: 10.1016/S0140-6736(20)32511-3. Online ahead of print.
Elizabeth E Powell 1, Vincent Wai-Sun Wong 2, Mary Rinella 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
978. | Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine |
|
Front Endocrinol (Lausanne). 2021 Mar 18;12:601160. doi: 10.3389/fendo.2021.601160.eCollection 2021.
Andrea M Mueller 1, Robert Kleemann 2 3, Eveline Gart 2 4, Wim van Duyvenvoorde 2, Lars Verschuren 5, Martien Caspers 5, Aswin Menke 2, Natascha Krömmelbein 1, Kanita Salic 2, Yvonne Burmeister 1, Bernd Seilheimer 1, Martine C Morrison 2 4
|
|
|
979. | The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD) |
|
PLoS One. 2021 Apr 6;16(4):e0249614. doi: 10.1371/journal.pone.0249614. eCollection 2021.
Roberta D'Ambrosio 1, Irene Campi 2, Marco Maggioni 3, Riccardo Perbellini 1, Enza Giammona 4, Roberta Stucchi 4, Marta Borghi 1, Elisabetta Degasperi 1, Annalisa De Silvestri 5, Luca Persani 2 6, Laura Fugazzola 2 7, Pietro Lampertico 1 7
|
|
|
980. | Allele Specific Variation at APOE Increases Non-alcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction |
|
Hum Mol Genet. 2021 Apr 15;ddab096. doi: 10.1093/hmg/ddab096. Online ahead of print.
Nicholette D Palmer 1, Bratati Kahali 2 3, Annapurna Kuppa 3, Yanhua Chen 3, Xiaomeng Du 3, Mary F Feitosa 4, Lawrence F Bielak 5, Jeffrey R O'Connell 6, Solomon K Musani 7, Xiuqing Guo 8, Albert V Smith 9, Kathleen A Ryan 6, Gudny Eirksdottir 9, Matthew A Allison 10, Donald W Bowden 1, Matthew J Budoff 11, J Jeffrey Carr 12, Yii-Der I Chen 8, Kent D Taylor 8, Adolfo Correa 7, Breland F Crudup 7, Brian Halligan 3, Jian Yang 13, Sharon L R Kardia 5, Lenore J Launer 14, Yi-Ping Fu 15 16, Thomas H Mosley 7, Jill M Norris 17, James G Terry 12, Christopher J O'Donnell 1, Jerome I Rotter 8, Lynne E Wagenknecht 18, Vilmundur Gudnason 9 19, Michael A Province 4, Patricia A Peyser 5, Elizabeth K Speliotes 3
|
|
|
981. | Saroglitazar, a PPAR-a/? Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial |
|
Hepatology. 2021 Apr 2. doi: 10.1002/hep.31843. Online ahead of print.
Samer Gawrieh 1, Mazen Noureddin 2, Nicole Loo 3, Rizwana Mohseni 4, Vivek Awasty 5, Kenneth Cusi 6, Kris V Kowdley 7, Michelle Lai 8, Eugene Schiff 9, Deven Parmar 10, Pankaj Patel 11, Naga Chalasani 1
|
|
|
982. | MAFLD in Obese Children: A Challenging Definition |
|
Children (Basel). 2021 Mar 23;8(3):247. doi: 10.3390/children8030247.
Anna Di Sessa 1, Stefano Guarino 1, Giuseppina Rosaria Umano 1, Mattia Arenella 1, Salvatore Alfiero 1, Gaetano Quaranta 1, Emanuele Miraglia Del Giudice 1, Pierluigi Marzuillo 1
|
|
|
|
|
|
|
985. | Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults |
|
Nutrients. 2021 Mar 17;13(3):966. doi: 10.3390/nu13030966.
Christopher D Crabtree 1, Madison L Kackley 1, Alexandru Buga 1, Brandon Fell 1, Richard A LaFountain 1, Parker N Hyde 1, Teryn N Sapper 1, William J Kraemer 1, Debbie Scandling 2, Orlando P Simonetti 2 3, Jeff S Volek 1
|
|
|
986. | PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center |
|
J Pers Med. 2021 Mar 1;11(3):165. doi: 10.3390/jpm11030165.
Georg Semmler 1 2 3, Lorenz Balcar 1 2, Hannes Oberkofler 4, Stephan Zandanell 1, Michael Strasser 1, David Niederseer 5, Alexandra Feldman 1, Felix Stickel 6, Pavel Strnad 7, Christian Datz 3, Bernhard Paulweber 1, Elmar Aigner 1
|
|
|
|
|
|
|
|
|
|
|
991. | Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes |
|
Front Endocrinol (Lausanne). 2021 Mar 4;12:642432. doi: 10.3389/fendo.2021.642432.eCollection 2021.
Jacqueline Bayliss 1, Geraldine J Ooi 2, William De Nardo 1, Yazmin Johari Halim Shah 2, Magdalene K Montgomery 1, Catriona McLean 3, William Kemp 4, Stuart K Roberts 4, Wendy A Brown 2, Paul R Burton 2, Matthew J Watt 1
|
|
|
|
|
|
|
|
|
|
|
996. | NASH limits anti-tumour surveillance in immunotherapy-treated HCC |
|
Nature. 2021 Mar 24. doi: 10.1038/s41586-021-03362-0. Online ahead of print.
Dominik Pfister 1 2, Nicolás Gonzalo Núñez 3, Roser Pinyol 4, Olivier Govaere 5, Matthias Pinter 6 7, Marta Szydlowska 1, Revant Gupta 8 9, Mengjie Qiu 10, Aleksandra Deczkowska 11, Assaf Weiner 11, Florian Müller 1, Ankit Sinha 12 13, Ekaterina Friebel 3, Thomas Engleitner 14 15 16, Daniela Lenggenhager 17, Anja Moncsek 18, Danijela Heide 1, Kristin Stirm 1, Jan Kosla 1, Eleni Kotsiliti 1, Valentina Leone 1 19, Michael Dudek 20, Suhail Yousuf 10, Donato Inverso 21 22, Indrabahadur Singh 1 23, Ana Teijeiro 24, Florian Castet 4, Carla Montironi 4, Philipp K Haber 25, Dina Tiniakos 5 26, Pierre Bedossa 5, Simon Cockell 27, Ramy Younes 5 28, Michele Vacca 29, Fabio Marra 30, Jörn M Schattenberg 31, Michael Allison 32, Elisabetta Bugianesi 28, Vlad Ratziu 33, Tiziana Pressiani 34, Antonio D'Alessio 34, Nicola Personeni 34 35, Lorenza Rimassa 34 35, Ann K Daly 5, Bernhard Scheiner 6 7, Katharina Pomej 6 7, Martha M Kirstein 36 37, Arndt Vogel 36, Markus Peck-Radosavljevic 38, Florian Hucke 38, Fabian Finkelmeier 39, Oliver Waidmann 39, Jörg Trojan 39, Kornelius Schulze 40, Henning Wege 40, Sandra Koch 41, Arndt Weinmann 41, Marco Bueter 42, Fabian Rössler 42, Alexander Siebenhüner 43, Sara De Dosso 44, Jan-Philipp Mallm 45, Viktor Umansky 46 47, Manfred Jugold 48, Tom Luedde 49, Andrea Schietinger 50 51, Peter Schirmacher 52, Brinda Emu 1, Hellmut G Augustin 21 22, Adrian Billeter 53, Beat Müller-Stich 53, Hiroto Kikuchi 54, Dan G Duda 54, Fabian Kütting 55, Dirk-Thomas Waldschmidt 55, Matthias Philip Ebert 56, Nuh Rahbari 57, Henrik E Mei 58, Axel Ronald Schulz 58, Marc Ringelhan 59 60 61, Nisar Malek 62, Stephan Spahn 62, Michael Bitzer 62, Marina Ruiz de Galarreta 25 63, Amaia Lujambio 25 63 64, Jean-Francois Dufour 65 66, Thomas U Marron 25 67, Ahmed Kaseb 68, Masatoshi Kudo 69, Yi-Hsiang Huang 70 71, Nabil Djouder 24, Katharina Wolter 72 73, Lars Zender 72 73 74, Parice N Marche 75 76, Thomas Decaens 75 76 77, David J Pinato 78 79, Roland Rad 14 15 16, Joachim C Mertens 18, Achim Weber 17 80, Kristian Unger 19, Felix Meissner 12, Susanne Roth 10, Zuzana Macek Jilkova 75 76 78, Manfred Claassen 8 9, Quentin M Anstee 5 81, Ido Amit 11, Percy Knolle 20, Burkhard Becher 3, Josep M Llovet 82 83 84, Mathias Heikenwalder 85
Affiliations collapse
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1004. | Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease |
|
Hepatology. 2021 Mar 20. doi: 10.1002/hep.31822. Online ahead of print.
Joseph W Beals 1, Gordon I Smith 1, Mahalakshmi Shankaran 2, Anja Fuchs 3, George G Schweitzer 1, Jun Yoshino 1, Tyler Field 2, Marcy Matthews 2, Edna Nyangau 2, Darya Morozov 4, Bettina Mittendorfer 1, Marc K Hellerstein 2, Samuel Klein 1
|
|
|
1005. | European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease? |
|
JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.
Jeffrey V Lazarus 1, Adam Palayew 2, Patrizia Carrieri 3, Mattias Ekstedt 4, Giulio Marchesini 5, Katja Novak 6, Vlad Ratziu 7, Manuel Romero-Gómez 8, Frank Tacke 9, Shira Zelber-Sagi 10, Helena Cortez-Pinto 11, Quentin M Anstee 12 13
|
|
|
|
|
|
|
|
|
1009. | The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis |
|
Contemp Clin Trials. 2021 Feb 28;106335. doi: 10.1016/j.cct.2021.106335. Online ahead of print.
Manal F Abdelmalek 1, Edgar D Charles 2, Arun J Sanyal 3, Stephen A Harrison 4, Brent A Neuschwander-Tetri 5, Zachary Goodman 6, Richard A Ehman 7, Morten Karsdal 8, Atsushi Nakajima 9, Shuyan Du 10, Giridhar S Tirucherai 10, George H Klinger 10, Johanna Mora 10, Masayuki Yamaguchi 10, Diane E Shevell 10, Rohit Loomba 11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016. | Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis |
|
Front Endocrinol (Lausanne). 2021 Jan 27;11:575843. doi: 10.3389/fendo.2020.575843.eCollection 2020.
Andrea Dennis 1, Matt D Kelly 1, Carolina Fernandes 1, Sofia Mouchti 1, Jonathan A Fallowfield 2, Gideon Hirschfield 3, Michael Pavlides 4 5 6, Stephen Harrison 4 7, Manu V Chakravarthy 8, Rajarshi Banerjee 1, Arun Sanyal 9
|
|
|
|
|
1018. | Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT |
|
ESC Heart Fail. 2021 Feb 14. doi: 10.1002/ehf2.13250. Online ahead of print.
Anthony E Peters 1, Ambarish Pandey 2, Colby Ayers 2, Kara Wegermann 3, Robert W McGarrah 1, Justin L Grodin 2, Manal F Abdelmalek 3, Tarek Bekfani 4, Vanessa L Blumer 1, Anna Mae Diehl 3, Cynthia A Moylan 3, Marat Fudim 1
|
|
|
|
|
1020. | A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis |
|
J Hepatol. 2021 Feb 10;S0168-8278(21)00099-4. doi: 10.1016/j.jhep.2021.01.047.Online ahead of print.
Stephen A Harrison 1, Mustafa R Bashir 2, Kyoung-Jin Lee 3, Jennifer Shim-Lopez 3, Jonathan Lee 3, Brandee Wagner 3, Nicholas D Smith 3, Hubert C Chen 4, Eric J Lawitz 5
|
|
|
1021. | Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition |
|
J Lipid Res. 2020 Dec;61(12):1629-1644. doi: 10.1194/jlr.RA120000924. Epub 2021 Jan 12.
Genta Kakiyama 1, Dalila Marques 2, Rebecca Martin 3, Hajime Takei 4, Daniel Rodriguez-Agudo 2, Sandra A LaSalle 5, Taishi Hashiguchi 6, Xiaoying Liu 7, Richard Green 7, Sandra Erickson 8, Gregorio Gil 9, Michael Fuchs 2, Mitsuyoshi Suzuki 10, Tsuyoshi Murai 11, Hiroshi Nittono 4, Phillip B Hylemon 12, Huiping Zhou 12, William M Pandak 13
|
|
|
|
|
|
|
|
|
|
|
1026. | NAFLD-related HCC |
|
Adv Cancer Res. 2021;149:143-169. doi: 10.1016/bs.acr.2020.11.001. Epub 2021 Jan 21.
Bubu A Banini 1, Arun J Sanyal 2
|
|
|
1027. | A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH |
|
Hepatology. 2021 Feb 11. doi: 10.1002/hep.31750. Online ahead of print.
Amaro Taylor-Weiner 1, Harsha Pokkalla 1, Ling Han 2, Catherine Jia 2, Ryan Huss 2, Chuhan Chung 2, Hunter Elliott 1, Benjamin Glass 1, Kishalve Pethia 1, Oscar Carrasco-Zevallos 1, Chinmay Shukla 1, Urmila Khettry 3, Robert Najarian 4, Ross Taliano 5, G Mani Subramanian 2, Robert P Myers 2, Ilan Wapinski 1, Aditya Khosla 1, Murray Resnick 1 5, Michael C Montalto 1, Quentin M Anstee 6, Vincent Wai-Sun Wong 7, Michael Trauner 8, Eric J Lawitz 9, Stephen A Harrison 10, Takeshi Okanoue 11, Manuel Romero-Gomez 12, Zachary Goodman 13 14, Rohit Loomba 15, Andrew H Beck 1, Zobair M Younossi 13 14
|
|
|
1028. | Human Nonalcoholic Steatohepatitis on a Chip |
|
Hepatol Commun. 2020 Nov 29;5(2):217-233. doi: 10.1002/hep4.1647. eCollection 2021 Feb.
May S Freag 1 2, Bumseok Namgung 1 2, Maria E Reyna Fernandez 1 2, Ermanno Gherardi 3, Shiladitya Sengupta 1 2 4, Hae Lin Jang 1
|
|
|
|
|
|
|
1031. | Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? |
|
Gut. 2021 Feb 4;gutjnl-2020-322564. doi: 10.1136/gutjnl-2020-322564. Online ahead of print.
Ramy Younes 1 2 3, Olivier Govaere 1, Salvatore Petta 4, Luca Miele 5 6, Dina Tiniakos 1 7, Alastair Burt 1, Ezio David 3, Fabio Maria Vecchio 5 8, Marco Maggioni 9, Daniela Cabibi 10, Duncan McLeod 11, Maria Jesus Pareja 12, Anna Ludovica Fracanzani 13, Rocio Aller 14, Chiara Rosso 3, Javier Ampuero 15, Rocío Gallego-Durán 15, Angelo Armandi 3, Gian Paolo Caviglia 3, Marco Y W Zaki 1 16, Antonio Liguori 5, Paolo Francione 13, Grazia Pennisi 4, Antonio Grieco 5 6, Giovanni Birolo 3, Piero Fariselli 3, Mohammed Eslam 17, Luca Valenti 18, Jacob George 17, Manuel Romero-Gómez 15, Quentin Mark Anstee 19 20, Elisabetta Bugianesi 21
|
|
|
|
|
1033. | Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement |
|
Hepatology. 2021 Jan 23. doi: 10.1002/hep.31726. Online ahead of print.
Hannes Hagström 1 2 3, Leon A Adams 4, Alina M Allen 5, Christopher D Byrne 6 7, Yoosoo Chang 8, Henning Grønbaek 9, Mona Ismail 10 11, Peter Jepsen 9, Fasiha Kanwal 12, Jennifer Kramer 12, Jeffrey V Lazarus 13, Michelle T Long 14, Rohit Loomba 15, Philip N Newsome 16 17, Ian A Rowe 18, Seungho Ryu 8 19, Jörn M Schattenberg 20, Marina Serper 21, Nick Sheron 22, Tracey G Simon 23 24, Elliot B Tapper 25, Sarah Wild 26, Vincent Wai-Sun Wong 27, Yusuf Yilmaz 28 29, Shira Zelber-Sagi 30, Fredrik Åberg 31 32
|
|
|
|
|
|
|
|
|
1037. | Association of liver enzymes with incident diabetes in US Hispanic/Latino adults |
|
Diabet Med. 2021 Jan 12;e14522. doi: 10.1111/dme.14522. Online ahead of print.
Simin Hua 1, Qibin Qi 1, Jorge R Kizer 2, Jessica Williams-Nguyen 3, Howard D Strickler 1, Bharat Thyagarajan 4, Martha Daviglus 5, Gregory A Talavera 6, Neil Schneiderman 7, Scott J Cotler 8, Jianwen Cai 9, Robert Kaplan 1 3, Carmen R Isasi 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1047. | Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis |
|
Obes Surg. 2021 Jan 6. doi: 10.1007/s11695-020-05084-0. Online ahead of print.
Saurabh Chandan 1, Babu P Mohan 2, Shahab R Khan 3, Antonio Facciorusso 4, Daryl Ramai 5, Lena L Kassab 6, Neil Bhogal 7, Ravishankar Asokkumar 8, Gortrand Lopez-Nava 8, Stephanie McDonough 2, Douglas G Adler 9
|
|
|
|
|
|
|
|
|
1051. | Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease |
|
Mol Metab. 2020 Dec 22;101154. doi: 10.1016/j.molmet.2020.101154. Online ahead of print.
Chris E Shannon 1, Mukundan Ragavan 2, Juan Pablo Palavicini 3, Marcel Fourcaudot 1, Terry Bakewell 1, Ivan A Valdez 1, Iriscilla Ayala 1, Eunsook S Jin 4, Muniswamy Madesh 5, Xianlin Han 6, Matthew E Merritt 2, Luke Norton 7
|
|
|
1052. | Glycogenosis is Common in Nonalcoholic Fatty Liver Disease and is Independently Associated with Ballooning, but Lower Steatosis and Lower Fibrosis |
|
Liver Int. 2020 Dec 22. doi: 10.1111/liv.14773. Online ahead of print.
Daniela S Allende 1, Samer Gawrieh 2, Oscar W Cummings 3, Patricia Belt 4, Laura Wilson 4, Mark Van Natta 4, Cynthia A Behling 5, Danielle Carpenter 6, Ryan M Gill 7, David E Kleiner 8, Mathew M Yeh 9, Naga Chalasani 2, Cynthia D Guy 10, NASH Clinical Research Network
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1068. | Regulation of gene transcription by thyroid hormone receptor ß agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH) |
|
PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. eCollection 2020.
Xuan G Luong 1, Sarah K Stevens 1, Andreas Jekle 1, Tse-I Lin 2, Kusum Gupta 1, Dinah Misner 1, Sushmita Chanda 1, Sucheta Mukherjee 1, Caroline Williams 1, Antitsa Stoycheva 1, Lawrence M Blatt 1, Leonid N Beigelman 1, Julian A Symons 1, Pierre Raboisson 2, David McGowan 2, Koen Vandyck 2, Jerome Deval 1
|
|
|
1069. | The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH) |
|
Gastroenterology. 2020 Dec 8;S0016-5085(20)35529-3. doi: 10.1053/j.gastro.2020.12.003.Online ahead of print.
Zobair M Younossi 1, Quentin M Anstee 2, Vincent Wai-Sun Wong 3, Michael Trauner 4, Eric J Lawitz 5, Stephen A Harrison 6, Marianne Camargo 7, Kathryn Kersey 7, G Mani Subramanian 7, Robert P Myers 7, Maria Stepanova 8
|
|
|
1070. | Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression |
|
Metabolism. 2020 Dec 1;154457. doi: 10.1016/j.metabol.2020.154457. Online ahead of print.
Nisreen Nimer 1, Ibrahim Choucair 2, Zeneng Wang 2, Ina Nemet 2, Lin Li 2, Janet Gukasyan 3, Taylor L Weeks 2, Naim Alkhouri 4, Nizar Zein 5, W H Wilson Tang 6, Michael A Fischbach 5, J Mark Brown 2, Hooman Allayee 3, Srinivasan Dasarathy 7, Valentin Gogonea 8, Stanley L Hazen 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1077. | A diabetologist |
|
Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.
Kenneth Cusi 1 2
|
|
|
|
|
1079. | Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016 |
|
Medicine (Baltimore). 2018 Aug;97(31):e11518.doi: 10.1097/MD.0000000000011518.
Pegah Golabi 1, Haley Bush 1, Maria Stepanova 2, Cameron T Locklear 3, Ira M Jacobson 4, Alita Mishra 3, Gregory Trimble 3, Madeline Erario 3, Chapy Venkatesan 3, Issah Younossi 2, Zachary Goodman 1 3, Zobair M Younossi 1 3
|
|
|
|
|
|
|
|
|
|
|
|
|
1085. | NAFLD and COVID-19: a Pooled Analysis |
|
SN Compr Clin Med. 2020 Nov 6;1-4. doi: 10.1007/s42399-020-00631-3. Online ahead of print.
Sonali Sachdeva 1, Harshwardhan Khandait 2, Jonathan Kopel 3, Mark M Aloysius 4, Rupak Desai 5, Hemant Goyal 4
|
|
|
|
|
1087. | Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes |
|
Hepatol Commun. 2020 Aug 28;4(11):1637-1650. doi: 10.1002/hep4.1581. eCollection 2020 Nov.
Zobair M Younossi 1 2, Vincent Wai-Sun Wong 3, Quentin M Anstee 4 5, Manuel Romero-Gomez 6, Michael H Trauner 7, Stephen A Harrison 8, Eric J Lawitz 9, Takeshi Okanoue 10, Marianne Camargo 11, Kathryn Kersey 11, Robert P Myers 11, Zachary Goodman 1 2, Maria Stepanova 12
|
|
|
1088. | Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH |
|
Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622. Online ahead of print.
Rohit Loomba 1, Mazen Noureddin 2, Kris V Kowdley 3, Anita Kohli 4, Aasim Sheikh 5, Guy Neff 6, Bal Raj Bhandari 7, Nadege Gunn 8, Stephen H Caldwell 9, Zachary Goodman 10, Ilan Wapinski 11, Murray Resnick 11, Andrew H Beck 11, Dora Ding 12, Catherine Jia 12, Jen-Chieh Chuang 12, Ryan S Huss 12, Chuhan Chung 12, G Mani Subramanian 12, Robert P Myers 12, Keyur Patel 13, Brian B Borg 14, Reem Ghalib 15, Heidi Kabler 16, John Poulos 17, Ziad Younes 18, Magdy Elkhashab 19, Tarek Hassanein 20, Rajalakshmi Iyer 21, Peter Ruane 22, Mitchell L Shiffman 23, Simone Strasser 24, Vincent Wai-Sun Wong 25, Naim Alkhouri 26, ATLAS Investigators
|
|
|
|
|
|
|
|
|
1092. | Relationship of IGF-1 and IGF Binding Proteins to Disease Severity and Glycemia in Non-Alcoholic Fatty Liver Disease |
|
J Clin Endocrinol Metab. 2020 Oct 30;dgaa792. doi: 10.1210/clinem/dgaa792.Online ahead of print.
Takara L Stanley 1, Lindsay T Fourman 1, Isabel Zheng 1, Colin M McClure 1, Meghan N Feldpausch 1, Martin Torriani 2, Kathleen E Corey 3, Raymond T Chung 3, Hang Lee 4, David E Kleiner 5, Colleen M Hadigan 6, Steven K Grinspoon 1
|
|
|
|
|
|
|
|
|
|
|
1097. | Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination |
|
Sci Rep. 2020 Oct 27;10(1):18345. doi: 10.1038/s41598-020-75227-x.
Valentin Blank 1 2, David Petroff 2 3, Sebastian Beer 1, Albrecht Böhlig 4, Maria Heni 1, Thomas Berg 4, Yvonne Bausback 5, Arne Dietrich 2 6, Anke Tönjes 7, Marcus Hollenbach 1, Matthias Blüher 2 7, Volker Keim 1, Johannes Wiegand 4, Thomas Karlas 8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1108. | Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis |
|
J Hepatol. 2020 Oct 7;S0168-8278(20)33673-4. doi: 10.1016/j.jhep.2020.09.029.Online ahead of print.
Catherine Frenette 1, Zeid Kayali 2, Edward Mena 3, Parvez S Mantry 4, Kathryn J Lucas 5, Guy Neff 6, Miguel Rodriguez 7, Paul J Thuluvath 8, Ethan Weinberg 9, Bal R Bhandari 10, James Robinson 11, Nicole Wedick 12, Jean L Chan 11, David T Hagerty 11, Kris V Kowdley 13, IDN-6556-17 Study Investigators
|
|
|
1109. | One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial |
|
J Clin Med. 2020 Oct 6;9(10):E3213. doi: 10.3390/jcm9103213.
Louise Vedtofte 1 2, Emilie Bahne 1 2, Signe Foghsgaard 1 2 3, Jonatan I Bagger 1 2, Camilla Andreasen 1 2, Charlotte Strandberg 4, Peter M Gørtz 5, Jens J Holst 6 7, Henning Grønbæk 8, Jens A Svare 9, Tine D Clausen 10, Elisabeth R Mathiesen 11 12, Peter Damm 12 13, Lise L Gluud 12 14, Filip K Knop 1 2 7 12, Tina Vilsbøll 1 2 12
|
|
|
1110. | The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease |
|
Contemp Clin Trials. 2020 Oct 9;106175. doi: 10.1016/j.cct.2020.106175. Online ahead of print.
Timothy Hardy 1, Kristy Wonders 2, Ramy Younes 3, Guruprasad P Aithal 4, Rocio Aller 5, Michael Allison 6, Pierre Bedossa 2, Fay Betsou 7, Jerome Boursier 8, M Julia Brosnan 9, Alastair Burt 1, Jeremy Cobbold 10, Helena Cortez-Pinto 11, Chris P Day 1, Jean-Francois Dufour 12, Mattias Ekstedt 13, Sven Francque 14, Stephen Harrison 15, Luca Miele 16, Patrik Nasr 13, George Papatheodoridis 17, Salvatore Petta 18, Dina Tiniakos 19, Richard Torstenson 20, Luca Valenti 21, Adriaan G Holleboom 22, Hannele Yki-Jarvinen 23, Andreas Geier 24, Manuel Romero-Gomez 25, Vlad Ratziu 26, Elisabetta Bugianesi 27, Jörn M Schattenberg 28, Quentin M Anstee 29, LITMUS Consortium
|
|
|
|
|
|
|
1113. | Non-Alcoholic Fatty Liver Disease in a sample of individuals with Bipolar Disorders: Results From the FACE-BD Cohort |
|
Acta Psychiatr Scand. 2020 Oct 4. doi: 10.1111/acps.13239. Online ahead of print.
Ophelia Godin 1 2, Marion Leboyer 1 2, Raoul Belzeaux 1 3, Frank Bellivier 1 4, Joséphine Loftus 1 5, Philippe Courtet 1 6, Caroline Dubertret 1 7, Sebastien Gard 1 8, Chantal Henry 9, Pierre-Michel Llorca 1 10, Raymund Schwan 1 11, Christine Passerieux 1 12, Mircea Polosan 1 13, Ludovic Samalin 1 10, Emilie Olié 1 6, Bruno Etain 1 4, FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators
Collaborators
- FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators:
B Etain, C Henry, E Olié, M Leboyer, E Haffen, P M Llorca, V Barteau, S Bensalem, O Godin, H Laouamri, K Souryis, H Mondor, S Hotier, A Pelletier, N Drancourt, J P Sanchez, E Saliou, C Hebbache, J Petrucci, L Willaume, E Bourdin, F Bellivier, M Carminati, B Etain, J Maruani, E Marlinge, M Meyrel, B Antoniol, A Desage, S Gard, A Jutant, K Mbailara, I Minois, L Zanouy, L Bardin, A Cazals, P Courtet, B Deffinis, D Ducasse, M Gachet, A Henrion, F Molière, B Noisette, E Olié, G Tarquini, R Belzeaux, N Correard, F Groppi, A Lefrere, L Lescalier, E Moreau, J Pastol, M Rebattu, B Roux, N Viglianese, R Cohen, Raymund Schwan, J P Kahn, M Milazzo, O Wajsbrot-Elgrabli, T Bougerol, B Fredembach, A Suisse, B Halili, A Pouchon, M Polosan, A M Galliot, I Grévin, A S Cannavo, N Kayser, C Passerieux, P Roux, V Aubin, I Cussac, M A Dupont, J Loftus, I Medecin, C Dubertret, N Mazer, C Portalier, C Scognamiglio, A Bing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1122. | The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care |
|
JHEP Rep. 2020 Aug 4;2(6):100168. doi: 10.1016/j.jhepr.2020.100168. eCollection 2020 Dec.
Wolf Peter Hofmann 1 2, Peter Buggisch 2 3, Lisa Schubert 1 4, Nektarios Dikopoulos 5, Jeannette Schwenzer 6, Marion Muche 4, Gisela Felten 7, Renate Heyne 8, Patrick Ingiliz 9, Anna Schmidt 10, Kerstin Stein 11, Heiner Wedemeyer 12, Thomas Berg 13, Johannes Wiegand 13, Frank Lammert 14, Stefan Zeuzem 15, Jörn M Schattenberg 16 17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1130. | Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers |
|
J Clin Med Res. 2020 Aug;12(8):472-482. doi: 10.14740/jocmr3932. Epub 2020 Jul 22.
Ebenezer T Oni 1, Vincent Figueredo 2, Ehimen Aneni 3, Emir Veladar 4, John W McEvoy 5, Michael J Blaha 5 6, Roger S Blumenthal 5, Raquel D Conceicao 7, Jose A M Carvalho 7, Raul D Santos 7 8, Khurram Nasir 9
|
|
|
1131. | Improvement in Insulin Resistance and Estimated Hepatic Steatosis and Fibrosis after Endoscopic Sleeve Gastroplasty |
|
Gastrointest Endosc. 2020 Aug 27;S0016-5107(20)34733-7. doi:10.1016/j.gie.2020.08.023.Online ahead of print.
Kaveh Hajifathalian 1, Amit Mehta 1, Bryan Ang 2, Daniel Skaf 2, Shawn Shah 1, Monica Saumoy 3, Qais Dawod 1, Enad Dawod 2, Alpana Shukla 4, Louis Aronne 4, Robert Brown 1, David Cohen 1, Andrew J Dannenberg 5, Brett Fortune 1, Sonal Kumar 1, Reem Z Sharaiha 6
|
|
|
1132. | Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging |
|
Alzheimers Dement (N Y). 2020 Aug 24;6(1):e12065.doi: 10.1002/trc2.12065. eCollection 2020.
Vincenzo Solfrizzi 1, Emanuele Scafato 2 3, Carlo Custodero 1, Francesca Loparco 1, Alessandro Ciavarella 1, Francesco Panza 4 5, Davide Seripa 4 6, Bruno Pietro Imbimbo 7, Madia Lozupone 8, Nicola Napoli 1, Giuseppina Piazzolla 1, Lucia Galluzzo 3, Claudia Gandin 2, Marzia Baldereschi 9, Antonio Di Carlo 9, Domenico Inzitari 9 10, Alberto Pilotto 1 11, Carlo Sabbà 1, Italian Longitudinal Study on Aging Working Group
|
|
|
1133. | Tackling NAFLD: Three Targeted Populations |
|
Hepatology. 2020 Aug 31. doi: 10.1002/hep.31533. Online ahead of print.
Kara Wegermann 1, Ayako Suzuki 1 2, Alisha M Mavis 3, Manal F Abdelmalek 1, Anna Mae Diehl 1, Cynthia A Moylan 1 2
|
|
|
|
|
1135. | NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes |
|
J Diabetes Complications. 2020 Jul 17;107684. doi: 10.1016/j.jdiacomp.2020.107684.Online ahead of print.
Rosa Lombardi 1, Lorena Airaghi 2, Giovanni Targher 3, Gaetano Serviddio 4, Gabriele Maffi 2, Alessandro Mantovani 3, Claudio Maffeis 5, Antonio Colecchia 6, Rosanna Villani 4, Luca Rinaldi 7, Emanuela Orsi 8, Giuseppina Pisano 2, Luigi Elio Adinolfi 7, Silvia Fargion 2, Anna Ludovica Fracanzani 2
|
|
|
|
|
|
|
1138. | Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program |
|
PLoS One. 2020 Aug 25;15(8):e0237430.doi: 10.1371/journal.pone.0237430. eCollection 2020.
Marina Serper 1 2 3, Marijana Vujkovic 1, David E Kaplan 1 2, Rotonya M Carr 1 2, Kyung Min Lee 4 5 6, Qing Shao 4, Donald R Miller 4, Peter D Reaven 7, Lawrence S Phillips 8 9, Christopher J O'Donnell 10 11, James B Meigs 12, Peter W F Wilson 8 9, Rachel Vickers-Smith 13, Henry R Kranzler 13 14, Amy C Justice 15 16 17, John M Gaziano 10 18, Sumitra Muralidhar 19, Saiju Pyarajan 10 11, Scott L DuVall 6 20, Themistocles L Assimes 21 22, Jennifer S Lee 21 22, Philip S Tsao 21 22, Daniel J Rader 2 23 24 25, Scott M Damrauer 1 26, Julie A Lynch 6 27, Danish Saleheen 1 28, Benjamin F Voight 1 23 29, Kyong-Mi Chang 1 2, VA Million Veteran Program
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1145. | Trimethylamine N-Oxide levels are associated with NASH in obese subjects with type 2 diabetes |
|
Diabetes Metab. 2020 Aug 10;S1262-3636(20)30102-6. doi: 10.1016/j.diabet.2020.07.010.Online ahead of print.
Paola León-Mimila 1, Hugo Villamil-Ramírez 2, Xinmin S Li 3, Diana M Shih 1, Simon T Hui 1, Elvira Ocampo-Medina 2, Blanca López-Contreras 2, Sofía Morán-Ramos 4, Marisol Olivares-Arevalo 2, Paula Grandini-Rosales 2, Luis Macías-Kauffer 2, Israel González-González 5, Rogelio Hernández-Pando 6, Francisco Gómez-Pérez 7, Francisco Campos-Pérez 5, Carlos Aguilar-Salinas 8, Elena Larrieta-Carrasco 9, Teresa Villarreal-Molina 10, Zeneng Wang 3, Aldons J Lusis 1, Stanley L Hazen 11, Adriana Huertas-Vazquez 12, Samuel Canizales-Quinteros 13
|
|
|
|
|
|
|
|
|
1149. | Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis |
|
Gastroenterology. 2020 Aug 8;S0016-5085(20)35018-6. doi: 10.1053/j.gastro.2020.08.004.Online ahead of print.
Stephen A Harrison 1, Guy Neff 2, Cynthia D Guy 3, Mustafa R Bashir 4, Angelo H Paredes 5, Juan P Frias 6, Ziad Younes 7, James F Trotter 8, Nadege T Gunn 9, Sam E Moussa 10, Anita Kohli 11, Kristin Nelson 12, Mildred Gottwald 12, William C G Chang 12, Andrew Z Yan 12, Alex M DePaoli 12, Lei Ling 13, Hsiao D Lieu 12
|
|
|
|
|
1151. | A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study |
|
Lancet Gastroenterol Hepatol. 2020 Aug 4;S2468-1253(20)30252-1.doi: 10.1016/S2468-1253(20)30252-1. Online ahead of print.
Stephen A Harrison 1, Vlad Ratziu 2, Jérôme Boursier 3, Sven Francque 4, Pierre Bedossa 5, Zouher Majd 6, Geneviève Cordonnier 6, Fouad Ben Sudrik 6, Raphael Darteil 7, Roman Liebe 8, Jérémy Magnanensi 6, Yacine Hajji 6, John Brozek 6, Alice Roudot 6, Bart Staels 9, Dean W Hum 6, Sophie Jeannin Megnien 10, Suneil Hosmane 6, Noémie Dam 6, Pierre Chaumat 6, Rémy Hanf 11, Quentin M Anstee 12, Arun J Sanyal 13
|
|
|
|
|
|
|
|
|
|
|
|
|
1157. | Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study |
|
Nutrients. 2020 Jul 18;12(7):E2141. doi: 10.3390/nu12072141.
Mikiko Watanabe 1, Renata Risi 1, Elisabetta Camajani 1, Savina Contini 1, Agnese Persichetti 1, Dario Tuccinardi 2, Ilaria Ernesti 3, Stefania Mariani 1, Carla Lubrano 1, Alfredo Genco 3, Giovanni Spera 1, Lucio Gnessi 1, Sabrina Basciani 1
|
|
|
|
|
|
|
|
|
|
|
1162. | Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases |
|
Ethan M Weinberg 1, Huy N Trinh 2, Roberto J Firpi 3, Kalyan Ram Bhamidimarri 4, Samuel Klein 5, Jonathan Durlam 6, Stephanie Watkins 6, K Rajender Reddy 1, Michael Weiss 7, Richard C Zink 6, Anna S Lok 8
Clin Gastroenterol Hepatol. 2020 Jul 3;S1542-3565(20)30930-7. doi:10.1016/j.cgh.2020.06.066.Online ahead of print.
|
|
|
1163. | Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices |
|
Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.
Zobair M Younossi 1, Kathleen E Corey 2, Naim Alkhouri 3, Mazen Noureddin 4, Ira Jacobson 5, Brian Lam 1, Stephen Clement 1, Rita Basu 6, Stuart Gordon 7, Natarajan Ravendhra 8, Puneet Puri 9, Mary Rinella 10, Peter Scudera 1, Ashwani K Singal 11, Linda Henry 12, US Members of the Global Nash Council
|
|
|
1164. | Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial |
|
Am J Gastroenterol. 2020 Jul;115(7):1055-1065. doi: 10.14309/ajg.0000000000000661.
Laura Craven 1, Adam Rahman 2 3, Seema Nair Parvathy 4, Melanie Beaton 2 3, Justin Silverman 5, Karim Qumosani 2 3, Irene Hramiak 2 6, Rob Hegele 2 6 7, Tisha Joy 2 6, Jon Meddings 8, Brad Urquhart 2, Ruth Harvie 9, Charles McKenzie 2 7, Kelly Summers 1 2, Gregor Reid 1 2 9, Jeremy P Burton 1 2 9, Michael Silverman 1 2 4
|
|
|
|
|
1166. | Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) |
|
Hepatol Int. 2020 Jul 4;1-11.doi: 10.1007/s12072-020-10072-8. Online ahead of print.
Shiv Kumar Sarin 1, Ashok Choudhury 2, George K Lau 3, Ming-Hua Zheng 3 4, Dong Ji 3 5, Sherief Abd-Elsalam 6, Jaeseok Hwang 7, Xiaolong Qi 8, Ian Homer Cua 9, Jeong Ill Suh 10, Jun Gi Park 10, Opass Putcharoen 11, Apichat Kaewdech 12, Teerha Piratvisuth 12, Sombat Treeprasertsuk 11, Sooyoung Park 13, Salisa Wejnaruemarn 11, Diana A Payawal 14, Oidov Baatarkhuu 15, Sang Hoon Ahn 16, Chang Dong Yeo 16, Uzziel Romar Alonzo 14, Tserendorj Chinbayar 17, Imelda M Loho 18, Osamu Yokosuka 19, Wasim Jafri 20, Soeksiam Tan 21, Lau Ing Soo 21, Tawesak Tanwandee 22, Rino Gani 23, Lovkesh Anand 24, Eslam Saber Esmail 6, Mai Khalaf 6, Shahinul Alam 25, Chun-Yu Lin 26, Wan-Long Chuang 26, A S Soin 27, Hitendra K Garg 28, Kemal Kalista 29, Badamnachin Batsukh 15, Hery Djagat Purnomo 30, Vijay Pal Dara 31, Pravin Rathi 32, Mamun Al Mahtab 25, Akash Shukla 33, Manoj K Sharma 2, Masao Omata 34 35, APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1176. | Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results From Randomized Phase III STELLAR Trials |
|
Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6.
Stephen A Harrison 1, Vincent Wai-Sun Wong 2, Takeshi Okanoue 3, Natalie Bzowej 4, Raj Vuppalanchi 5, Ziad Younes 6, Anita Kohli 7, Shiv Sarin 8, Stephen H Caldwell 9, Naim Alkhouri 10, Mitchell L Shiffman 11, Marianne Camargo 12, Georgia Li 12, Kathryn Kersey 12, Catherine Jia 12, Yanni Zhu 12, C Stephen Djedjos 12, G Mani Subramanian 12, Robert P Myers 12, Nadege Gunn 13, Aasim Sheikh 14, Quentin M Anstee 15, Manuel Romero-Gomez 16, Michael Trauner 17, Zachary Goodman 18, Eric J Lawitz 10, Zobair Younossi 18, STELLAR-3 and STELLAR-4 Investigators
|
|
|
|
|
|
|
1179. | Novel Antisense Inhibition of Diacylglycerol O-acyltransferase 2 for Treatment of Non-Alcoholic Fatty Liver Disease: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial |
|
Lancet Gastroenterol Hepatol. 2020 Jun 15;S2468-1253(20)30186-2.doi: 10.1016/S2468-1253(20)30186-2. Online ahead of print.
Rohit Loomba 1, Erin Morgan 2, Lynnetta Watts 2, Shuting Xia 2, Lisa A Hannan 2, Richard S Geary 2, Brenda F Baker 2, Sanjay Bhanot 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1186. | Prediction of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease Using Gut Microbiota-Based Approaches Compared With Simple Non-Invasive Tools |
|
Sci Rep. 2020 Jun 10;10(1):9385. doi: 10.1038/s41598-020-66241-0.
Sonja Lang 1 2, Fedja Farowski 3 4 5, Anna Martin 1, Hilmar Wisplinghoff 6 7 8, Maria J G T Vehreschild 3 4 5, Marcin Krawczyk 9 10, Angela Nowag 6 8, Anne Kretzschmar 6, Claus Scholz 6, Philipp Kasper 1, Christoph Roderburg 11, Frank Lammert 9, Tobias Goeser 1, Hans-Michael Steffen 1, Münevver Demir 12 13
|
|
|
|
|
|
|
1189. | Burden of Nonalcoholic Fatty Liver Disease in Canada, 2019-2030: A Modelling Study |
|
CMAJ Open. 2020 Jun 9;8(2):E429-E436. doi: 10.9778/cmajo.20190212. Print Apr-Jun 2020.
Mark G Swain 1, Alnoor Ramji 1, Keyur Patel 1, Giada Sebastiani 1, Abdel Aziz Shaheen 1, Edward Tam 1, Paul Marotta 1, Magdy Elkhashab 1, Harpreet S Bajaj 1, Chris Estes 2, Homie Razavi 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1201. | Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum |
|
J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9.doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.
Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
|
|
|
1202. | Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial |
|
Gastroenterol. 2020 May 15. doi: 10.14309/ajg.0000000000000661. Online ahead of print.
Laura Craven 1, Adam Rahman 2 3, Seema Nair Parvathy 4, Melanie Beaton 2 3, Justin Silverman 5, Karim Qumosani 2 3, Irene Hramiak 2 6, Rob Hegele 2 6 7, Tisha Joy 2 6, Jon Meddings 8, Brad Urquhart 2, Ruth Harvie 9, Charles McKenzie 2 7, Kelly Summers 1 2, Gregor Reid 1 2 9, Jeremy P Burton 1 2 9, Michael Silverman 1 2 4
|
|
|
1203. | Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease |
|
Gastroenterol. 2020 May 25. doi: 10.14309/ajg.0000000000000676. Online ahead of print.
Ramy Younes 1 2, Olivier Govaere 2, Salvatore Petta 3, Luca Miele 4 5, Dina Tiniakos 2, Alastair Burt 2, Ezio David 6, Fabio M Vecchio 4 7, Marco Maggioni 8, Daniela Cabibi 9, Anna L Fracanzani 10, Chiara Rosso 1, Maria J Garcia Blanco 11, Angelo Armandi 1, Gian Paolo Caviglia 1, Marco Y W Zaki 2 12, Antonio Liguori 4, Paolo Francione 10, Grazia Pennisi 3, Antonio Grieco 4 5, Luca Valenti 13, Quentin M Anstee 2 14, Elisabetta Bugianesi 1
|
|
|
|
|
1205. | Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis |
|
Hepatology. 2020 May 16.doi: 10.1002/hep.31317. Online ahead of print.
Kimberly P Newton 1 2, Joel E Lavine 3, Laura Wilson 4 5, Cynthia Behling 6 7, Miriam B Vos 8, Jean P Molleston 9, Philip Rosenthal 10, Tamir Miloh 11, Mark H Fishbein 12, Ajay K Jain 13, Karen F Murray 14, Jeffrey B Schwimmer 1 2, Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN):
Donna Garner, Paula Hertel, Ryan Himes, Alicia Lawson, Tamir Miloh, Nicole Triggs, Kristin Bramlage, April Carr, Kim Cecil, Meghan McNeill, Marialena Mouzaki, Andrew Trout, Stavra Xanthakos, Kimberlee Bernstein, Stephanie DeVore, Rohit Kohli, Kathleen Lake, Daniel Podberesky, Alex Towbin, Joel E Lavine, Ali Mencin, Elena Reynoso, Adina Alazraki, Rebecca Cleeton, Maria Cordero, Albert Hernandez, Saul Karpen, Jessica Cruz Munos, Nicholas Raviele, Miriam Vos, Molly Bozic, Laura Carr, Oscar W Cummings, Kathryn Harlow, Ann Klipsch, Jean P Molleston, Emily Ragozzino, Girish Rao, Kimberly Kafka, Ann Scheimann, Mark H Fishbein, Saeed Mohammad, Peter F Whitington, Sarah Barlow, Elizabeth M Brunt, Danielle Carpenter, Theresa Cattoor, Jose Derdoy, Janet Freebersyser, Ajay Jain Debra King, Jinping Lai, Joan Siegner, Susan Stewart, Susan Torretta, Kristina Wriston, Jennifer Arin, Cynthia Behling, Craig Bross, Carissa Carrier, Diana De La Pena, Janis Durelle, Mary Catherine Huckaby, Michael S Middleton, Kimberly Newton, Jeffrey B Schwimmer, Claude Sirlin, Patricia Ugalde-Nicalo, Jesse Courtier, Ryan Gill, Camille Langlois, Emily Rothbaum Perito, Philip Rosenthal, Patrika Tsai, Niviann Blondet, Kara Cooper, Karen Murray, Randolph Otto, Matthew Yeh, Melissa Young, Elizabeth M Brunt, Kathryn Fowler, David E Kleiner, Edward C Doo, Sherry Hall, Jay H Hoofnagle, Patricia R Robuck, Averell H Sherker, Rebecca Torrance, Patricia Belt, Jeanne M Clark, John Dodge, Michele Donithan, Milana Isaacson, Mariana Lazo, Jill Meinert, Laura Miriel, Emily P Sharkey, Jacqueline Smith, Michael Smith, Alice Sternberg, James Tonascia, Mark L Van Natta, Annette Wagoner, Laura A Wilson, Goro Yamada, Katherine P Yates
|
|
|
|
|
|
|
1208. | Non-alcoholic Liver Disease and Childhood Obesity |
|
Arch Dis Child. 2020 May 14;archdischild-2019-318063.doi: 10.1136/archdischild-2019-318063. Online ahead of print.
Meera Shaunak 1, Christopher D Byrne 2 3, Nikki Davis 1 2, Paul Afolabi 2 3, Saul N Faust 2 3 4, Justin Huw Davies 5 2
|
|
|
|
|
1210. | Risk Stratification of Patients With Nonalcoholic Fatty Liver Disease Using a Case Identification Pathway in Primary Care: A Cross-Sectional Study |
|
MAJ Open. 2020 May 15;8(2):E370-E376.doi: 10.9778/cmajo.20200009. Print Apr-Jun 2020.
Abdel Aziz Shaheen 1, Kiarash Riazi 2, Alexandra Medellin 2, Deepak Bhayana 2, Gilaad G Kaplan 2, Jason Jiang 2, Roy Park 2, Wendy Schaufert 2, Kelly W Burak 2, Monica Sargious 2, Mark G Swain 2
|
|
|
|
|
1212. | Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis |
|
Clin Gastroenterol Hepatol. 2020 Apr 30;S1542-3565(20)30613-3.doi: 10.1016/j.cgh.2020.04.068. Online ahead of print.
Fateh Bazerbachi 1, Eric J Vargas 2, Monika Rizk 2, Daniel B Maselli 2, Taofic Mounajjed 3, Sudhakar K Venkatesh 4, Kymberly D Watt 2, John D Port 4, Rita Basu 5, Andres Acosta 2, Ibrahim Hanouneh 2, Naveen Gara 6, Meera Shah 7, Manpreet Mundi 7, Matthew Clark 7, Karen Grothe 7, Andrew C Storm 2, Michael J Levy 2, Barham K Abu Dayyeh 8
|
|
|
1213. | Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis |
|
Immunity. 2020 May 1;S1074-7613(20)30159-X. doi: 10.1016/j.immuni.2020.04.001.Online ahead of print.
Jason S Seidman 1, Ty D Troutman 2, Mashito Sakai 1, Anita Gola 3, Nathanael J Spann 1, Hunter Bennett 1, Cassi M Bruni 1, Zhengyu Ouyang 1, Rick Z Li 1, Xiaoli Sun 4, BaoChau T Vu 1, Martina P Pasillas 1, Kaori M Ego 1, David Gosselin 5, Verena M Link 6, Ling-Wa Chong 7, Ronald M Evans 8, Bonne M Thompson 9, Jeffrey G McDonald 9, Mojgan Hosseini 10, Joseph L Witztum 4, Ronald N Germain 3, Christopher K Glass 11
|
|
|
|
|
1215. | Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum |
|
J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9 doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.
Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
|
|
|
|
|
1217. | Biomarkers of NAFLD and NASH |
|
Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.
Michelle T Long 1, Sanil Gandhi 2, Rohit Loomba 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1233. | Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum |
|
J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9. doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.
Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1241. | Bile acids associate with specific gut microbiota, low level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease |
|
Adams LA1,2, Wang Z1,2, Liddle C3, Melton PE4,5, Ariff A4, Chandraratna H6, Tan J7, Ching H1, Coulter S3, de Boer B8, Christophersen CT9,10, O'Sullivan TA9, Morrison M11, Jeffrey GP1,2. Liver Int. 2020 Apr 3. doi: 10.1111/liv.14453. [Epub ahead of print]
|
|
|
1242. | Dietary Factors in Relation to Liver Fat Content: A Cross-sectional Study |
|
Watzinger C1, Nonnenmacher T2, Grafetstätter M1, Sowah SA1,3, Ulrich CM4, Kauczor HU2, Kaaks R1, Schübel R1,2, Nattenmüller J2, Kühn T1. Nutrients. 2020 Mar 20;12(3). pii: E825. doi: 10.3390/nu12030825.
|
|
|
|
|
1244. | Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study |
|
Newsome PN1, Palmer M2, Freilich B3, Sheikh MY4, Sheikh A5, Sarles H6, Herring R7, Mantry P8, Kayali Z9, Hassanein T10, Lee HM2, Aithal GP11; Volixibat in Adults study group. J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186-0. doi: 10.1016/j.jhep.2020.03.024. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1253. | Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk |
|
Han E1, Lee YH2,3, Kim YD4, Kim BK2,5,6, Park JY2,5,6, Kim DY2,5,6, Ahn SH2,5,6, Lee BW2,3, Kang ES2,3, Cha BS2,3, Han KH2,5,6, Nam HS4, Heo JH4, Kim SU2,5,6. Am J Gastroenterol. 2020 Mar 3. doi: 10.14309/ajg.0000000000000572. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1257. | Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials |
|
Harrison SA1, Wai-Sun Wong V2, Okanoue T3, Bzowej N4, Vuppalanchi R5, Younes Z6, Kohli A7, Sarin S8, Caldwell SH9, Alkhouri N10, Shiffman ML11, Camargo M12, Li G12, Kersey K12, Jia C12, Zhu Y12, Djedjos CS12, Subramanian GM12, Myers RP12, Gunn N13, Sheikh A14, Anstee QM15, Romero-Gomez M16, Trauner M17, Goodman Z18, Lawitz EJ10, Younossi Z18; STELLAR-3 and STELLAR-4 Investigators. J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126-4. doi: 10.1016/j.jhep.2020.02.027. [Epub ahead of print]
|
|
|
1258. | Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial |
|
Patel K1, Harrison SA2, Elkashab M3, Trotter JF4, Herring R5, Rojter S6, Kayali Z7, Wong VW8, Greenbloom S9, Jayakumar S10, Shiffman ML11, Freilich B12, Lawitz EJ, Gane E13,14, Harting E15, Xu J15, Billin AN15, Chung C15, Djedjos CS15, Subramanian GM15, Myers RP15, Middleton MS10, Rinella M16, Noureddin M17. Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1263. | A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic LiverDisease Mainly Due to NAFLD |
|
Dong TS1, Katzka W1,2, Lagishetty V1,2, Luu K1,2, Hauer M1,2, Pisegna J3, Jacobs JP4,5,6. Sci Rep. 2020 Feb 17;10(1):2771. doi: 10.1038/s41598-020-59535-w.
|
|
|
1264. | Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study |
|
VanWagner LB1,2, Wilcox JE2,3, Ning H2, Lewis CE4, Carr JJ5, Rinella ME1, Shah SJ3, Lima JAC6, Lloyd-Jones DM2,3. J Am Heart Assoc. 2020 Feb 18;9(4):e014279. doi: 10.1161/JAHA.119.014279. Epub 2020 Feb 6.
|
|
|
|
|
|
|
|
|
|
|
1269. | New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent? |
|
Guaraldi G1, Maurice JB2, Marzolini C3, Monteith K4, Milic J1, Tsochatzis E5, Bhagani S6, Morse CG7, Price JC8, Ingiliz P9,10, Lemoine M11, Sebastiani G12; SHIVER Network. Hepatology. 2020 Feb 13. doi: 10.1002/hep.31177. [Epub ahead of print]
|
|
|
1270. | The association of nonalcoholic steatohepatitis and hepatocellular carcinoma |
|
Asfari MM1,2, Talal Sarmini M2, Alomari M2, Lopez R3, Dasarathy S4,5,6, McCullough AJ4,5,6. Eur J Gastroenterol Hepatol. 2020 Feb 18. doi: 10.1097/MEG.0000000000001681. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1274. | NAFLD 2020: The State of the Disease |
|
Cotter TG1, Rinella M2. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30223-7. doi: 10.1053/j.gastro.2020.01.052. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1286. | Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis |
|
Taylor RS1, Taylor RJ2, Bayliss S3, Hagstrom H4, Nasr P5, Schattenberg JM6, Ishigami M7, Toyoda H8, Wai-Sun Wong V9, Peleg N10, Shlomai A11, Sebastiani G12, Seko Y13, Bhala N14, Younossi ZM15, Anstee QM16, McPherson S17, Newsome PN18; Collaborators. Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043. [Epub ahead of print]
|
|
|
|
|
|
|
1289. | Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study |
|
Ratziu V1, Sanyal A2, Harrison SA3, Wong VW4, Francque S5, Goodman Z6, Aithal GP7, Kowdley KV8, Seyedkazemi S9, Fischer L9, Loomba R10,11, Abdelmalek MF12, Tacke F13,14. Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108. [Epub ahead of print]
|
|
|
1290. | Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis |
|
Loomba R1, Neuschwander-Tetri BA2, Sanyal A3, Chalasani N4, Diehl AM5, Terrault N6, Kowdley K7, Dasarathy S8, Kleiner D9, Behling C1, Lavine J10, Van Natta M11, Middleton M1, Tonascia J11, Sirlin C1; NASH Clinical Research Network. Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121. [Epub ahead of print]
|
|
|
|
|
1292. | Multiparametric Magnetic Resonance Elastography Improves the Detection of NASHRegression Following Bariatric Surgery |
|
Allen AM1, Shah VH1, Therneau TM2, Venkatesh SK3, Mounajjed T4, Larson JJ2, Mara KC2, Kellogg TA5, Kendrick ML5, McKenzie TJ5, Greiner SM1, Li J3, Glaser KJ3, Wells ML3, Gunneson TJ6, Ehman RL3, Yin M3. Hepatol Commun. 2019 Nov 5;4(2):185-192. doi: 10.1002/hep4.1446. eCollection 2020 Feb.
|
|
|
1293. | FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study |
|
Newsome PN1, Sasso M2, Deeks JJ3, Paredes A4, Boursier J5, Chan WK6, Yilmaz Y7, Czernichow S8, Zheng MH9, Wong VW10, Allison M11, Tsochatzis E12, Anstee QM13, Sheridan DA14, Eddowes PJ15, Guha IN15, Cobbold JF16, Paradis V17, Bedossa P18, Miette V2, Fournier-Poizat C19, Sandrin L2, Harrison SA20. Lancet Gastroenterol Hepatol. 2020 Feb 3. pii: S2468-1253(19)30383-8. doi: 10.1016/S2468-1253(19)30383-8. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1298. | Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease |
|
Scorletti E1, Afolabi PR2, Miles EA3, Smith DE2, Almehmadi A3, Alshathry A3, Childs CE3, Del Fabbro S3, Beavis J3, Moyses HE4, Clough GF3, Sethi JK5, Patel J6, Wright M6, Breen DJ7, Peebles C7, Darekar A8, Aspinall R9, Fowell AJ9, Dowman JK9, Nobili V10, Targher G11, Delzenne NM12, Bindels LB12, Calder PC13, Byrne CD2. Gastroenterology. 2020 Jan 24. pii: S0016-5085(20)30124-4. doi: 10.1053/j.gastro.2020.01.031. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1302. | Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack |
|
Oates JR1,2,3, McKell MC1,3,4, Moreno-Fernandez ME1,2, Damen MSMA1,2, Deepe GS Jr5, Qualls JE1,3,4, Divanovic S1,2,3,6. Front Immunol. 2019 Dec 12;10:2893. doi: 10.3389/fimmu.2019.02893. eCollection 2019.
|
|
|
|
|
|
|
|
|
1306. | A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression |
|
Delacôte C1, Bauvin P1, Louvet A2, Dautrecque F3, Ntandja Wandji LC3, Lassailly G2, Voican C4, Perlemuter G4, Naveau S4, Mathurin P2, Deuffic-Burban S5. Clin Gastroenterol Hepatol. 2020 Jan 10. pii: S1542-3565(20)30039-2. doi: 10.1016/j.cgh.2019.12.041. [Epub ahead of print]
|
|
|
|
|
1308. | Continued muscle loss increases mortality in cirrhosis- impact of etiology of liver disease |
|
Welch N1,2, Dasarathy J3, Runkana A4, Penumatsa R2, Bellar A2, Reen J2, Rotroff D5, McCullough AJ1, Dasarathy S1,2. Liver Int. 2019 Dec 31. doi: 10.1111/liv.14358. [Epub ahead of print]
|
|
|
|
|
|
|
1311. | Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression |
|
Du K1, Chitneni SK2, Suzuki A1, Wang Y1, Henao R3, Hyun J1, Premont RT1, Naggie S4, Moylan CA1, Bashir MR5, Abdelmalek MF1, Diehl AM6. Cell Mol Gastroenterol Hepatol. 2019 Dec 24. pii: S2352-345X(19)30182-1. doi: 10.1016/j.jcmgh.2019.12.006. [Epub ahead of print]
|
|
|
1312. | A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis |
|
Harrison SA1, Goodman Z2, Jabbar A3, Vemulapalli R4, Younes ZH5, Freilich B6, Sheikh MY7, Schattenberg JM8, Kayali Z9, Zivony A10, Sheikh A11, Garcia-Samaniego J12, Satapathy SK13, Therapondos G14, Mena E15, Schuppan D16, Robinson J17, Chan JL17, Hagerty DT18, Sanyal AJ19. J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30758-5. doi: 10.1016/j.jhep.2019.11.024. [Epub ahead of print]
|
|
|
1313. | A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH |
|
Gawrieh S1, Guo X2, Tan J2, Lauzon M2, Taylor KD2, Loomba R3, Cummings OW4, Pillai S5, Bhatnagar P5, Kowdley KV6, Yates K7, Wilson LA7, Chen YI2, Rotter JI2, Chalasani N1; NASH Clinical Research Network. Hepatol Commun. 2019 Nov 3;3(12):1571-1584. doi: 10.1002/hep4.1439. eCollection 2019 Dec.
|
|
|
|
|
|
|
|
|
1317. | Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension |
|
Zhao YC1,2, Zhao GJ1,2, Chen Z1,2, She ZG1,2,3,4, Cai J1,5,2, Li H1,2,3. Hypertension. 2020 Feb;75(2):275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419. Epub 2019 Dec 23.
|
|
|
1318. | Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic FattyLiver Disease in Patients With Crohn |
|
McHenry S1, Tirath A2, Tsai R3, Sharma Y4, Flores AG1, Davidson NO1, Fowler KJ3,5, Ciorba MA1,4, Deepak P1,6. Inflamm Bowel Dis. 2020 Jan 7. pii: izz324. doi: 10.1093/ibd/izz324. [Epub ahead of print]
|
|
|
|
|
1320. | Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension |
|
Garcia-Tsao G1, Bosch J2, Kayali Z3, Harrison SA4, Abdelmalek MF5, Lawitz E6, Satapathy SK7, Ghabril M8, Shiffman ML9, Younes ZH10, Thuluvath PJ11, Berzigotti A12, Albillos A13, Robinson JM14, Hagerty DT14, Chan JL14, Sanyal AJ15; IDN-6556-14 Investigators. J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724-X. doi: 10.1016/j.jhep.2019.12.010. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1327. | Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease |
|
Danford CJ1, Jiang ZG1, Salomaa V2, Färkkilä M3, Jula A2, Männistö S2, Lundqvist A2, Valsta L2, Perola M2, Åberg F4,5. Hepatol Commun. 2019 Oct 10;3(12):1704-1705. doi: 10.1002/hep4.1437. eCollection 2019 Dec.
|
|
|
1328. | Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features |
|
Bullón-Vela V1, Abete I2, Tur JA3, Pintó X4, Corbella E4, Martínez-González MA5, Toledo E5, Corella D6, Macías M7, Tinahones F7, Fitó M8, Estruch R9, Ros E10, Salas-Salvadó J11, Daimiel L12, Zulet MA13, Martínez JA2; PREDIMED Plus investigators. Nutrition. 2019 Oct 25;71:110620. doi: 10.1016/j.nut.2019.110620. [Epub ahead of print]
|
|
|
1329. | Association between neck circumference and non-alcoholic fatty liver disease in Mexican children and adolescents with obesity |
|
Peña-Vélez R1,2, Garibay-Nieto N1,2,3, Cal-Y-Mayor-Villalobos M4, Laresgoiti-Servitje E5, Pedraza-Escudero K1,2, García-Blanco MDC4, Heredia-Nieto OA6, Villanueva-Ortega E1,2. J Pediatr Endocrinol Metab. 2019 Dec 16. pii: /j/jpem.ahead-of-print/jpem-2019-0204/jpem-2019-0204.xml. doi: 10.1515/jpem-2019-0204. [Epub ahead of print]
|
|
|
|
|
1331. | Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered |
|
Plaz Torres MC1,2,3, Aghemo A3,4, Lleo A3,4, Bodini G1,2,3, Furnari M1, Marabotto E1, Miele L5, Giannini EG1,2,6. Nutrients. 2019 Dec 5;11(12). pii: E2971. doi: 10.3390/nu11122971.
|
|
|
|
|
|
|
|
|
1335. | Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis |
|
Siddiqui MS1, Van Natta ML2, Connelly MA3, Vuppalanchi R4, Neuschwander-Tetri BA5, Tonascia J2, Guy C6, Loomba R7, Dasarathy S8, Wattacheril J9, Chalasani N4, Sanyal AJ10; NASH CRN. J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30607-5. doi: 10.1016/j.jhep.2019.10.006. [Epub ahead of print]
|
|
|
1336. | Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development |
|
Mouries J1, Brescia P1, Silvestri A1, Spadoni I2, Sorribas M3, Wiest R4, Mileti E5, Galbiati M6, Invernizzi P6, Adorini L7, Penna G8, Rescigno M9. J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
|
|
|
1337. | REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis |
|
Ratziu V1, Sanyal AJ2, Loomba R3, Rinella M4, Harrison S5, Anstee QM6, Goodman Z7, Bedossa P8, MacConell L9, Shringarpure R9, Shah A9, Younossi Z7. Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.
|
|
|
1338. | Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis |
|
Loomba R1, Sanyal AJ2, Kowdley KV3, Terrault N4, Chalasani NP5, Abdelmalek MF6, McCullough AJ7, Shringarpure R8, Ferguson B8, Lee L8, Chen J8, Liberman A8, Shapiro D8, Neuschwander-Tetri BA9. Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.
|
|
|
1339. | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial |
|
Younossi ZM1, Ratziu V2, Loomba R3, Rinella M4, Anstee QM5, Goodman Z1, Bedossa P6, Geier A7, Beckebaum S8, Newsome PN9, Sheridan D10, Sheikh MY11, Trotter J12, Knapple W13, Lawitz E14, Abdelmalek MF15, Kowdley KV16, Montano-Loza AJ17, Boursier J18, Mathurin P19, Bugianesi E20, Mazzella G21, Olveira A22, Cortez-Pinto H23, Graupera I24, Orr D25, Gluud LL26, Dufour JF27, Shapiro D28, Campagna J28, Zaru L28, MacConell L28, Shringarpure R28, Harrison S29, Sanyal AJ30; REGENERATE Study Investigators.
Collaborators (336) Lancet. 2019 Dec 5. pii: S0140-6736(19)33041-7. doi: 10.1016/S0140-6736(19)33041-7. [Epub ahead of print]
|
|
|
1340. | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
|
Poynard T1,2, Peta V2,3, Deckmyn O3, Pais R1,2, Ngo Y2,3, Charlotte F4, Ngo A3, Munteanu M2,3, Imbert-Bismut F5, Monneret D5, Housset C2, Thabut D1,2, Valla D6, Boitard C7, Castera L6, Ratziu V1; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group.
|
|
|
|
|
1342. | Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany |
|
Labenz C1,2, Huber Y1,2, Michel M1,2, Nagel M1,2, Galle PR1,2, Kostev K3, Schattenberg JM4,5. Dig Dis Sci. 2019 Dec 3. doi: 10.1007/s10620-019-05986-9. [Epub ahead of print]
|
|
|
|
|
1344. | Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease |
|
Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. J Clin Invest. 2019 Dec 5. pii: 134165. doi: 10.1172/JCI134165. [Epub ahead of print]
|
|
|
1345. | A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. |
|
Pedrosa M1, Seyedkazemi S2, Francque S3, Sanyal A4, Rinella M5, Charlton M6, Loomba R7, Ratziu V8, Kochuparampil J1, Fischer L2, Vaidyanathan S9, Anstee QM10. Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889. [Epub ahead of print]
|
|
|
1346. | Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease |
|
Shili-Masmoudi S1, Wong GL2,3, Hiriart JB1, Liu K4,5, Chermak F1, Shu SS2,3, Foucher J1, Tse YK2,3, Bernard PH1, Yip TC2,3, Merrouche W1, Chan HL2,3, Wong VW2,3, de Lédinghen V1,6. Liver Int. 2019 Nov 20. doi: 10.1111/liv.14301. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1354. | GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis |
|
Best J1, Bechmann LP1, Sowa JP1, Sydor S1, Dechêne A2, Pflanz K3, Bedreli S3, Schotten C3, Geier A4, Berg T5, Fischer J5, Vogel A6, Bantel H6, Weinmann A7, Schattenberg JM7, Huber Y7, Wege H8, von Felden J8, Schulze K8, Bettinger D9, Thimme R10, Sinner F1, Schütte K1, Weiss KH11, Toyoda H12, Yasuda S12, Kumada T13, Berhane S14, Wichert M15, Heider D16, Gerken G3, Johnson P14, Canbay A17. Clin Gastroenterol Hepatol. 2019 Nov 8. pii: S1542-3565(19)31267-4. doi: 10.1016/j.cgh.2019.11.012. [Epub ahead of print]
|
|
|
1355. | Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
|
Harrison SA1, Bashir MR2, Guy CD2, Zhou R3, Moylan CA2, Frias JP4, Alkhouri N5, Bansal MB6, Baum S7, Neuschwander-Tetri BA8, Taub R9, Moussa SE10. Lancet. 2019 Nov 11. pii: S0140-6736(19)32517-6. doi: 10.1016/S0140-6736(19)32517-6. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1359. | Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study |
|
Harrison SA1, Alkhouri N2, Davison BA3, Sanyal A4, Edwards C3, Colca JR5, Lee BH5, Loomba R6, Cusi K7, Kolterman O8, Cotter G3, Dittrich HC5. J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]
|
|
|
|
|
1361. | Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non-alcoholic Fatty Liver Disease |
|
Kanwal F1,2,3, Kramer J2,3, Li L4, Dai J4, Natarajan Y1, Yu X2,3, Asch SM5,6, El-Serag HB1,2,3. Hepatology. 2019 Nov 1. doi: 10.1002/hep.31014. [Epub ahead of print]
|
|
|
1362. | A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health |
|
Moolla A1,2, Motohashi K1, Marjot T1,3, Shard A3, Ainsworth M3, Gray A4, Holman R2,5, Pavlides M2,3, Ryan JD2,3, Tomlinson JW1,2, Cobbold JF2,3. Frontline Gastroenterol. 2019 Oct;10(4):337-346. doi: 10.1136/flgastro-2018-101155. Epub 2019 Apr 30.
|
|
|
|
|
1364. | Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol |
|
Labenz C1, Prochaska JH2,3,4, Huber Y1, Nagel M1, Straub BK5, Wild P2,3,4, Galle PR1, Schattenberg JM1,6. Hepatol Commun. 2019 Sep 30;3(11):1472-1481. doi: 10.1002/hep4.1428. eCollection 2019 Nov.
|
|
|
|
|
1366. | Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial |
|
Navarro VJ1, Belle SH2, D'Amato M3, Adfhal N4, Brunt EM5, Fried MW6, Reddy KR7, Wahed AS2, Harrison S8; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. PLoS One. 2019 Sep 19;14(9):e0221683. doi: 10.1371/journal.pone.0221683. eCollection 2019.
|
|
|
1367. | Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients |
|
Sebastiani G1,2, Saeed S3, Lebouche B1, de Pokomandy A1, Szabo J1, Haraoui LP1, Routy JP1,4, Wong P2, Deschenes M2, Ghali P2, Klein M1; LIVEHIV Study Group. AIDS. 2019 Oct 16. doi: 10.1097/QAD.0000000000002412. [Epub ahead of print]
|
|
|
|
|
1369. | Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease |
|
Seth A1, Orkin S2, Yodoshi T2, Liu C3, Fei L3, Hardy J2, Trout AT4, Arce Clachar AC2, Bramlage K2, Xanthakos S2, Mouzaki M2. Pediatr Obes. 2019 Oct 27. doi: 10.1111/ijpo.12581. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1380. | Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial |
|
Stanley TL1, Fourman LT1, Feldpausch MN1, Purdy J2, Zheng I1, Pan CS1, Aepfelbacher J2, Buckless C3, Tsao A3, Kellogg A4, Branch K5, Lee H6, Liu CY7, Corey KE8, Chung RT8, Torriani M3, Kleiner DE9, Hadigan CM2, Grinspoon SK10. Lancet HIV. 2019 Oct 11. pii: S2352-3018(19)30338-8. doi: 10.1016/S2352-3018(19)30338-8. [Epub ahead of print]
|
|
|
|
|
|
|
1383. | Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults |
|
Alexander M1, Loomis AK2, van der Lei J3, Duarte-Salles T4, Prieto-Alhambra D5, Ansell D6,7, Pasqua A8, Lapi F8, Rijnbeek P3, Mosseveld M3, Avillach P3,9, Egger P1, Dhalwani NN10, Kendrick S11, Celis-Morales C12, Waterworth DM13, Alazawi W14, Sattar N12. BMJ. 2019 Oct 8;367:l5367. doi: 10.1136/bmj.l5367.
|
|
|
|
|
1385. | A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe |
|
Lazarus JV1, Ekstedt M2, Marchesini G3, Mullen J4, Novak K5, Pericàs JM6, Roel E7, Romero-Gómez M8, Ratziu V9, Tacke F10, Cortez-Pinto H11, Anstee QM12; EASL International Liver Foundation NAFLD Policy Review Collaborators. J Hepatol. 2019 Sep 10. pii: S0168-8278(19)30521-5. doi: 10.1016/j.jhep.2019.08.027. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
1391. | Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life |
|
Younossi ZM1,2, Stepanova M3, Lawitz EJ4, Reddy KR5, Wai-Sun Wong V6, Mangia A7, Muir AJ8, Jacobson I9, Djedjos CS10, Gaggar A10, Myers RP10, Younossi I3, Nader F3, Racila A3. Am J Gastroenterol. 2019 Oct;114(10):1636-1641. doi: 10.14309/ajg.0000000000000375.
|
|
|
|
|
|
|
1394. | Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liverdisease in the United States |
|
Adejumo AC1,2,3,4, Samuel GO5, Adegbala OM6, Adejumo KL4, Ojelabi O3, Akanbi O7, Ogundipe OA8, Pani L1,2. Ann Gastroenterol. 2019 Sep-Oct;32(5):504-513. doi: 10.20524/aog.2019.0402. Epub 2019 Jul 17.
|
|
|
1395. | Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic FattyLiver Disease Who Have Normal Aminotransferase Levels |
|
Gawrieh S1, Wilson LA2, Cummings OW3, Clark JM2, Loomba R4, Hameed B5, Abdelmalek MF6, Dasarathy S7, Neuschwander-Tetri BA8, Kowdley K9, Kleiner D10, Doo E11, Tonascia J2, Sanyal A12, Chalasani N1; and the NASH Clinical Research Network. Am J Gastroenterol. 2019 Oct;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388.
|
|
|
1396. | Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study |
|
Gawrieh S1, Dakhoul L1, Miller E2, Scanga A3, deLemos A4, Kettler C1, Burney H1, Liu H1, Abu-Sbeih H2, Chalasani N1, Wattacheril J5. Aliment Pharmacol Ther. 2019 Oct;50(7):809-821. doi: 10.1111/apt.15464. Epub 2019 Sep 1.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1403. | HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease |
|
McCullough A1, Previs SF2, Dasarathy J3, Lee K4, Osme A4, Kim C4, Ilchenko S4, Lorkowski SW5, Smith JD5, Dasarathy S1, Kasumov T6. Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00193.2019. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1408. | HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease |
|
McCullough A1, Previs SF2, Dasarathy J3, Lee K4, Osme A4, Kim C4, Ilchenko S4, Lorkowski SW5, Smith JD5, Dasarathy S1, Kasumov T6. Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00193.2019. [Epub ahead of print]
|
|
|
|
|
1410. | Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study |
|
Reddavide R1, Cisternino AM1, Inguaggiato R1, Rotolo O1, Zinzi I1, Veronese N1, Guerra V2, Fucilli F3, Di Giovanni G3, Leandro G4, Giannico S1, Caruso MG5. Nutrients. 2019 Aug 7;11(8). pii: E1830. doi: 10.3390/nu11081830.
|
|
|
|
|
1412. | Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis |
|
Chen VL1,2, Wright AP1,3, Halligan B1, Chen Y1, Du X1, Handelman SK1,2, Long MT4, Kiel DP5,6, Speliotes EK1,2. Hepatol Commun. 2019 Jun 18;3(8):1073-1084. doi: 10.1002/hep4.1391. eCollection 2019 Aug.
|
|
|
|
|
1414. | Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life |
|
Younossi ZM1,2, Stepanova M3, Lawitz EJ4, Reddy KR5, Wai-Sun Wong V6, Mangia A7, Muir AJ8, Jacobson I9, Djedjos CS10, Gaggar A10, Myers RP10, Younossi I3, Nader F3, Racila A3. Am J Gastroenterol. 2019 Aug 20. doi: 10.14309/ajg.0000000000000375. [Epub ahead of print]
|
|
|
1415. | Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study |
|
Reddavide R1, Cisternino AM1, Inguaggiato R1, Rotolo O1, Zinzi I1, Veronese N1, Guerra V2, Fucilli F3, Di Giovanni G3, Leandro G4, Giannico S1, Caruso MG5. Nutrients. 2019 Aug 7;11(8). pii: E1830. doi: 10.3390/nu11081830.
|
|
|
1416. | Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation |
|
Chen F1, Esmaili S1,2, Rogers G3, Bugianesi E4, Petta S5, Marchesini G6, Bayoumi A1, Metwally M1, Azardaryany MK1, Coulter S1, Choo JM3, Younes R4, Rosso C4, Liddle C1, Adams LA7, Craxì A5, George J1, Eslam M1. Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1423. | CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients |
|
Pockros PJ1, Fuchs M2, Freilich B3, Schiff E4, Kohli A5, Lawitz EJ6, Hellstern PA7, Owens-Grillo J8, Van Biene C8, Shringarpure R8, MacConell L8, Shapiro D8, Cohen DE9. Liver Int. 2019 Aug 11. doi: 10.1111/liv.14209. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1428. | Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program |
|
Huber Y1, Pfirrmann D2, Gebhardt I1, Labenz C1, Gehrke N1, Straub BK3, Ruckes C4, Bantel H5, Belda E6, Clément K7, Leeming DJ8, Karsdal MA8, Galle PR1, Simon P2, Schattenberg JM1. Aliment Pharmacol Ther. 2019 Jul 25. doi: 10.1111/apt.15427. [Epub ahead of print]
|
|
|
1429. | Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial |
|
Bril F1, Biernacki DM1, Kalavalapalli S1, Lomonaco R1, Subbarayan SK1, Lai J2, Tio F3, Suman A4, Orsak BK5, Hecht J6, Cusi K7,8. Diabetes Care. 2019 Aug;42(8):1481-1488. doi: 10.2337/dc19-0167. Epub 2019 May 21.
|
|
|
|
|
|
|
|
|
|
|
|
|
1435. | Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation? |
|
Moris W1,2,3, Verhaegh P#2,3, Jonkers D2,3, Deursen CV1,2, Koek G2,3,4. Semin Liver Dis. 2019 Jul 22. doi: 10.1055/s-0039-1693114. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1439. | Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes |
|
Barata L1, Feitosa MF1, Bielak LF2, Halligan B3, Baldridge AS4, Guo X5, Yerges-Armstrong LM6, Smith AV7, Yao J5, Palmer ND8, VanWagner LB4,9, Carr JJ10, Chen YI5, Allison M11, Budoff MJ12, Handelman SK3, Kardia SLR2, Mosley TH Jr13, Ryan K6, Harris TB14, Launer LJ14, Gudnason V15,16, Rotter JI5, Fornage M17, Rasmussen-Torvik LJ4, Borecki IB1, O'Connell JR6, Peyser PA2, Speliotes EK3, Province MA1. Hepatol Commun. 2019 Apr 18;3(7):894-907. doi: 10.1002/hep4.1353. eCollection 2019 Jul.
|
|
|
|
|
1441. | Relationship between abdominal fat stores and liver fat, pancreatic fat, and metabolic comorbidities in a pediatric population with non-alcoholic fatty liver disease |
|
Trout AT1,2,3, Hunte DE4, Mouzaki M5,6, Xanthakos SA5,6, Su W7, Zhang B5,8, Dillman JR4,9. Abdom Radiol (NY). 2019 Jul 16. doi: 10.1007/s00261-019-02123-y. [Epub ahead of print]
|
|
|
1442. | Clinically Significant Fibrosis is Associated With Longitudinal Increases in Fibrosis-4 and NAFLD Fibrosis Scores |
|
Patel PJ1, Cheng JC2, Banh X2, Gracen L2, Radford-Smith D3, Hossain F4, Horsfall LU1, Lee Hayward K2, Williams S4, Johnson T4, Brown NN5, Saad N6, Stuart KA7, Russell AW8, Valery PC9, Clouston AD2, Irvine KM10, Bernard A11, Powell EE12. Clin Gastroenterol Hepatol. 2019 Jul 25. pii: S1542-3565(19)30780-3. doi: 10.1016/j.cgh.2019.07.036. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1447. | Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults |
|
Lee SB#1,2, Kim MK#3, Kang S1,2, Park K1,2, Kim JH1,2, Baik SJ4, Nam JS1,2, Ahn CW1,2, Park JS1,5. Endocrinol Metab (Seoul). 2019 Jun;34(2):179-186. doi: 10.3803/EnM.2019.34.2.179.
|
|
|
|
|
|
|
1450. | Epidemiology of chronic liver diseases in the USA in the past three decades |
|
Younossi ZM1,2, Stepanova M3, Younossi Y3, Golabi P4,2, Mishra A4,2, Rafiq N4,2, Henry L3. Gut. 2019 Jul 31. pii: gutjnl-2019-318813. doi: 10.1136/gutjnl-2019-318813. [Epub ahead of print]
|
|
|
|
|
1452. | Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B |
|
Choi HSJ1,2, Brouwer WP3, Zanjir WMR1, de Man RA3, Feld JJ1, Hansen BE1,3,4, Janssen HLA1, Patel K1. Hepatology. 2019 Jul 15. doi: 10.1002/hep.30857. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1470. | Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease |
|
Schwimmer JB1, Johnson JS2, Angeles JE3, Behling C4, Belt PH5, Borecki I6, Bross C7, Durelle J8, Goyal NP9, Hamilton G10, Holtz ML11, Lavine JE12, Mitreva M13, Newton KP14, Pan A15, Simpson PM16, Sirlin CB17, Sodergren E18, Tyagi R19, Yates KP20, Weinstock G21, Salzman NH22. Gastroenterology. 2019 Jun 27. pii: S0016-5085(19)41037-8. doi: 10.1053/j.gastro.2019.06.028. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1482. | Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum |
|
Cheung A1, Neuschwander-Tetri BA2, Kleiner DE3, Schabel E4, Rinella M5, Harrison S6, Ratziu V7, Sanyal AJ8, Loomba R9, Jeannin Megnien S10, Torstenson R11, Miller V12; Liver Forum Case Definitions Working Group. Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1490. | Non-Alcoholic Fatty Liver Disease, Liver Fibrosis Score and Cognitive Function in Middle-Aged Adults: The Framingham Study |
|
Weinstein G1, Davis-Plourde K2,3, Himali JJ2,3,4, Zelber-Sagi S1,5, Beiser AS2,3,4, Seshadri S3,4,6. Liver Int. 2019 Jun 2. doi: 10.1111/liv.14161. [Epub ahead of print]
|
|
|
1491. | The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content |
|
Gepner Y1, Shelef I2, Komy O3, Cohen N3, Schwarzfuchs D4, Bril N3, Rein M3, Serfaty D3, Kenigsbuch S3, Zelicha H3, Yaskolka Meir A3, Tene L3, Bilitzky A3, Tsaban G3, Chassidim Y2, Sarusy B5, Ceglarek U6, Thiery J6, Stumvoll M6, Blüher M6, Stampfer MJ7, Rudich A3, Shai I8. J Hepatol. 2019 May 8. pii: S0168-8278(19)30274-0. doi: 10.1016/j.jhep.2019.04.013. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1496. | Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study |
|
De Silva NMG1,2,3, Borges MC1,2, Hingorani A4,5, Engmann J4, Shah T4, Zhang X6,7,8, Luan J6, Langenberg C6, Wong A9, Kuh D9, Chambers JC3,10,11, Zhang W12,13, Jarvelin MR12,14,15, Sebert S14, Auvinen J14,16; UCLEB consortium, Gaunt TR1,2, Lawlor DA17,2. Diabetes. 2019 May 14. pii: db181048. doi: 10.2337/db18-1048. [Epub ahead of print]
|
|
|
1497. | Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease |
|
Gan D1, Wang L1, Jia M1, Ru Y1, Ma Y2, Zheng W3, Zhao X1, Yang F1, Wang T4, Mu Y5, Zhu S6. Clin Nutr. 2019 Apr 25. pii: S0261-5614(19)30199-2. doi: 10.1016/j.clnu.2019.04.023. [Epub ahead of print]
|
|
|
1498. | Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis |
|
Mantovani A1, Lonardo A2, Vinco G1, Zoppini G1, Lippi G3, Bonora E1, Loomba R4, Tilg H5, Byrne CD6, Fabbri L7, Targher G8. Diabetes Metab. 2019 May 5. pii: S1262-3636(19)30068-0. doi: 10.1016/j.diabet.2019.04.008. [Epub ahead of print]
|
|
|
|
|
1500. | Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta-Analysis |
|
Zhou F1,2,3,4, Zhou J1,2,3, Wang W1,2,3, Zhang XJ1,2,3, Ji YX1,2,3, Zhang P1,2,3, She ZG1,2,3, Zhu L1,2,3, Cai J1,5,2, Li H1,2,3. Hepatology. 2019 May 9. doi: 10.1002/hep.30702. [Epub ahead of print]
|
|
|
1501. | Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study |
|
Haldar D1, Kern B2, Hodson J3, James Armstrong M4, Adam R5, Berlakovich G6, Fritz J7, Feurstein B8, Popp W8, Karam V5, Muiesan P9, O'Grady J10, Jamieson N11, Wigmore SJ12, Pirenne J13, Ali Malek-Hosseini S14, Hidalgo E15, Tokat Y16, Paul A17, Pratschke J18, Bartels M19, Trunecka P20, Settmacher U21, Pinzani M22, Duvoux C23, Noel Newsome P24, Schneeberger S8; European Liver, Intestine Transplant Association (ELITA). J Hepatol. 2019 May 6. pii: S0168-8278(19)30272-7. doi: 10.1016/j.jhep.2019.04.011. [Epub ahead of print]
|
|
|
1502. | Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions! |
|
Berger A1,2, Shili S3, Zuberbuhler F1,2, Hiriart JB3, Lannes A1,2, Chermak F3, Hunault G2, Foucher J3, Oberti F1,2, Fouchard-Hubert I1,2, Cales P1,2, de Ledinghen V3,4, Boursier J1,2. Clin Transl Gastroenterol. 2019 Apr;10(4):e00023. doi: 10.14309/ctg.0000000000000023.
|
|
|
|
|
1504. | New sequential combinations of noninvasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD |
|
Boursier J1, Guillaume M2, Leroy V3, Irlès M4, Roux M5, Lannes A6, Foucher J4, Zuberbuhler F6, Delabaudière C7, Barthelon J8, Michalak S9, Hiriart JB4, Peron JM2, Gerster T8, Le Bail B10, Riou J11, Hunault G5, Merrouche W4, Oberti F6, Pelade L8, Fouchard I6, Bureau C2, Calès P6, de Ledinghen V12. J Hepatol. 2019 May 15. pii: S0168-8278(19)30284-3. doi: 10.1016/j.jhep.2019.04.020. [Epub ahead of print]
|
|
|
1505. | Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts |
|
Alexander M1, Loomis AK2, van der Lei J3, Duarte-Salles T4, Prieto-Alhambra D5, Ansell D6, Pasqua A7, Lapi F7, Rijnbeek P3, Mosseveld M3, Waterworth DM8, Kendrick S9, Sattar N10, Alazawi W11. BMC Med. 2019 May 20;17(1):95. doi: 10.1186/s12916-019-1321-x.
|
|
|
|
|
1507. | Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014 |
|
Kim D1, Cholankeril G1, Li AA2, Kim W3, Tighe SP1, Hameed B4, Kwo PY1, Harrison SA5, Younossi ZM6, Ahmed A1. Liver Int. 2019 May 13. doi: 10.1111/liv.14135. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1512. | Novel MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of an SCD1 inhibitor (ARRIVE Trial) |
|
Ajmera VH1,2, Cachay E3, Ramers C4, Vodkin I2, Bassirian S1, Singh S1, Mangla N1, Bettencourt R1, Aldous JL5, Park D5, Lee D3, Blanchard J3, Mamidipalli A6, Boehringer A6, Aslam S7, Leinhard OD8,9, Richards L1, Sirlin C6, Loomba R1,2,10. Hepatology. 2019 Apr 23. doi: 10.1002/hep.30674. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1517. | Helicobacter pylori infection and NAFLD |
|
Mantovani A1, Turino T1, Altomari A1, Lonardo A2, Zoppini G1, Valenti L3, Tilg H4, Byrne CD5, Targher G6. Metabolism. 2019 Apr 29. pii: S0026-0495(19)30084-8. doi: 10.1016/j.metabol.2019.04.012. [Epub ahead of print]
|
|
|
1518. | Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution |
|
Alferink LJM1, Trajanoska K2,3, Erler NS4, Schoufour JD2,3, de Knegt RJ1, Ikram MA2, Janssen HLA1,5, Franco OH2,6, Metselaar HJ1, Rivadeneira F2,3, Darwish Murad S1. J Bone Miner Res. 2019 May 10. doi: 10.1002/jbmr.3713. [Epub ahead of print]
|
|
|
1519. | Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis |
|
Vitaglione P1,2, Mazzone G3, Lembo V3, D'Argenio G3, Rossi A3, Guido M4, Savoia M5, Salomone F6, Mennella I1, De Filippis F1,2, Ercolini D1,2, Caporaso N2,3, Morisco F2,3. J Nutr Sci. 2019 Apr 22;8:e15. doi: 10.1017/jns.2019.10. eCollection 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1529. | Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department |
|
Likhitsup A1,2, Dundulis J1, Ansari S3, El-Halawany H1, Michelson R1, Hutton C4, Kennedy K5, Helzberg JH1,2, Chhabra R1,2. Ann Gastroenterol. 2019 May-Jun;32(3):283-286. doi: 10.20524/aog.2019.0371. Epub 2019 Mar 15.
|
|
|
|
|
1531. | A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease |
|
Ma J1,2, Nano J3,4,5, Ding J6, Zheng Y7, Hennein R1, Liu C1,8, Speliotes EK9, Huan T1, Song C1,10, Mendelson MM1,11, Joehanes R1, Long MT12, Liang L13,14, Smith JA15, Reynolds LM6, Ghanbari M3,16, Muka T3, van Meurs JBJ3,17, Alferink LJM18, Franco OH3, Dehghan A3,19, Ratliff S15, Zhao W15, Bielak L15, Kardia SLR15, Peyser PA15, Ning H7, VanWagner LB7,20, Lloyd-Jones DM7, Carr JJ21, Greenland P7, Lichtenstein AH22, Hu FB23, Liu Y6, Hou L7, Darwish Murad S18, Levy D24. Diabetes. 2019 May;68(5):1073-1083. doi: 10.2337/DB18-1193. Epub 2019 Apr 1.
|
|
|
|
|
|
|
1534. | A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease |
|
Caussy C1,2, Tripathi A3,4,5,6, Humphrey G4, Bassirian S1, Singh S1, Faulkner C1, Bettencourt R1,7, Rizo E1, Richards L1, Xu ZZ4, Downes MR8, Evans RM8, Brenner DA1,9, Sirlin CB10, Knight R3,4,11,12, Loomba R13,14,15. Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.
|
|
|
|
|
|
|
|
|
1538. | The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials |
|
Sanyal AJ1, Harrison SA2, Ratziu V3, Abdelmalek MF4, Diehl AM4, Caldwell S5, Shiffman ML6, Schall RA7, Jia C7, McColgan B7, Djedjos CS7, McHutchison JG7, Subramanian GM7, Myers RP7, Younossi Z8, Muir AJ4, Afdhal NH9, Bosch J10,11, Goodman Z8. Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1547. | Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule |
|
Yabut JM1,2, Crane JD3, Green AE1,2, Keating DJ4, Khan WI2,5,6, Steinberg GR1,2,6,7. Endocr Rev. 2019 Mar 22. pii: er.2018-00283. doi: 10.1210/er.2018-00283. [Epub ahead of print]
|
|
|
1548. | Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease |
|
Srivastava A1, Gailer R1, Tanwar S1, Trembling P1, Parkes J2, Rodger A3, Suri D4, Thorburn D1, Sennett K5, Morgan S6, Tsochatzis EA7, Rosenberg W8. J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30227-2. doi: 10.1016/j.jhep.2019.03.033. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1555. | Obesity in the critically ill: a narrative review |
|
Schetz M1, De Jong A2, Deane AM3,4, Druml W5, Hemelaar P6, Pelosi P7,8, Pickkers P6,9, Reintam-Blaser A10,11, Roberts J12,13,14,15, Sakr Y16, Jaber S2.
Intensive Care Med. 2019 Mar 19. doi: 10.1007/s00134-019-05594-1. [Epub ahead of print]
|
|
|
|
|
1557. | Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography |
|
Yin Z1, Murphy MC1, Li J1, Glaser KJ1, Mauer AS2, Mounajjed T3, Therneau TM4, Liu H4, Malhi H2, Manduca A1,5, Ehman RL1, Yin M6. Eur Radiol. 2019 Mar 18. doi: 10.1007/s00330-019-06076-0. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1561. | Sarcopenic obesity in fatty liver |
|
Merli M1, Lattanzi B, Aprile F. JCurr Opin Clin Nutr Metab Care. 2019 Mar 18. doi: 10.1097/MCO.0000000000000558. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
1566. | Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis |
|
Klebanoff MJ1, Corey KE2,3, Samur S4,5, Choi JG5, Kaplan LM2,3, Chhatwal J2,3,5, Hur C6. JAMA Netw Open. 2019 Feb 1;2(2):e190047. doi: 10.1001/jamanetworkopen.2019.0047.
|
|
|
1567. | Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume |
|
Abeles RD1, Mullish BH1, Forlano R1, Kimhofer T2, Adler M1, Tzallas A3, Giannakeas N3, Yee M4, Mayet J5, Goldin RD6, Thursz MR1, Manousou P1. Aliment Pharmacol Ther. 2019 Mar 5. doi: 10.1111/apt.15192. [Epub ahead of print]
|
|
|
1568. | An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease(NAFLD) associated with obesity |
|
Nistal E1, Sáenz de Miera LE2, Ballesteros Pomar M3, Sánchez Campos S2, García Mediavilla MV2, Álvarez Cuenllas B4, Linares P5, Olcoz JL3, Arias Loste MT6, García Lobo JM7, Crespo J8, González Gallego J2, Jorquera Plaza F9. Rev Esp Enferm Dig. 2019 Feb 27;111. doi: 10.17235/reed.2019.6068/2018. [Epub ahead of print]
|
|
|
1569. | Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease(NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study |
|
Vilar-Gomez E1, Athinarayanan SJ2, Adams RN2, Hallberg SJ2,3, Bhanpuri NH2, McKenzie AL2, Campbell WW4, McCarter JP2,5, Phinney SD2, Volek JS2,6, Chalasani N1. BMJ Open. 2019 Feb 25;9(2):e023597. doi: 10.1136/bmjopen-2018-023597.
|
|
|
|
|
|
|
1572. | Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis |
|
Regev A1, Palmer M2, Avigan MI3, Dimick-Santos L3, Treem WR4, Marcinak JF5, Seekins D6, Krishna G7, Anania FA3, Freston JW8, Lewis JH9, Sanyal AJ10, Chalasani N1. Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153. Epub 2019 Feb 13.
|
|
|
|
|
|
|
|
|
|
|
|
|
1578. | NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis |
|
Harrison SA1,2, Rossi SJ3, Paredes AH4, Trotter JF5, Bashir MR6, Guy CD7, Banerjee R8, Jaros MJ9, Owers S2, Baxter BA3, Ling L3, DePaoli AM3. Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590. [Epub ahead of print]
|
|
|
|
|
|
|
1581. | Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial |
|
Parker HM1,2, Cohn JS3, O'Connor HT4,5, Garg ML6, Caterson ID7, George J8, Johnson NA9,10,11. Nutrients. 2019 Feb 23;11(2). pii: E475. doi: 10.3390/nu11020475.
|
|
|
|
|
|
|
|
|
|
|
1586. | Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study |
|
Ren XY1,2, Shi D1,2, Ding J3, Cheng ZY2,4, Li HY3, Li JS2, Pu HQ3, Yang AM2,5, He CL2, Zhang JP2, Ma YB2, Zhang YW4, Zheng TZ5, Bai YN6, Cheng N7. Lipids Health Dis. 2019 Feb 11;18(1):47. doi: 10.1186/s12944-019-0984-9.
|
|
|
|
|
|
|
1589. | Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis |
|
Younossi ZM1, Stepanova M2, Anstee QM3, Lawitz EJ4, Wong VW5, Romero-Gomez M6, Kersey K7, Li G7, Subramanian GM7, Myers RP7, Djedjos CS7, Okanoue T8, Trauner M9, Goodman Z10, Harrison SA11. Clin Gastroenterol Hepatol. 2019 Feb 16. pii: S1542-3565(19)30187-9. doi: 10.1016/j.cgh.2019.02.024. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
1593. | Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease |
|
Eddowes PJ1, Sasso M2, Allison M3, Tsochatzis E4, Anstee QM5, Sheridan D6, Guha IN7, Cobbold JF8, Deeks JJ9, Paradis V10, Bedossa P10, Newsome PN11. Gastroenterology. 2019 Jan 25. pii: S0016-5085(19)30105-2. doi: 10.1053/j.gastro.2019.01.042. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1600. | Clinical Practice Approach to Nonalcoholic Fatty Liver Disease by Pediatric Gastroenterologists in the United States |
|
Shapiro WL1,2,3, Yu EL1,3, Arin JC1, Murray KF4, Ali S5, Desai NK6, Xanthakos SA7,8, Lin HC9, Alkhouri N10,11, Abdou R12, Abrams SH13,14,15,16, Butler MW17, Faasse SA18,19, Gillis LA20, Hadley TA18, Jain AK21, Kavan M22, Kordy K23, Lee P24, Panganiban J25, Pohl JF22, Potter C26, Rudolph B27, Sundaram SS28,29, Joshi S1,30, Proudfoot JA31, Goyal NP1,3, Harlow KE1,3, Newton KP1,3, Schwimmer JB1,3. J Pediatr Gastroenterol Nutr. 2019 Feb;68(2):182-189. doi: 10.1097/MPG.0000000000002194. |
|
|
1601. | Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial |
|
Schwimmer JB1,2, Ugalde-Nicalo P1, Welsh JA3,4,5, Angeles JE1, Cordero M3, Harlow KE1,2, Alazraki A6, Durelle J1, Knight-Scott J6, Newton KP1,2, Cleeton R3, Knott C7, Konomi J3, Middleton MS8, Travers C9, Sirlin CB8, Hernandez A3, Sekkarie A5, McCracken C4,9, Vos MB3,4,5. JAMA. 2019 Jan 22;321(3):256-265. doi: 10.1001/jama.2018.20579. |
|
|
|
|
|
|
|
|
|
|
|
|
1607. | Prevalence and Risk Factors if Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis |
|
Pelusi S1, Cespiati A2, Rametta R3, Pennisi G4, Mannisto V5, Rosso C6, Baselli G1, Dongiovanni P3, Fracanzani AL2, Badiali S7, Maggioni M8, Craxi A4, Fargion S2, Prati D9, Nobili V10, Bugianesi E6, Romeo S11, Pihlajamaki J5, Petta S4, Valenti L12. Clin Gastroenterol Hepatol. 2019 Jan 29. pii: S1542-3565(19)30074-6. doi: 10.1016/j.cgh.2019.01.027. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1611. | Perinatal Nutritional Reprogramming of the Epigenome Promotes Subsequent Development of Nonalcoholic Steatohepatitis |
|
Gutierrez Sanchez LH1, Tomita K2, Guo Q2, Furuta K2, Alhuwaish H2, Hirsova P2,3, Baheti S4, Alver B5, Hlady R5, Robertson KD5, Ibrahim SH1,2. Hepatol Commun. 2018 Oct 1;2(12):1493-1512. doi: 10.1002/hep4.1265. eCollection 2018 Dec. |
|
|
1612. | Long-term Results of Bariatric Surgery for Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis Treatment in Morbidly Obese Japanese Patients |
|
Uehara D1,2, Seki Y3, Kakizaki S4, Horiguchi N2, Tojima H2, Yamazaki Y2, Sato K2, Yamada M1,5, Uraoka T2, Kasama K3. Obes Surg. 2018 Dec 12. doi: 10.1007/s11695-018-03641-2. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1620. | NASH in Lean Individuals |
|
Younes R1, Bugianesi E1. Semin Liver Dis. 2019 Jan 17. doi: 10.1055/s-0038-1677517. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1624. | Predictors of De NovoNonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis |
|
Galvin Z1,2, Rajakumar R1, Chen E1, Adeyi O1,2, Selzner M1,3, Grant D1,3, Sapisochin G1,3, Greig P1,3, Cattral M1,3, McGilvray I1,3, Ghanekar A1,3, Selzner N1,2, Lilly L1,2, Patel K1,2, Bhat M1,2. Liver Transpl. 2019 Jan;25(1):56-67. doi: 10.1002/lt.25338. |
|
|
|
|
|
|
|
|
|
|
|
|
1630. | Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies |
|
Prat LI1,2, Roccarina D1, Lever R3, Lombardi R1, Rodger A3,4, Hall A1,5, Luong TV1, Bhagani S3, Tsochatzis E1. J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001942. [Epub ahead of print] |
|
|
1631. | Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD): results from the ECHAM study |
|
Lemoine M1, Assoumou L2, De Wit S3, Girard PM4, Valantin MA5, Katlama C5, Necsoi C3, Campa P4, Huefner AD6, Schulze Zur Wiesch J6, Rougier H4, Bastard JP7,8, Stocker H9, Mauss S10, Serfaty L11, Ratziu V12, Menu Y13, Schlue J14, Behrens G15, Bedossa P16, Capeau J8, Ingiliz P17, Costagliola D2. J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001936. [Epub ahead of print] |
|
|
1632. | Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity |
|
Yu EL1, Golshan S2, Harlow KE1, Angeles JE3, Durelle J3, Goyal NP1, Newton KP1, Sawh MC1, Hooker J4, Sy EZ4, Middleton MS4, Sirlin CB4, Schwimmer JB5. J Pediatr. 2018 Dec 14. pii: S0022-3476(18)31609-3. doi: 10.1016/j.jpeds.2018.11.021. [Epub ahead of print] |
|
|
|
|
|
|
1635. | Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand |
|
Calzadilla-Bertot L1, Jeffrey GP1,2, Jacques B2, McCaughan G3, Crawford M3, Angus P4, Jones R4, Gane E5, Munn S5, Macdonald G6, Fawcett J6, Wigg A7, Chen J7, Fink M8, Adams LA1,2. Liver Transpl. 2019 Jan;25(1):25-34. doi: 10.1002/lt.25361. |
|
|
|
|
|
|
1638. | Pediatric Fatty Liver and Obesity: Not Always Justa Matter of Non-Alcoholic Fatty Liver Disease |
|
Alfani R1,2, Vassallo E3,4, De Anseris AG5, Nazzaro L6, D'Acunzo I7,8, Porfito C9,10, Mandato C11, Vajro P12,13,14,15. Children (Basel). 2018 Dec 13;5(12). pii: E169. doi: 10.3390/children5120169. |
|
|
|
|
|
|
|
|
|
|
1643. | Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK |
|
Williams R1, Alexander G2, Aspinall R3, Batterham R4, Bhala N5, Bosanquet N6, Severi K7, Burton A8, Burton R9, Cramp ME10, Day N11, Dhawan A12, Dillon J13, Drummond C14, Dyson J15, Ferguson J16, Foster GR17, Gilmore I18, Greenberg J19, Henn C9, Hudson M15, Jarvis H20, Kelly D21, Mann J22, McDougall N23, McKee M24, Moriarty K25, Morling J26, Newsome P27, O'Grady J12, Rolfe L9, Rice P28, Rutter H29, Sheron N30, Thorburn D31, Verne J9, Vohra J32, Wass J33, Yeoman A34. Lancet. 2018 Dec 1;392(10162):2398-2412. doi: 10.1016/S0140-6736(18)32561-3. Epub 2018 Nov 22. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1655. | Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Non-alcoholic and Alcohol-Related Fatty Liver Disease |
|
Younossi ZM1, Stepanova M2, Ong J3, Yilmaz Y4, Duseja A5, Eguchi Y6, El Kassas M7, Castellanos-Fernandez M8, George J9, Jacobson IM10, Bugianesi E11, Wai-Sun Wong V12, Arrese M13, de Ledinghen V14, Romero-Gomez M15, Mendez-Sanchez N16, Ahmed A17, Wong R18, Papatheodoridis G19, Serfaty L20, Younossi I2, Nader F2, Ziayee M2, Afendy A2; Global NASH Council. Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31276-X. doi: 10.1016/j.cgh.2018.11.033. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1666. | European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale |
|
Mann JP1, Vreugdenhil A2, Socha P3, Ja?czyk W3, Baumann U4, Rajwal S5, Casswall T6, Marcus C7, van Mourik I8, O'Rahilly S9, Savage DB9, Noble-Jamieson G10, Lacaille F11, Dabbas M11, Dubern B12, Kelly DA8, Nobili V13, Anstee QM14. Contemp Clin Trials. 2018 Dec;75:67-71. doi: 10.1016/j.cct.2018.11.003. Epub 2018 Nov 5. |
|
|
|
|
1668. | Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease |
|
Glass O1, Henao R2,3, Patel K4, Guy CD5, Gruss HJ6, Syn WK7,8, Moylan CA9, Streilein R10, Hall R10, Mae Diehl A9, Abdelmalek MF9. Hepatol Commun. 2018 Sep 21;2(11):1344-1355. doi: 10.1002/hep4.1237. eCollection 2018 Nov. |
|
|
1669. | Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design |
|
Rudolph B1, Bjorklund N2, Ovchinsky N3, Kogan-Liberman D3, Perez A3, Liszewski M4, Levin TL4, Ewart M4, Liu Q4, Xue X5, Viswanathan S5, Strickler HD5. Contemp Clin Trials. 2018 Dec;75:51-58. doi: 10.1016/j.cct.2018.10.012. Epub 2018 Oct 27. |
|
|
|
|
|
|
1672. | Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC |
|
Grohmann M1, Wiede F2, Dodd GT1, Gurzov EN3, Ooi GJ4, Butt T1, Rasmiena AA5, Kaur S1, Gulati T5, Goh PK2, Treloar AE5, Archer S6, Brown WA4, Muller M7, Watt MJ3, Ohara O8, McLean CA9, Tiganis T10. Cell. 2018 Nov 15;175(5):1289-1306.e20. doi: 10.1016/j.cell.2018.09.053. Epub 2018 Oct 25. |
|
|
|
|
|
|
1675. | Validation of Serum Test for Advanced Liver Fibrosis in Patients with Nonalcoholic Steatohepatitis |
|
Loomba R1, Jain A2, Diehl AM3, Guy CD4, Portenier D5, Sudan R5, Singh S6, Faulkner C6, Richards L6, Hester KD2, Okada L2, Li XJ2, Mimms L2, Abdelmalek MF7. Clin Gastroenterol Hepatol. 2018 Nov 15. pii: S1542-3565(18)31247-3. doi: 10.1016/j.cgh.2018.11.004. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1683. | Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH |
|
Chalasani N1, Abdelmalek MF2, Loomba R3, Kowdley KV4, McCullough AJ5, Dasarathy S5, Neuschwander-Tetri BA6, Terrault N7, Ferguson B, Shringarpure R8, Shapiro D8, Sanyal AJ9. Liver Int. 2018 Sep 25. doi: 10.1111/liv.13974. [Epub ahead of print] |
|
|
|
|
1685. | Longitudinal analysis of risk of Non-Alcoholic Fatty Liver Disease (NAFLD) in adulthood |
|
Cuthbertson DJ1, Brown E1, Koskinen J2,3, Magnussen CG2,4, Hutri-Kähönen N5, Sabin M6,7, Tossavainen P8, Jokinen E9, Laitinen T10, Viikari J11,12, Raitakari OT2, Juonala M6,11,12. Liver Int. 2018 Oct 22. doi: 10.1111/liv.13993. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1693. | Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease |
|
Munteanu M1,2,3, Pais R2,3, Peta V1, Deckmyn O1, Moussalli J2, Ngo Y1, Rudler M2, Lebray P2, Charlotte F2, Thibault V2, Lucidarme O2,3, Ngo A2,3, Imbert-Bismut F2, Housset C3, Thabut D2,3, Ratziu V2,3, Poynard T2,3; FibroFrance Group. Aliment Pharmacol Ther. 2018 Nov;48(10):1117-1127. doi: 10.1111/apt.14990. Epub 2018 Oct 17. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1706. | Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study |
|
Ooi GJ1,2, Burton PR3,4, Bayliss J5,6, Raajendiran A5,6, Earnest A7, Laurie C3,4, Kemp WW8, McLean CA9, Roberts SK8, Watt MJ5,6, Brown WA3,4. Obes Surg. 2018 Sep 18. doi: 10.1007/s11695-018-3479-2. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1711. | Factors Associated with Histologic Response in Adult Patients with Nonalcoholic Steatohepatitis |
|
Loomba R1, Sanyal AJ2, Kowdley KV3, Terrault N4, Chalasani NP5, Abdelmalek MF6, McCullough AJ7, Shringarpure R8, Ferguson B8, Lee L8, Chen J8, Liberman A8, Shapiro D8, Neuschwander-Tetri BA9. Gastroenterology. 2018 Sep 14. pii: S0016-5085(18)34977-1. doi: 10.1053/j.gastro.2018.09.021. [Epub ahead of print] |
|
|
1712. | An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease |
|
Younossi ZM1,2,3, Karrar A4,5, Pierobon M6, Birerdinc A4, Stepanova M4,5, Abdelatif D4,7, Younoszai Z5, Jeffers T5, Felix S5, Jeiran K6, Hodge A6, Zhou W6, Monge F4,7, Alaparthi L4,7, Chandhoke V5,6, Goodman ZD4,7, Petricoin EF6. BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1. |
|
|
|
|
|
|
|
|
1716. | Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial |
|
Harrison SA1, Dennis A2, Fiore MM2, Kelly MD2, Kelly CJ2, Paredes AH3, Whitehead JM3, Neubauer S1,2, Traber PG4, Banerjee R2. PLoS One. 2018 Sep 7;13(9):e0203054. doi: 10.1371/journal.pone.0203054. eCollection 2018. |
|
|
|
|
|
|
|
|
|
|
1721. | Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis |
|
Hooker JC1, Hamilton G1, Park CC1, Liao S1, Wolfson T2, Dehkordy SF1, Hong CW1, Mamidipalli A1, Gamst A2, Loomba R3, Sirlin CB4. Abdom Radiol (NY). 2018 Aug 20. doi: 10.1007/s00261-018-1745-3. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1725. | Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models |
|
Green CJ1, Parry SA1, Gunn PJ1, Ceresa CDL1,2, Rosqvist F1,3, Piché ME1,4, Hodson L5. Horm Mol Biol Clin Investig. 2018 Aug 11. pii: /j/hmbci.ahead-of-print/hmbci-2018-0038/hmbci-2018-0038.xml. doi: 10.1515/hmbci-2018-0038. [Epub ahead of print] |
|
|
|
|
1727. | Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease |
|
Alexander M1, Loomis AK2, Fairburn-Beech J1, van der Lei J3, Duarte-Salles T4, Prieto-Alhambra D5, Ansell D6, Pasqua A7, Lapi F7, Rijnbeek P3, Mosseveld M3, Avillach P8, Egger P1, Kendrick S1, Waterworth DM1, Sattar N9, Alazawi W10. BMC Med. 2018 Aug 13;16(1):130. doi: 10.1186/s12916-018-1103-x. |
|
|
1728. | Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis |
|
Younossi Z1,2, Tacke F3, Arrese M4,5, Sharma BC6, Mostafa I7, Bugianesi E8, Wong VW9, Yilmaz Y10, George J11, Fan J12, Vos MB13. Hepatology. 2018 Sep 4. doi: 10.1002/hep.30251. [Epub ahead of print] |
|
|
1729. | The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options |
|
Younossi Z1, Stepanova M2, Sanyal AJ3, Harrison SA4, Ratziu V5, Abdelmalek MF6, Diehl AM6, Caldwell S7, Shiffman ML8, Schall RA9, McColgan B9, Mani Subramanian G9, Myers RP9, Muir A6, Afdhal NH10, Bosch J11, Goodman Z2. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32295-5. doi: 10.1016/j.jhep.2018.08.013. [Epub ahead of print] |
|
|
|
|
|
|
1732. | GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease |
|
Loomba R1, Kayali Z2, Noureddin M3, Ruane P4, Lawitz EJ5, Bennett M6, Wang L7, Harting E7, Tarrant JM7, McColgan BJ7, Chung C7, Ray AS7, Subramanian GM7, Myers RP7, Middleton MS8, Lai M9, Charlton M10, Harrison SA11. Gastroenterology. 2018 Jul 27. pii: S0016-5085(18)34815-7. doi: 10.1053/j.gastro.2018.07.027. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1740. | Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts |
|
Mayo R1, Crespo J2, MartÃnez-Arranz I1, Banales JM3, Arias M2, Mincholé I1, Aller de la Fuente R4, Jimenez-Agüero R3, Alonso C1, de Luis DA5, Vitek L6, Stritesky J6, CaballerÃa J7, Romero-Gómez M8, MartÃn-Duce A9, Mugüerza Huguet JM10, Busteros-Moraza JI11, Idowu MO12, Castro A1, MartÃnez-Chantar ML13, Ortiz P1, Bruha R6, Lu SC14, Bedossa P15, Noureddin M14, Sanyal AJ16, Mato JM13. Hepatol Commun. 2018 May 4;2(7):807-820. doi: 10.1002/hep4.1188. eCollection 2018 Jul. |
|
|
|
|
|
|
|
|
|
|
1745. | Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis |
|
Harrison SA1, Abdelmalek MF2, Caldwell S3, Shiffman ML4, Diehl AM2, Ghalib R5, Lawitz EJ6, Rockey DC7, Schall RA8, Jia C8, McColgan BJ8, McHutchison JG8, Subramanian GM8, Myers RP8, Younossi Z9, Ratziu V10, Muir AJ2, Afdhal NH11, Goodman Z9, Bosch J12, Sanyal AJ13; GS-US-321-0105GS-US-321-0106 Investigators. Gastroenterology. 2018 Jul 7. pii: S0016-5085(18)34758-9. doi: 10.1053/j.gastro.2018.07.006. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1751. | Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study |
|
Eriksson JW1, Lundkvist P2, Jansson PA3, Johansson L4, Kvarnström M5, Moris L6, Miliotis T5, Forsberg GB5, Risérus U7, Lind L2, Oscarsson J5. Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2. Epub 2018 Jul 3. |
|
|
1752. | Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis |
|
Thanda Han MA1, Altayar O2, Hamdeh S3, Takyar V4, Rotman Y4, Etzion O4, Lefebvre E5, Safadi R6, Ratziu V7, Prokop LJ8, Murad MH9, Noureddin M10. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30621-9. doi: 10.1016/j.cgh.2018.06.011. [Epub ahead of print] |
|
|
|
|
|
|
1755. | Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies |
|
Snyder HS1,2, Sakaan SA1,2, March KL1,2, Siddique O3, Cholankeril R4, Cummings CD1,2, Gadiparthi C5, Satapathy SK5, Ahmed A6, Cholankeril G5,6. J Clin Transl Hepatol. 2018 Jun 28;6(2):168-174. doi: 10.14218/JCTH.2017.00050. Epub 2018 Mar 25. |
|
|
|
|
1757. | A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis |
|
Awosika O1,2,3,4, Eleryan MG1,2,3,4, Rengifo-Pardo M1,2,3,4, Doherty L1,2,3,4, Martin LW1,2,3,4, Ehrlich A1,2,3,4. J Clin Aesthet Dermatol. 2018 Jun;11(6):33-37. Epub 2018 Jun 1. |
|
|
|
|
|
|
|
|
1761. | Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates |
|
Younossi Z1, Stepanova M2, Ong JP3, Jacobson IM4, Bugianesi E5, Duseja A6, Eguchi Y7, Wong VW8, Negro F9, Yilmaz Y10, Romero-Gomez M11, George J12, Ahmed A13, Wong R14, Younossi I2, Ziayee M2, Afendy A2; Global NASH Council.. Clin Gastroenterol Hepatol. 2018 Jun 13. pii: S1542-3565(18)30611-6. doi: 10.1016/j.cgh.2018.05.057. [Epub ahead of print] |
|
|
1762. | Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-stage Liver Disease Scores Compared With Placebo |
|
Frenette CT1, Morelli G2, Shiffman ML3, Frederick RT4, Rubin RA5, Fallon MB6, Cheng JT7, Cave M8, Khaderi SA9, Massoud O10, Pyrsopoulos N11, Park JS12, Robinson JM13, Yamashita M13, Spada AP13, Chan JL13, Hagerty DT13. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30622-0. doi: 10.1016/j.cgh.2018.06.012. [Epub ahead of print] |
|
|
1763. | Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption |
|
Sanders FWB1, Acharjee A1,2, Walker C1, Marney L1, Roberts LD1,2,3, Imamura F4, Jenkins B1, Case J2, Ray S1,5, Virtue S6, Vidal-Puig A6, Kuh D7, Hardy R7, Allison M8, Forouhi N4, Murray AJ9, Wareham N4, Vacca M1,2,5,6, Koulman A1, Griffin JL10,1Genome Biol. 2018 Jun 20;19(1):79. doi: 10.1186/s13059-018-1439-8. 1. |
|
|
|
|
|
|
|
|
1767. | Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial |
|
Bomhof MR1,2, Parnell JA3, Ramay HR4, Crotty P5, Rioux KP5,6, Probert CS7, Jayakumar S5, Raman M5, Reimer RA8,9. Eur J Nutr. 2018 May 19. doi: 10.1007/s00394-018-1721-2. [Epub ahead of print] |
|
|
1768. | Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis |
|
Thanda Han MA1, Altayar O2, Hamdeh S3, Takyar V4, Rotman Y4, Etzion O4, Lefebvre E5, Safadi R6, Ratziu V7, Prokop LJ8, Murad MH9, Noureddin M10. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30621-9. doi: 10.1016/j.cgh.2018.06.011. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1772. | Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease |
|
Mitchell T1, Jeffrey GP1,2, de Boer B3, MacQuillan G1,2, Garas G1,2, Ching H2, Hamdorf J2, Adams LA4,5. Am J Gastroenterol. 2018 Jun 14. doi: 10.1038/s41395-018-0133-5. [Epub ahead of print] |
|
|
1773. | NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances |
|
Noureddin M1,2, Vipani A3, Bresee C4, Todo T5, Kim IK5, Alkhouri N6, Setiawan VW7, Tran T8,3, Ayoub WS8,3, Lu SC8,3, Klein AS5, Sundaram V8,3, Nissen NN5. Am J Gastroenterol. 2018 Jun 8. doi: 10.1038/s41395-018-0088-6. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1777. | Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease |
|
Britton L1,2,3,4, Bridle K1,2, Reiling J1,2,5, Santrampurwala N1,2,4, Wockner L4, Ching H6, Stuart K1,3, Subramaniam VN4,7, Jeffrey G6,8, St Pierre T9, House M9, Gummer J10, Trengove R10, Olynyk J11,12, Crawford D1,2, Adams L6,8. Hepatol Commun. 2018 Apr 27;2(6):644-653. doi: 10.1002/hep4.1190. eCollection 2018 Jun. |
|
|
|
|
1779. | The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease |
|
Lewis JE1, Atlas SE1, Higuera OL1, Fiallo A1, Rasul A1, Farooqi A1, Kromo O2, Lantigua LA1, Tiozzo E1, Woolger JM3, Goldberg S4, Mendez A3, Rodriguez AE3, Konefal J5. Evid Based Complement Alternat Med. 2018 May 3;2018:1751583. doi: 10.1155/2018/1751583. eCollection 2018. |
|
|
|
|
1781. | Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration |
|
Patel YA1, Gifford EJ2, Glass LM3,4, Turner MJ5, Han B5, Moylan CA6, Choi S6, Suzuki A6, Provenzale D6,5, Hunt CM6,5. Dig Dis Sci. 2018 May 19. doi: 10.1007/s10620-018-5123-3. [Epub ahead of print] |
|
|
1782. | Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis |
|
Petta S1, Sebastiani G2, Bugianesi E3, Viganò M4, Wong VW5, Berzigotti A6, Fracanzani AL7, Anstee QM8, Marra F9, Barbara M10, Calvaruso V10, Cammà C10, Di Marco V10, Craxì A10, de Ledinghen V11. J Hepatol. 2018 May 23. pii: S0168-8278(18)32065-8. doi: 10.1016/j.jhep.2018.05.019. [Epub ahead of print] |
|
|
|
|
1784. | Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data |
|
Arsik I1, Frediani JK2, Frezza D3, Chen W4, Ayer T5, Keskinocak P6, Jin R7, Konomi JV8, Barlow SE9, Xanthakos SA10, Lavine JE11, Vos MB12. Children (Basel). 2018 May 25;5(6). pii: E64. doi: 10.3390/children5060064. |
|
|
|
|
|
|
|
|
|
|
|
|
1790. | Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030 |
|
Estes C1, Anstee QM2, Arias-Loste MT3, Bantel H4, Bellentani S5, Caballeria J6, Colombo M7, Craxi A8, Crespo J9, Day CP2, Geier A10, Kondili LA11, Lazarus JV12, Loomba R13, Manns MP4, Marchesini G14, Negro F15, Petta S16, Ratziu V17, Romero-Gomez M18, Sanyal A19, Schattenberg JM20, Tacke F21, Trautwein C22, Wei L23, Zeuzem S24, Razavi H25. J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32121-4. doi: 10.1016/j.jhep.2018.05.036. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1794. | Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure |
|
Valbusa F1, Agnoletti D1, Scala L1, Grillo C1, Arduini P2, Bonapace S3, Calabria S1, Scaturro G1, Mantovani A4, Zoppini G4, Turcato E2, Maggioni AP5, Arcaro G1, Targher G6. Int J Cardiol. 2018 May 2. pii: S0167-5273(18)30544-8. doi: 10.1016/j.ijcard.2018.04.129. [Epub ahead of print] |
|
|
1795. | US Time-Harmonic Elastography: Detection of Liver Fibrosis in Adolescents with Extreme Obesity with Nonalcoholic Fatty Liver Disease |
|
Hudert CA1, Tzschätzsch H1, Guo J1, Rudolph B1, Bläker H1, Loddenkemper C1, Luck W1, Müller HP1, Baumgart DC1, Hamm B1, Braun J1, Holzhütter HG1, Wiegand S1, Sack I1. Radiology. 2018 May 15:172928. doi: 10.1148/radiol.2018172928. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1800. | Liver fat imaging - a clinical overview of ultrasound, CT, and MR imaging |
|
Zhang Y1, Fowler KJ2, Hamilton G1, Cui J1, Sy EZ1, Balanay M1, Hooker JC1, Szeverenyi NM1, Sirlin CB1. Br J Radiol. 2018 May 3:20170959. doi: 10.1259/bjr.20170959. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1804. | Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings from a Multi-ethnic Cohort |
|
Tricò D1,2, Caprio S3, Umano GR3,4, Pierpont B3, Nouws J3, Galderisi A3, Kim G5, Mata MM3, Santoro N3. Hepatology. 2018 Apr 17. doi: 10.1002/hep.30035. [Epub ahead of print] |
|
|
|
|
1806. | Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients with Nonalcoholic Steatohepatitis |
|
Lawitz EJ1, Coste A2, Poordad F2, Alkhouri N2, Loo N2, McColgan BJ3, Tarrant JM3, Nguyen T3, Han L3, Chung C3, Ray AS3, McHutchison JG3, Subramanian GM3, Myers RP3, Middleton MS4, Sirlin C4, Loomba R4, Nyangau E5, Fitch M5, Li K5, Hellerstein M5. Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30404-X. doi: 10.1016/j.cgh.2018.04.042. [Epub ahead of print] |
|
|
|
|
1808. | Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors |
|
Mariabeatrice P1, Andrea I1, Giuseppe L1, Michela M1, Endrit S1, Francesca A1, Rizzi SF1, La Fortezza RF1, Rosa L1, Antonella C1, Michele B1, Gioacchino L2, Enzo I1, Alfredo DL1. Inflamm Bowel Dis. 2018 Apr 23. doi: 10.1093/ibd/izy051. [Epub ahead of print] |
|
|
|
|
|
|
1811. | Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH |
|
Boursier J1, Anty R2, Vonghia L3, Moal V1, Vanwolleghem T3, Canivet CM2, Michalak S1, Bonnafous S2, Michielsen P3, Oberti F1, Iannelli A2, Van Gaal L3, Patouraux S2, Blanchet O1, Verrijken A3, Gual P2, Rousselet MC1, Driessen A3, Hunault G1, Bertrais S1, Tran A2, Calès P1, Francque S3. Aliment Pharmacol Ther. 2018 May;47(10):1387-1396. doi: 10.1111/apt.14621. Epub 2018 Mar 25. |
|
|
1812. | Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease |
|
Harlow KE1, Africa JA1, Wells A2, Belt PH3, Behling CA4, Jain AK5, Molleston JP6, Newton KP1, Rosenthal P7, Vos MB8, Xanthakos SA9, Lavine JE10, Schwimmer JB11; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). J Pediatr. 2018 Apr 13. pii: S0022-3476(18)30281-6. doi: 10.1016/j.jpeds.2018.02.038. [Epub ahead of print] |
|
|
|
|
1814. | Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD |
|
Caussy C1,2, Hsu C1, Lo MT3, Liu A1, Bettencourt R1, Ajmera VH1, Bassirian S1, Hooker J4, Sy E4, Richards L1, Schork N5, Schnabl B1,6, Brenner DA1,6, Sirlin CB4, Chen CH3, Loomba R1,6,7; Genetics of NAFLD in Twins Consortium. Hepatology. 2018 Mar 23. doi: 10.1002/hep.29892. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1827. | Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver disease |
|
Grove JI1,2, Thiagarajan P1,2, Astbury S1,2, Harris R1,2, Delahooke T3, Guha IN1,2, Aithal GP1,2. Liver Int. 2018 Mar 1. doi: 10.1111/liv.13733. [Epub ahead of print] |
|
|
|
|
1829. | Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease |
|
Bertot LC1, Jeffrey GP1,2, de Boer B3, MacQuillan G1,2, Garas G1,2, Chin J2, Huang Y1, Adams LA1,2. Liver Int. 2018 Mar 25. doi: 10.1111/liv.13739. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1835. | Use of a Metabolomic Approach to Non-invasively Diagnose Nonalcoholic FattyLiver Disease in Patients with Type 2 Diabetes Mellitus |
|
Bril F1,2, Millán L3, Kalavalpalli S1, McPhaul MJ4, Caulfield MP4, Martinez-Arranz I3, Alonso C3, Ortiz Betes P3, Mato JM5, Cusi K1,2. Diabetes Obes Metab. 2018 Mar 12. doi: 10.1111/dom.13285. [Epub ahead of print] |
|
|
1836. | Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort |
|
Alexander KS1, Zakai NA1,2, Lidofsky SD1, Callas PW3, Judd SE4, Tracy RP2,5, Cushman M1,2. PLoS One. 2018 Mar 12;13(3):e0194153. doi: 10.1371/journal.pone.0194153. eCollection 2018. |
|
|
1837. | Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research |
|
Mancini M1, Summers P2, Faita F3, Brunetto MR4, Callea F5, De Nicola A6, Di Lascio N3, Farinati F7, Gastaldelli A8, Gridelli B9, Mirabelli P10, Neri E11, Salvadori PA3, Rebelos E4, Tiribelli C12, Valenti L13, Salvatore M10, Bonino F1. World J Hepatol. 2018 Feb 27;10(2):231-245. doi: 10.4254/wjh.v10.i2.231. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1844. | NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
|
Harrison SA1, Rinella ME2, Abdelmalek MF3, Trotter JF4, Paredes AH5, Arnold HL6, Kugelmas M7, Bashir MR8, Jaros MJ9, Ling L10, Rossi SJ10, DePaoli AM10, Loomba R11. Lancet. 2018 Mar 5. pii: S0140-6736(18)30474-4. doi: 10.1016/S0140-6736(18)30474-4. [Epub ahead of print] |
|
|
1845. | De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients |
|
Gitto S1, de Maria N1, di Benedetto F2, Tarantino G2, Serra V2, Maroni L3, Cescon M3, Pinna AD3, Schepis F1, Andreone P4, Villa E1. Eur J Gastroenterol Hepatol. 2018 Mar 2. doi: 10.1097/MEG.0000000000001105. [Epub ahead of print] |
|
|
|
|
|
|
1848. | Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference |
|
Poynard T1,2, Munteanu M3, Charlotte F1, Perazzo H1,2, Ngo Y3, Deckmyn O3, Pais R1,2, Merrouche W4, de Ledinghen V4, Mathurin P4, Ratziu V1,2; for the FLIP Consortium, the FibroFrance-CPAM Group, the FibroFrance-Obese Group. Eur J Gastroenterol Hepatol. 2018 Feb 26. doi: 10.1097/MEG.0000000000001064. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1852. | Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fattyliver disease in severe and morbid obesity |
|
Ooi GJ1,2, Earnest A3, Kemp WW4, Burton PR5,6, Laurie C5, Majeed A4, Johnson N7, McLean C8, Roberts SK4, Brown WA5,6. Int J Obes (Lond). 2018 Jan 30. doi: 10.1038/s41366-018-0007-3. [Epub ahead of print] |
|
|
1853. | Genetic Variants Associated With Obesity and Insulin Resistance in Hispanic Boys With Nonalcoholic Fatty Liver Disease |
|
Rausch JC1, Lavine JE1, Chalasani N2, Guo X3, Kwon S3, Schwimmer JB4, Molleston JP5, Loomba R6, Brunt EM7, Chen YI3, Goodarzi MO8, Taylor KD3, Yates KP9, Rotter JI3; NASH Clinical Research Network. J Pediatr Gastroenterol Nutr. 2018 Feb 21. doi: 10.1097/MPG.0000000000001926. [Epub ahead of print] |
|
|
1854. | Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease |
|
Younossi ZM1,2, Stepanova M3,2, Rafiq N1,2, Henry L3,2, Loomba R4, Makhlouf H5, Goodman Z1,2. Hepatol Commun. 2017 Jun 6;1(5):421-428. doi: 10.1002/hep4.1054. eCollection 2017 Jul. |
|
|
|
|
1856. | DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis |
|
Loomba R1, Gindin Y2, Jiang Z2, Lawitz E3, Caldwell S4, Djedjos CS2, Xu R2, Chung C2, Myers RP2, Subramanian GM2, Goodman Z5, Charlton M6, Afdhal NH7, Diehl AM8. JCI Insight. 2018 Jan 25;3(2). pii: 96685. doi: 10.1172/jci.insight.96685. [Epub ahead of print] |
|
|
1857. | Fructose and sugar: A major mediator of non-alcoholic fatty liver disease |
|
Jensen T1, Abdelmalek MF2, Sullivan S3, Nadeau KJ4, Green M4, Roncal C3, Nakagawa T5, Kuwabara M3, Sato Y3, Kang DH6, Tolan DR7, Sanchez-Lozada LG8, Rosen HR3, Lanaspa MA3, Diehl AM2, Johnson RJ3. J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30066-7. doi: 10.1016/j.jhep.2018.01.019. [Epub ahead of print] |
|
|
|
|
|
|
1860. | Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis |
|
Loffredo L1, Baratta F2, Ludovica P2, Battaglia S2, Carnevale R2, Nocella C2, Novo M2, Pannitteri G3, Ceci F4, Angelico F5, Violi F2, Del Ben M2. Nutr Metab Cardiovasc Dis. 2018 Feb;28(2):143-149. doi: 10.1016/j.numecd.2017.10.027. Epub 2017 Nov 13. |
|
|
1861. | Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
|
Kamada Y1,2, Ono M3, Hyogo H4, Fujii H5, Sumida Y6, Yamada M7, Mori K8, Tanaka S8, Maekawa T1, Ebisutani Y1, Yamamoto A1, Takamatsu S1, Yoneda M6, Kawada N5, Chayama K9, Saibara T3, Takehara T2, Miyoshi E1; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG?NAFLD). Hepatol Commun. 2017 Aug 16;1(8):780-791. doi: 10.1002/hep4.1080. eCollection 2017 Oct. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1868. | A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study |
|
Long MT1,2, Pedley A2,3, Massaro JM2,4, Hoffmann U5, Ma J2, Loomba R6,7,8, Chung RT9, Benjamin EJ2,10,11. Liver Int. 2018 Jan 29. doi: 10.1111/liv.13709. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1884. | Low Circulating Levels of Neurotensin in Women with Nonalcoholic Fatty LiverDisease Associated with Severe Obesity |
|
Auguet T1,2, Aragonès G1, Berlanga A1, MartÃnez S3, Sabench F4, Aguilar C1, Villar B2, Sirvent JJ3, Del Castillo D4, Richart C1,2. Obesity (Silver Spring). 2018 Feb;26(2):274-278. doi: 10.1002/oby.22058. Epub 2017 Dec 25. |
|
|
|
|
|
|
1887. | Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) |
|
Tully DC1,2, Rucker PV1, Chianelli D1, Williams J1, Vidal A1, Alper PB1, Mutnick D1, Bursulaya B1, Schmeits J1, Wu X1, Bao D1, Zoll J1, Kim Y1, Groessl T1, McNamara P1, Seidel HM1, Molteni V1, Liu B1, Phimister A2, Joseph SB1, Laffitte B1. J Med Chem. 2017 Dec 28;60(24):9960-9973. doi: 10.1021/acs.jmedchem.7b00907. Epub 2017 Dec 8. |
|
|
|
|
1889. | Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma |
|
Sadler EM1,1, Mehta N1, Bhat M1,1, Ghanekar A1,1, Greig PD1,1, Grant DR1,1, Yao F1, Sapisochin G1,1. Transplantation. 2018 Jan 10. doi: 10.1097/TP.0000000000002043. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1894. | Impact of steatosis and inflammation definitions on the performance of NASHtests |
|
Poynard T1,2,3, Munteanu M4, Charlotte F1,2, Perazzo H1,2,3, Ngo Y4, Deckmyn O4, Pais R1,2,3, Mathurin P5, Ratziu V1,2,3; for the FLIP consortium, the FibroFrance-CPAM group; and the FibroFrance-Obese group. Eur J Gastroenterol Hepatol. 2017 Dec 26. doi: 10.1097/MEG.0000000000001033. [Epub ahead of print] |
|
|
|
|
1896. | Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid |
|
Yoo W1, Gjuka D1, Stevenson HL2, Song X3, Shen H1, Yoo SY4, Wang J4, Fallon M5, Ioannou GN6, Harrison SA7, Beretta L1. PLoS One. 2017 Dec 15;12(12):e0189965. doi: 10.1371/journal.pone.0189965. eCollection 2017. |
|
|
|
|
1898. | Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease |
|
Eddowes PJ1, McDonald N2, Davies N1, Semple SIK2, Kendall TJ2, Hodson J1, Newsome PN1, Flintham RB1, Wesolowski R1, Blake L1, Duarte RV3, Kelly CJ4, Herlihy AH4, Kelly MD4, Olliff SP1, Hübscher SG1, Fallowfield JA2, Hirschfield GM1. Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14469. [Epub ahead of print] |
|
|
|
|
1900. | Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study |
|
Lee SB1, Park GM2, Lee JY3, Lee BU1, Park JH1, Kim BG1, Jung SW1, Jeong ID1, Bang SJ1, Shin JW1, Park NH1, Yang DH4, Kang JW4, Lim TH4, Kim HK5, Choe J5, Lee HC6. J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32527-8. doi: 10.1016/j.jhep.2017.12.012. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1907. | Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279?013 individuals |
|
Lauridsen BK1,2, Stender S1,2, Kristensen TS2,3, Kofoed KF2,4, Køber L2,4, Nordestgaard BG2,5,6,7, Tybjærg-Hansen A1,2,5,7. Eur Heart J. 2017 Dec 8. doi: 10.1093/eurheartj/ehx662. [Epub ahead of print] |
|
|
1908. | Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial |
|
Cheng S1,2,3, Ge J4, Zhao C5, Le S6, Yang Y6, Ke D5, Wu N6, Tan X6,7, Zhang X6, Du X4, Sun J8, Wang R5, Shi Y9, Borra RJH10,11, Parkkola R10, Wiklund P7,12,13, Lu D14. Sci Rep. 2017 Nov 21;7(1):15952. doi: 10.1038/s41598-017-16159-x. |
|
|
1909. | Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease |
|
Patel PJ1,2, Smith D3, Connor JP4, Horsfall LU1,2, Hayward KL2, Hossain F5, Williams S5, Johnson T5, Stuart KA1, Brown NN6, Saad N7, Clouston AD2, Irvine KM2,8, Russell AW9,10, Valery PC2,3,9, Powell EE1,2. Can J Gastroenterol Hepatol. 2017;2017:7927685. doi: 10.1155/2017/7927685. Epub 2017 Nov 1. |
|
|
|
|
|
|
|
|
|
|
1914. | Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis |
|
Younossi ZM1, Loomba R2, Anstee QM3, Rinella ME4, Bugianesi E5, Marchesini G6, Neuschwander-Tetri BA7, Serfaty L8, Negro F9, Caldwell SH10, Ratziu V11, Corey KE12, Friedman SL13, Abdelmalek MF14, Harrison SA15, Sanyal AJ16, Lavine JE17, Mathurin P18, Charlton MR19, Goodman ZD1, Chalasani NP9,20, Kowdley KV21, George J22, Lindor K23. Hepatology. 2017 Dec 9. doi: 10.1002/hep.29721. [Epub ahead of print] |
|
|
|
|
1916. | Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) |
|
Younossi ZM1, Loomba R2, Rinella ME3, Bugianesi E4, Marchesini G5, Neuschwander-Tetri BA6, Serfaty L7, Negro F8, Caldwell SH9, Ratziu V10, Corey KE11, Friedman SL12, Abdelmalek MF13, Harrison SA14, Sanyal AJ15, Lavine JE16, Mathurin P17, Charlton MR18, Chalasani NP19, Anstee QM20, Kowdley KV21, George J22, Goodman ZD1, Lindor K23. Hepatology. 2017 Dec 9. doi: 10.1002/hep.29724. [Epub ahead of print] |
|
|
|
|
1918. | Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-Aged Adults in the Framingham Study |
|
Weinstein G1, Zelber-Sagi S1,2, Preis SR3,4, Beiser AS3,4,5, DeCarli C6, Speliotes EK7,8, Satizabal CL4,5, Vasan RS4,5,9, Seshadri S4,5. JAMA Neurol. 2017 Nov 20. doi: 10.1001/jamaneurol.2017.3229. [Epub ahead of print] |
|
|
1919. | Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission |
|
Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, McGurnaghan S, McCrimmon R, Read SH, Sattar N, Byrne CD; Scottish Diabetes Research Network Epidemiology Group. Diabetes Care. 2017 Nov 22. pii: dc171590. doi: 10.2337/dc17-1590. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1928. | Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Diseasein a Prospective Study with 1-Year Follow-up : BariScan Study |
|
Nickel F1, Tapking C1, Benner L2, Sollors J3, Billeter AT1, Kenngott HG1, Bokhary L1, Schmid M1, von Frankenberg M1, Fischer L1, Mueller S3, Müller-Stich BP4. Obes Surg. 2017 Nov 9. doi: 10.1007/s11695-017-3012-z. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1933. | Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet |
|
Schwenger KJP1,2, Fischer SE2,3, Jackson TD4,5, Okrainec A1,4,5, Allard JP6,7,8. Obes Surg. 2017 Nov 2. doi: 10.1007/s11695-017-2980-3. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1939. | Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey |
|
Sheridan DA1, Aithal G2, Alazawi W3, Allison M4, Anstee Q5, Cobbold J6, Khan S7, Fowell A8, McPherson S9, Newsome PN10,11, Oben J12, Tomlinson J13, Tsochatzis E14. Frontline Gastroenterol. 2017 Oct;8(4):252-259. doi: 10.1136/flgastro-2017-100806. Epub 2017 Apr 28. |
|
|
|
|
|
|
1942. | Steatosis and NASH in type 2 diabetes |
|
Hu M1, Phan F1, Bourron O2, Ferré P1, Foufelle F3. . Biochimie. 2017 Oct 31. pii: S0300-9084(17)30271-7. doi: 10.1016/j.biochi.2017.10.019. [Epub ahead of print] |
|
|
|
|
|
|
1945. | Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance |
|
Baratta F1,2, Pastori D1,2, Polimeni L1, Bucci T3, Ceci F4, Calabrese C1, Ernesti I5, Pannitteri G6, Violi F1, Angelico F7, Del Ben M1. Am J Gastroenterol. 2017 Oct 24. doi: 10.1038/ajg.2017.371. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1951. | Diagnostic Accuracy of Magnetic Resonance Imaging Hepatic Proton Density Fat Fraction in Pediatric Nonalcoholic Fatty Liver Disease |
|
Middleton MS1, Van Natta ML2, Heba ER1, Alazraki A3, Trout AT4, Masand P5, Brunt EM6, Kleiner DE7, Doo E8, Tonascia J2, Lavine JE9, Shen W9, Hamilton G1, Schwimmer JB10, Sirlin CB1; NASH Clinical Research Network. Hepatology. 2017 Oct 13. doi: 10.1002/hep.29596. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1955. | Developmental Programming of Obesity and Liver Metabolism by Maternal Perinatal Nutrition Involves the Melanocortin System |
|
Cordero P1, Li J2, Nguyen V3, Pombo J4, Maicas N5, Novelli M6, Taylor PD7, Samuelsson AM8, Vinciguerra M9,10, Oben JA11,12. Nutrients. 2017 Sep 20;9(9). pii: E1041. doi: 10.3390/nu9091041. |
|
|
|
|
|
|
|
|
|
|
|
|
1961. | Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects |
|
Legry V1, Francque S2,3, Haas JT1, Verrijken A3,4, Caron S1, Chávez-Talavera O1, Vallez E1, Vonghia L2,3, Dirinck E4, Verhaegen A4, Kouach M5, Lestavel S1, Lefebvre P1, Van Gaal L3,4, Tailleux A1, Paumelle R1, Staels B1. J Clin Endocrinol Metab. 2017 Aug 4. doi: 10.1210/jc.2017-01397. [Epub ahead of print] |
|
|
|
|
|
|
1964. | Fatty liver without a large |
|
Yousef MH1, Al Juboori A1, Albarrak AA1, Ibdah JA1, Tahan V1. World J Gastrointest Pathophysiol. 2017 Aug 15;8(3):100-107. doi: 10.4291/wjgp.v8.i3.100. |
|
|
|
|
1966. | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention |
|
Younossi Z1,2, Anstee QM3,4, Marietti M5, Hardy T3,4, Henry L1,2, Eslam M6, George J6, Bugianesi E5. Nat Rev Gastroenterol Hepatol. 2017 Sep 20. doi: 10.1038/nrgastro.2017.109. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1971. | Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease |
|
Brady GF1, Kwan R1, Ulintz PJ2, Nguyen P3, Bassirian S3, Basrur V2, Nesvizhskii AI2,4, Loomba R3, Omary MB1. Hepatology. 2017 Sep 13. doi: 10.1002/hep.29522. [Epub ahead of print] |
|
|
|
|
1973. | The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial |
|
Loomba R1, Lawitz E2, Mantry PS3, Jayakumar S4, Caldwell SH5, Arnold H6, Diehl AM7, Djedjos CS8, Han L8, Myers RP8, Subramanian GM8, McHutchison JG8, Goodman ZD9, Afdhal NH10, Charlton MR11; GS-US-384-1497 Investigators. Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1999. | Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease |
|
Jiang ZG1, Tapper EB1, Connelly MA2, Pimentel CM1, Feldbrügge L1, Kim M3, Krawczyk S3, Afdh Al N1, Robson SC1, Herman M3, Otvos JD2, Mukamal KJ4, Lai M1. Liver Int. 2016 Jan 27. doi: 10.1111/liv.13076. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
2005. | Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study |
|
Armstrong MJ1, Gaunt P2, Aithal GP3, Barton D4, Hull D4, Parker R1, Hazlehurst JM5, Guo K4; LEAN trial team, Abouda G6, Aldersley MA7, Stocken D8, Gough SC5, Tomlinson JW5, Brown RM9, Hübscher SG10, Newsome PN11. Lancet. 2015 Nov 19. pii: S0140-6736(15)00803-X. doi: 10.1016/S0140-6736(15)00803-X. [Epub ahead of print] |
|
|
|
|
|
|
|
|
2009. | Non-alcoholic Steatohepatitis is Associated with Increased Mortality in Obese Patients Undergoing Bariatric Surgery |
|
Goossens N1, Hoshida Y2, Song WM3, Jung M4, Morel P4, Nakagawa S5, Zhang B3, Frossard JL6, Spahr L6, Friedman SL5, Negro F7, Rubbia-Brandt L8, Giostra E6. Clin Gastroenterol Hepatol. 2015 Oct 19. pii: S1542-3565(15)01406-8. doi: 10.1016/j.cgh.2015.10.010. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020. | Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability |
|
Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232. |
|
|
|
|
|
|
|
|
2024. | Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability |
|
Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2033. | Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH? |
|
Kohli R1, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KD. Dig Dis. 2015;33(3):440-6. doi: 10.1159/000371699. Epub 2015 May 27. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|